STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 200606

TO:	From:
Satyanarayana Gudibande Location: 3a20 / 3c18 Thursday, September 07, 2006 Art Unit: 1654 Phone: 571-272-8146 Serial Number: 10 / 078247	Jan Delaval Location: EIC 1700 Remsen 4b30 Phone: 571-272-2504 jan.delaval@uspto.gov

Search Notes

=> d l57 bib abs hitrn fhitstr retable tot

L57 ANSWER 1 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:77534 HCAPLUS
DN 138:142467
TI Compositions and methods for enhancing drug delivery across and into ocular tissues
IN **Rothbard, Jonathan B.**; **Wender, Paul A.**; McGrane, P. Leo; Sista, Lalitha V. S.; Kirschberg, Thorsten A.
PA Cellgate, Inc., USA
SO U.S. Pat. Appl. Publ., 64 pp., Cont.-in-part of U.S. Ser. No. 792,480. CODEN: USXXCO
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003022831	A1	20030130	US 2002-83960	20020225 <--
	US 6593292	B1	20030715	US 2000-648400	20000824 <--
	US 2002127198	A1	20020912	US 2001-792480	20010223 <--
	US 6669951	B2	20031230		
PRAI	US 1999-150510P	P	19990824	<--	
	US 2000-648400	A2	20000824	<--	
	US 2001-792480	A2	20010223	<--	

OS MARPAT 138:142467
AB This invention provides compns. and methods for enhancing delivery of drugs and other agents across epithelial tissues, including into and across ocular tissues and the like. The compns. and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compns. and methods employ a delivery-enhancing transporter that has sufficient guanidino or amidino side chain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound The delivery-enhancing polymers include, for example, polyarginine mols. that are preferably between about 6 and 25 residues in length.
IT **491875-87-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(delivery-enhancing transporters for drug delivery across and into ocular tissues)
IT **328234-41-9P 328234-42-0P 452337-48-3P 452337-51-8P 455282-35-6P 455282-36-7P 457906-55-7P 457906-67-1P 491875-89-9P 491875-91-3P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(delivery-enhancing transporters for drug delivery across and into ocular tissues)
IT **491875-87-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(delivery-enhancing transporters for drug delivery across and into ocular tissues)
RN 491875-87-7 HCAPLUS
CN D-Argininamide, D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L57 ANSWER 2 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:696457 HCAPLUS
DN 137:237728
TI Peptide conjugates for enhancing drug delivery across and into epithelial tissues
IN **Rothbard, Jonathan B.**; **Wender, Paul A.**; McGrane, P. Leo; Sista, Lalitha V. S.; Kirschberg, Thorsten A.
PA Cellgate, Inc., USA
SO U.S. Pat. Appl. Publ., 80 pp., Cont.-in-part of U.S. Ser. No. 648,400. CODEN: USXXCO
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002127198	A1	20020912	US 2001-792480	20010223 <--
	US 6669951	B2	20031230		
	US 6593292	B1	20030715	US 2000-648400	20000824 <--

	CA 2438784	AA	20020906	CA 2002-2438784	20020225 <--
	WO 2002067917	A1	20020906	WO 2002-US5804	20020225 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2438326	AA	20020912	CA 2002-2438326	20020225 <--
	WO 2002069930	A1	20020912	WO 2002-US5829	20020225 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003022831	A1	20030130	US 2002-83960	20020225 <--
	EP 1367995	A1	20031210	EP 2002-731103	20020225 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EP 1372626	A1	20040102	EP 2002-713692	20020225 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004530657	T2	20041007	JP 2002-569108	20020225 <--
	JP 2004533414	T2	20041104	JP 2002-567285	20020225 <--
	US 2003083256	A1	20030501	US 2002-209421	20020730 <--
	US 6759387	B2	20040706		
	US 2004186045	A1	20040923	US 2003-740365	20031217 <--
PRAI	US 1999-150510P	P	19990824 <--		
	US 2000-648400	A2	20000824 <--		
	US 2001-792480	A	20010223 <--		
	WO 2002-US5804	W	20020225		
	WO 2002-US5829	W	20020225		

OS MARPAT 137:237728

AB This invention provides compns. and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compns. and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compns. and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino side-chain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound The delivery-enhancing polymers include, for example, poly-arginine mols. that are preferably between about 6 and 25 residues in length. E.g., biotinylated polymers of D-arginine were prepared and their penetration into the skin of nude mice studied.

IT **328234-41-9P 328234-42-0P 455282-32-3P 457906-19-3P**

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(peptide conjugates for enhancing drug delivery across and into epithelial tissues)

IT **165893-48-1 216584-13-3**

RL: RCT (Reactant); RACT (Reactant or reagent)
(peptide conjugates for enhancing drug delivery across and into epithelial tissues)

IT **457906-65-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(peptide conjugates for enhancing drug delivery across and into epithelial tissues)

IT **123251-89-8P 452337-48-3P 452337-52-9P 452337-56-3P 455282-15-2P 455282-35-6P 457906-55-7P 457906-67-1P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide conjugates for enhancing drug delivery across and into epithelial tissues)

IT **328234-41-9P**
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide conjugates for enhancing drug delivery across and into epithelial tissues)

RN 328234-41-9 HCAPLUS

CN Cyclosporin A, 6-[(2S,3R,4R,6E)-3-[(mercaptoacetyl)oxy]-4-methyl-2-(methylamino)-6-octenoic acid]-, (6→8')-thioether with N2-[6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]-1-oxohexyl]-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-L-cysteinamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



L57 ANSWER 3 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:675821 HCAPLUS
DN 137:222033
TI Compositions and methods for enhancing drug delivery across and into ocular tissues
IN **Rothbard, Jonathan B.**; **Wender, Paul A.**; McGrane, P. Leo; Sista, Lalitha Vs; Kirschberg, Thorsten A.
PA Cellgate, Inc., USA
SO PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002067917	A1	20020906	WO 2002-US5804	20020225 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002127198	A1	20020912	US 2001-792480	20010223 <--
	US 6669951	B2	20031230		
	CA 2438784	AA	20020906	CA 2002-2438784	20020225 <--
	EP 1372626	A1	20040102	EP 2002-713692	20020225 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004533414	T2	20041104	JP 2002-567285	20020225 <--
PRAI	US 2001-792480	A	20010223 <--		
	US 1999-150510P	P	19990824 <--		
	US 2000-648400	A2	20000824 <--		
	WO 2002-US5804	W	20020225		

OS MARPAT 137:222033

AB Compns. and methods for enhancing delivery of drugs, diagnostic and other agents across epithelial tissues, including into and across ocular tissues and blood-brain barrier are provided. The compns. and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino side chain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound The delivery-enhancing polymers include, for example, poly-arginine mols. that are preferably between about 6 and 25 residues in length. For example, a series of structural characteristics including sequence length, amino acid composition, and chirality that influence the ability of Tat49-57 to enter cells is identified. These characteristics provided the blueprint for the design of a series of novel peptoids, of which 17 members were synthesized and assayed for cellular uptake. This research established that the peptide backbone and hydrogen bonding along that backbone are not required for cellular uptake, that the guanidino head group is superior to other cationic subunits, and most significantly, that an extension of the alkyl chain between the backbone and the head group provides superior transporters. In addition to better uptake performance, these novel peptoids offer several advantages over Tat49-57 including cost-effectiveness, ease of synthesis of analogs, and protease stability. These features along with their significant water solubility (>100 mg/mL) indicate that these novel peptoids could serve as effective transporters for the mol. delivery of drugs, drug candidates, and other agents into cells.

IT **153127-44-7DP**, fluorescein conjugate **216584-13-3DP**, fluorescein conjugate
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(drug conjugates with peptide transporter containing amidino or guanidino moieties for enhanced delivery across epithelium)

IT **455282-28-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(drug conjugates with peptide transporter containing amidino or guanidino moieties for enhanced delivery across epithelium)

IT **123251-89-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(drug conjugates with peptide transporter containing amidino or guanidino moieties for enhanced delivery across epithelium)

IT **452337-48-3P 452337-52-9P 452337-56-3P 455282-15-2P 455282-30-1P 455282-31-2P 455282-33-4P 455282-35-6P 455282-36-7P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug conjugates with peptide transporter containing amidino or guanidino moieties for enhanced delivery across epithelium)

IT **216584-13-3D**, cyclosporin A conjugate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug conjugates with peptide transporter containing amidino or guanidino moieties for enhanced delivery across epithelium)

IT **153127-44-7DP**, fluorescein conjugate
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(drug conjugates with peptide transporter containing amidino or guanidino moieties for enhanced delivery across epithelium)

RN 153127-44-7 HCAPLUS

CN D-Arginine, D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-A



RETABLE

Referenced Author	Year	VOL	PG	Referenced Work	Referenced

(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
Bretton, R	2000			US 6089234 A	
Cellgate Inc	2001			WO 0113957 A2	HCAPLUS
Katz	1998			US 5716614 A	HCAPLUS
Rothbard	2000	6	1253	Nature Medicine	HCAPLUS
Skubitz	2000			US 6013628 A	HCAPLUS

L57 ANSWER 4 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:657914 HCAPLUS
DN 137:206525
TI Transporters comprising spaced arginine moieties
IN **Wender, Paul A.; Rothbard, Jonathan B.; Wright, Lee; Kreider, Erik L.; Vandeusen, Christopher L.**
PA Cellgate, Inc., USA; Univ. Leland Stanford Junior
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002065986	A2	20020829	WO 2002-US4491	20020214 <--
	WO 2002065986	C2	20030313		
	WO 2002065986	A3	20040122		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2437983	AA	20020829	CA 2002-2437983	20020214 <--
	US 2003032593	A1	20030213	US 2002-78247	20020214 <--
	EP 1401473	A2	20040331	EP 2002-742477	20020214 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2005508832	T2	20050407	JP 2002-565547	20020214 <--
PRAI	US 2001-269627P	P	20010216 <--		
	WO 2002-US4491	W	20020214		

OS MARPAT 137:206525
AB The present invention provides compns. and methods for enhancing transport of biol. active compds. across biol. membranes and across and into animal epithelial or endothelial tissues. The composition includes a biol. active agent and a transport moiety. The transport moiety includes a structure selected from the group consisting of (ZYZ)nZ, (ZY)nZ, (ZYY)nZ and (ZYYY)nZ. Subunit "Z" is L-arginine or D-arginine, and subunit "Y" is an amino acid that does not comprise an amidino or guanidino moiety. Subscript "n" is an integer ranging from 2 to 10. The method for enhancing transport involves the administration of the aforementioned composition
IT **452337-48-3P 452337-52-9P 452337-56-3P**
RL: BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(cell-membrane drug transporters comprising spaced arginine moieties)

IT **452337-26-7P 452337-29-0P 452337-30-3P**
RL: PAC (Pharmacological activity); PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cell-membrane drug transporters comprising spaced arginine moieties)

IT **165893-48-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(cell-membrane drug transporters comprising spaced arginine moieties)

IT **452337-48-3P**
RL: BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(cell-membrane drug transporters comprising spaced arginine moieties)

RN 452337-48-3 HCAPLUS

CN L-Cysteinamide, N2-[6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]-1-oxohexyl]-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-S-[2-[[(11β)-11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl]oxy]-2-oxoethyl]-, heptakis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 452337-47-2
CMF C84 H147 N33 O17 S2

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L57 ANSWER 5 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:515124 HCAPLUS
DN 137:210414
TI Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake
AU **Rothbard, Jonathan B.; Kreider, Erik; VanDeusen, Christopher L.; Wright, Lee;** Wylie, Bryan L.; **Wender, Paul A.**
CS CellGate Inc., Sunnyvale, CA, 94085, USA
SO Journal of Medicinal Chemistry (2002), 45(17), 3612-3618
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB Short oligomers of arginine, either alone or when conjugated to therapeutic agents or large biopolymers, have been shown to cross readily

a variety of biol. barriers (e.g., lipid bilayers and epithelial tissue). Mol. modeling suggests that only a subset of the side chain guanidinium groups of these transporters might be required for transport involving contact with a common surface such as a plasma membrane or cell surface receptor. To evaluate this hypothesis, a series of decamers were prepared that incorporated seven arginines and three nonarginine residues. Several of these mixed decamers were comparable to the all arginine decamer in their ability to enter cells. More significantly, these decamers containing seven arginines performed almost without exception better than hepta-arginine itself, suggesting that spacing between residues is also important for transport. The influence of spacing was more fully evaluated with a library of oligomers incorporating seven arginines separated by one or more nonconsecutive, non-α-amino acids. This study led to the identification of a new series of highly efficient mol. transporters.

IT **452337-26-7P 457633-17-9P**
RL: PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(arginine-rich mol. transporters for drug delivery: role of backbone spacing in cellular uptake)

IT **452337-26-7P**
RL: PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(arginine-rich mol. transporters for drug delivery: role of backbone spacing in cellular uptake)

RN 452337-26-7 HCAPLUS

CN L-Argininamide, N2-[6-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]thioxomethyl]amino]-1-oxohexyl]-L-arginyl-6-aminohexanoyl-L-arginyl-6-aminohexanoyl-L-arginyl-6-aminohexanoyl-L-arginyl-6-aminohexanoyl-L-arginyl-6-aminohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



PAGE 2-A



PAGE 2-B

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bellet-Amalric, E	2000	1467	131	Biochim Biophys Acta	HCAPLUS
Dathe, M	1999	1462	71	Biochim Biophys Acta	HCAPLUS
Derossi, D	1994	269	10444	J Biol Chem	HCAPLUS
Fischer, P	2001	12	825	Bioconjugate Chem	HCAPLUS
Frankel, A	1988	55	1189	Cell	HCAPLUS
Futaki, S	2001	276	5836	J Biol Chem	HCAPLUS
Humphrey, W	1996	14	33	J Mol Graph	HCAPLUS
Kale, L	1999	151	283	J Comput Phys	HCAPLUS
Kown, M	2001	121	971	J Thorac Cardiovasc	HCAPLUS
Kown, M	2001	71	1542	Transplantation	HCAPLUS
Lebleu, B	1996	14	109	Trends Biotechnol	HCAPLUS
Mackerell, A	1998	102	3586	J Phys Chem	HCAPLUS
Magzoub, M	2001	1512	77	Biochim Biophys Acta	HCAPLUS
Mitchell, D	2000	56	318	J Pept Res	HCAPLUS

Rothbard, J	2000	6	1253	Nat Med	HCAPLUS
Schwartz, J	2000	2	162	Curr Opin Mol Ther	HCAPLUS
Schwarze, S	1999	285	1569	Science	HCAPLUS
Shai, Y	1999	1462	55	Biochim Biophys Acta	HCAPLUS
Uemura, S	2000	102	2629	Circulation	HCAPLUS
Wender, P	2000	97	13003	Proc Natl Acad Sci U	HCAPLUS

L57 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:2517 HCAPLUS
DN 137:237523
TI Molecular transporters for peptides: delivery of a cardioprotective εPKC agonist peptide into cells and intact ischemic heart using a transport system, R7
AU Chen, Leon; **Wright, Lee R.**; Chen, Che-Hong; Oliver, Steven F.; **Wender, Paul A.**; Mochly-Rosen, Daria
CS Department of Molecular Pharmacology, Stanford University School of Medicine, Stanford, CA, 94305-5174, USA
SO Chemistry & Biology (**2001**), 8(12), 1123-1129
CODEN: CBOLE2; ISSN: 1074-5521
PB Elsevier Science Ltd.
DT Journal
LA English
AB Background: Recently, we reported a novel oligoguanidine transporter system, polyarginine (R7), which, when conjugated to spectroscopic probes (e.g., fluorescein) and drugs (e.g., cyclosporin A), results in highly water-soluble conjugates that rapidly enter cells and tissues. We report herein the preparation of the first R7 peptide conjugates and a study of their cellular and organ uptake and functional activity. The octapeptide ψεRACK was selected for this study as it is known to exhibit selective ε protein kinase C isoenzyme agonist activity and to reduce ischemia-induced damage in cardiomyocytes. However, ψεRACK is not cell-permeable. Results: Here we show that an R7-ψεRACK conjugate readily enters cardiomyocytes, significantly outperforming ψεRACK conjugates of the transporters derived from HIV Tat and from Antennapedia. Moreover, R7-ψεRACK conjugate reduced ischemic damage when delivered into intact hearts either prior to or after the ischemic insult. Conclusions: Our data suggest that R7 converts a peptide lead into a potential therapeutic agent for the ischemic heart.
IT **165893-48-1**
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(delivery of cardioprotective εPKC agonist peptide into cells and intact ischemic heart using polyarginine transport system)
IT **165893-48-1**
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(delivery of cardioprotective εPKC agonist peptide into cells and intact ischemic heart using polyarginine transport system)
RN 165893-48-1 HCAPLUS
CN L-Arginine, L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Carr, D	1992	267	13376	J Biol Chem	HCAPLUS
Chen, C	1999	96	12784	Proc Natl Acad Sci U	HCAPLUS
Derossi, D	1994	269	10444	J Biol Chem	HCAPLUS
Dorn, G	1999	96	12798	Proc Natl Acad Sci U	HCAPLUS
Gray, M	1997	272	30945	J Biol Chem	HCAPLUS
Johnson, J	1996	271	24962	J Biol Chem	HCAPLUS
Koch, W	1993	268	8256	J Biol Chem	HCAPLUS
Lester, L	1997	94	14942	Proc Natl Acad Sci U	HCAPLUS
Lindgren, M	2000	21	99	Trends Pharmacol Sci	HCAPLUS
Mitchell, D	2000	56	318	J Peptide Res	HCAPLUS
Mochly-Rosen, D	2000	86	1173	Circ Res	HCAPLUS
Mochly-Rosen, D	1991	266	14866	J Biol Chem	HCAPLUS
Mochly-Rosen, D	1991	88	3997	Proc Natl Acad Sci U	HCAPLUS
Murry, C	1986	74	1124	Circulation	MEDLINE
Rabanal, F	1996	37	1347	Tetrahedron Lett	HCAPLUS
Ron, D	1995	270	24180	J Biol Chem	HCAPLUS
Rosenmund, C	1994	368	853	Nature	HCAPLUS
Rothbard, J	2000	6	1253	Nature Med	HCAPLUS
Schwarze, S	1999	285	1569	Science	HCAPLUS
Souroujon, M	1998	16	919	Nature Biotechnol	HCAPLUS

Stauffer, T	1997	36	9388	Biochemistry	HCAPLUS
Sternson, L	1987	507	19	Ann NY Acad Sci	MEDLINE
Strauss, E	1999	285	1466	Science	HCAPLUS
Vijayaraghavan, S	1997	272	4747	J Biol Chem	HCAPLUS
Vives, E	1997	272	16010	J Biol Chem	HCAPLUS

L57 ANSWER 7 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:513877 HCAPLUS
DN 136:268064
TI L-Arginine polymer mediated inhibition of graft coronary artery disease after cardiac transplantation
AU Kown, Murray H.; van der Steenhoven, Tim; Uemura, Shiro; Jahncke, Christina L.; Hoyt, Grant E.; **Rothbard, Jonathon B.**; Robbins, Robert C.
CS Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, 94025, USA
SO Transplantation (**2001**), 71(11), 1542-1548
CODEN: TRPLAU; ISSN: 0041-1337
PB Lippincott Williams & Wilkins
DT Journal
LA English
AB Nitric oxide (NO) limits the development of graft coronary artery disease (GCAD) in transplanted hearts. We hypothesized that L-arginine polymers administered to cardiac allografts ex vivo would translocate across vascular cellular membranes, upregulate inducible nitric oxide synthase (iNOS) production of NO, and inhibit the development of GCAD. Three groups of PVG rat donor hearts were incubated with either 0.8 mL phosphate-buffered saline, (PBS, n=12) or 50 μM L-arginine polymer solns. of length five (R5, n=12) or nine (R9, n=12) prior to heterotopic transplantation into ACI recipients. Graft vessels were scored at POD 60 and 90 for percentage luminal narrowing (%LN), intima to media ratio (I/M), and percentage affected vessels (%AV). Translocation efficiency was determined by treatment with biotinylated polymers. NO production of treated aortic segments was determined in vitro by Griess reaction. Translocation efficiencies were 89±19% (R9), 7±10% (R5), and 0±0% PBS (ANOVA, P<0.001) which corresponded to NO production in treated aortic segments of 0.175±0.17 (R9), 0.120±0.006 (R5), and 0.135±0.035 μM/mg (PBS), (ANOVA, P=0.002). GCAD scores at POD 60 were: %LN: 3.2±3.8% (R9), 12.6±6.7% (R5), 11.3±4.2% (PBS) (ANOVA, P=0.025); I/M: 0.03±0.04 (R9), 0.13±0.07 (R5), 0.12±0.05 (PBS) (ANOVA, P=0.037); %AV: 7±7% (R9), 19±7%(R5), 22±9%(PBS) (ANOVA, P=0.021). Reduction of GCAD parameters was maintained at POD 90. R9 efficiently translocated across cytoplasmic membranes, enhanced vascular NO production, and decreased neointimal hyperplasia. This ex vivo treatment may have a therapeutic role in preventing GCAD.
IT **208646-06-4**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(arginine polymer-mediated inhibition of graft coronary artery disease after cardiac transplantation)
IT **208646-06-4**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(arginine polymer-mediated inhibition of graft coronary artery disease after cardiac transplantation)
RN 208646-06-4 HCAPLUS
CN L-Argininamide, L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Azuma, H	1995	115	1001	Br J Pharmacol	HCAPLUS
Azuma, H	1994	6	770	Curr Opin Immunol	HCAPLUS
Best, P	1999	19	14	Arterioscler Thromb	MEDLINE
Billingham, M	1994	8	289	Clin Transplant	MEDLINE
Chester, A	1998	38	814	Cardiovasc Res	HCAPLUS
Cooke, J	1992	90	1168	J Clin Invest	HCAPLUS
Dusting, G	1995	27	395	Ann Med	HCAPLUS
Efthymiadis, A	1998	273	1623	J Biol Chem	HCAPLUS
Hill, C	1994	152	2890	J Immunol	HCAPLUS
Ignarro, L	1987	84	9265	Proc Natl Acad Sci U	HCAPLUS
Jeremy, R	1996	94	498	Circulation	HCAPLUS

Koglin, J	1999	99	836	Circulation	MEDLINE
Koide, M	1993	268	24959	J Biol Chem	HCAPLUS
Kown, M	2000			J Thorac Cardiovasc	
Kown, M	2001	121	971	J Thorac Cardiovasc	HCAPLUS
Lafond-Walker, A	1997	151	919	Am J Pathol	MEDLINE
Lee, P	1999	26	1013	Clin Exp Pharmacol P	HCAPLUS
Lloyd-Jones, D	1996	47	365	Annu Rev Med	MEDLINE
Lou, H	1996	15	1248	J Heart Lung Transpl	MEDLINE
Maulik, N	1996	94	II398	Circulation	HCAPLUS
McNamara, D	1993	193	291	Biochem Biophys Res	HCAPLUS
Mitchell, D	2000	56	318	J Pept Res	HCAPLUS
Morishita, R	1995	92	5855	Proc Natl Acad Sci U	HCAPLUS
Newman, K	1995	96	2955	J Clin Invest	HCAPLUS
Okazaki, J	1997	36	429	Cardiovasc Res	HCAPLUS
Ono, K	1969	57	225	J Thorac Cardiovasc	MEDLINE
Poston, R	1999	100	67	Circulation	HCAPLUS
Schmid, C	1997	64	222	Transplantation	MEDLINE
Schwarzacher, S	1997	95	1863	Circulation	HCAPLUS
Shears, L	1997	100	2035	J Clin Invest	HCAPLUS
Uemura, S	2000	102	2629	Circulation	HCAPLUS
Vives, E	1997	272	16010	J Biol Chem	HCAPLUS
Von der, L	1995	92	1137	Proc Natl Acad Sci U	
Wang, C	2000	86	982	Circ Res	HCAPLUS
Weis, M	1997	96	2069	Circulation	MEDLINE
Yao, S	1992	86	1302	Circulation	HCAPLUS

L57 ANSWER 8 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:382668 HCAPLUS
DN 136:128766
TI L-arginine polymers inhibit the development of vein graft neointimal hyperplasia
AU Kown, Murray H.; Yamaguchi, Atsushi; Jahncke, Christina L.; Miniati, Douglas; Murata, Seiichiro; Grunenfelder, Jurg; Koransky, Mark L.; **Rothbard, Jonathan B.**; Robbins, Robert C.
CS Department of Cardiothoracic Surgery, University School of Medicine, Stanford, CA, USA
SO Journal of Thoracic and Cardiovascular Surgery (**2001**), 121(5), 971-980
CODEN: JTCSAQ; ISSN: 0022-5223
PB Mosby, Inc.
DT Journal
LA English
AB We sought to determine whether L-arginine polymer treatment of vein grafts enhances vascular production of nitric oxide and inhibits the development of neointimal hyperplasia. External jugular veins of New Zealand White rabbits (n = 42) were harvested; treated intraluminally for 15 min with phosphate-buffered saline solution or L-arginine polymer 5, 7, or 9 at either 10 or 100 μmol/L; and then grafted into the contralateral carotid artery. Rabbits were killed after 28 days, and 5-μm sections of vessels were stained with hematoxylin and scored for intima/media ratio by using computerized morphometric anal. Sep. veins were treated in a similar fashion with biotinylated polymers and phosphate-buffered saline solution to assess for translocation efficiencies. Finally, vein segments pretreated with either phosphate-buffered saline solution or L-arginine polymers were cultured in Dulbecco's modified Eagle's medium containing lipopolysaccharide (100 μg/mL) and interferon γ (200 U/mL) for 48 h before measuring nitric oxide levels by means of the Griess reaction. Biotinylated L-arginine polymers demonstrated a dose- and length-dependent uptake into intimal and medial cells of treated vessels. Nitric oxide levels were significantly higher in vein segments treated with 100

μmol/L of L-arginine polymer compared with control segments. Finally, the intima/media ratio also reflected both length- and concentration-dependent inhibition of neointimal hyperplasia. Arginine polymers of sufficient length and concentration were effective in increasing nitric oxide levels and reducing neointimal hyperplasia in this vein graft model.

IT **208646-04-2 208646-06-4**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(L-arginine polymers inhibit development of vein graft neointimal hyperplasia)

IT **208646-04-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(L-arginine polymers inhibit development of vein graft neointimal hyperplasia)

RN 208646-04-2 HCAPLUS

CN L-Argininamide, L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RETABLE

Referenced Author	Year	VOL	PG	Referenced Work	Referenced

(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
Best, P	1999	19	14	Arterioscler Thromb	MEDLINE
Canver, C	1995	108	1150	Chest	MEDLINE
Castillo, L	1994	43	114	Metabolism	HCAPLUS
Chester, A	1998	38	814	Cardiovasc Res	HCAPLUS
Cohen, J	1998	397	169	Prog Clin Biol Res	HCAPLUS
Cooke, J	1992	90	1168	J Clin Invest	HCAPLUS
Davies, M	1995	59	35	J Surg Res	HCAPLUS
Dusting, G	1995	27	395	Ann Med	HCAPLUS
Efthymiadis, A	1998	273	1623	J Biol Chem	HCAPLUS
Fitzgibbon, G	1996	28	616	J Am Coll Cardiol	MEDLINE
Fulton, G	1998	15	279	Eur J Vasc Endovasc	MEDLINE
Hansson, G	1994	180	733	J Exp Med	HCAPLUS
Hecker, M	1999	32	9	Gen Pharmacol	HCAPLUS
Hill, C	1994	152	2890	J Immunol	HCAPLUS
Jeremy, R	1996	94	498	Circulation	HCAPLUS
Koide, M	1993	268	24959	J Biol Chem	HCAPLUS
Masini, E	1999	48	561	Inflamm Res	HCAPLUS
Mitchell, D	2000	56	318	J Pept Res	HCAPLUS
Morishita, R	1995	92	5855	Proc Natl Acad Sci U	HCAPLUS
Motwani, J	1998	97	916	Circulation	MEDLINE
Okazaki, J	1997	36	429	Cardiovasc Res	HCAPLUS
Sarkar, R	1996	78	225	Circ Res	HCAPLUS
Shears, L	1997	100	2035	J Clin Invest	HCAPLUS
Southern, L	1982	55	857	J Anim Sci	HCAPLUS
Tsao, P	1994	89	2176	Circulation	HCAPLUS
Uemura, S	2000	702	2629	Circulation	
Vinten-Johansen, J	1995	50	273	Int J Cardiol	MEDLINE
Vives, E	1997	272	16010	J Biol Chem	HCAPLUS
Von der, L	1995	92	1137	Proc Natl Acad Sci U	
Wu, G	1998	336	1	Biochem J	HCAPLUS

L57 ANSWER 9 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:900053 HCAPLUS
DN 135:55761
TI Rapid and efficient vascular transport of arginine polymers inhibits myointimal hyperplasia
AU Uemura, Shiro; Fathman, C. Garrison; **Rothbard, Jonathan B.**; Cooke, John P.
CS Department of Medicine, Stanford University School of Medicine, Stanford, USA
SO Circulation (**2000**), 102(21), 2629-2635
CODEN: CIRCAZ; ISSN: 0009-7322
PB Lippincott Williams & Wilkins
DT Journal
LA English
AB We recently discovered that short polymers of arginine efficiently translocate across the cytoplasmic membrane independent of the basic amino acid transporter. We evaluated the kinetics and biol. effects of heptamers of L-arginine and D-arginine (L-R7 and D-R7, resp.) in vascular cells. We assessed the effects of these peptides on the NO synthesis pathway and vascular cell proliferation. Human umbilical vein endothelial cell and rabbit vascular segments were incubated in medium containing biotin-labeled L-R7 or D-R7. Both polymers rapidly translocated through the vessel wall and into the vascular cells in a dose- and time-dependent fashion. At a dose of 10 μmol/L for 30 min, 100% of the endothelial cells showed evidence of cytoplasmic and nuclear localization of the peptides. To evaluate the biol. effects of the polymer translocation on myointimal formation, rabbit jugular vein segments were incubated with

polymers (10 μmol/L, 30 min) or vehicle before arterial interposition grafting. Planimetric measurement 28 days after surgery revealed that L-R7 and D-R7 substantially reduced myointimal formation compared with the control condition (intima/media ratio: control 1.50.5, L-R7 0.40.2, and D-R7 0.80.2). Furthermore, basal nitrate and nitrite production from L-R7-treated grafts was significantly higher than that from both control and D-R7-treated veins. Studies in vitro of cultured vascular smooth muscle cells revealed that both polymers also exhibit an NO-independent inhibition of vascular smooth muscle cell proliferation. Short polymers of arginine have the unique ability of vascular cell translocation, and they also have direct biol. effects. These attributes are potentially useful in treating myointimal hyperplasia.

IT **165893-48-1 216584-13-3**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(arginine polymer rapid and efficient vascular transport inhibits myointimal hyperplasia)

IT **165893-48-1**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(arginine polymer rapid and efficient vascular transport inhibits myointimal hyperplasia)

RN 165893-48-1 HCAPLUS

CN L-Arginine, L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Azuma, H	1995	115	1001	Br J Pharmacol	HCAPLUS
Boger, R	1998	98	1842	Circulation	HCAPLUS
Cooke, J	1997	48	489	Annu Rev Med	HCAPLUS
Currie, A	1979	39	613	Br J Cancer	
Dattilo, J	1997	174	177	Am J Surg	MEDLINE
Davies, M	1994	116	557	Surgery	MEDLINE
D'Aniello, A	1993	105	731	Comp Biochem Physiol	MEDLINE
Efthymiadis, A	1998	273	1623	J Biol Chem	HCAPLUS
Forrester, J	1991	17	758	J Am Coll Cardiol	MEDLINE
Frankel, A	1988	55	1189	Cell	HCAPLUS
Garg, U	1989	90	1774	J Clin Invest	
Girerd, X	1990	67	1301	Circ Res	HCAPLUS
Guoyao, W	1998	366	1	Biochem J	
Hansson, G	1994	180	733	J Exp Med	HCAPLUS
Hill, C	1994	152	2890	J Immunol	HCAPLUS
Joly, G	1992	71	331	Circ Res	HCAPLUS
Kaye, D	1998	98	II-74	Circulation	
Kikuta, K	1998	83	1088	Circ Res	HCAPLUS
Kraiss, L	1997		289	The Basic Science of	
Masuda, H	1999	126	211	Br J Pharmacol	HCAPLUS
McNamara, D	1993	193	291	Biochem Biophys Res	HCAPLUS
Mitchell, D				To be published in P	
Morris, S	1994	266	E829	Am J Physiol	HCAPLUS
Motwani, J	1998	97	916	Circulation	MEDLINE
Nagase, S	1997	233	150	Biochem Biophys Res	HCAPLUS
Najbauer, J	1993	268	10501	J Biol Chem	HCAPLUS
Pastan, I	1981	214	504	Science	HCAPLUS
Pollman, M	1996	79	748	Circ Res	HCAPLUS
Ruben, S	1989	63	1	J Virol	HCAPLUS
Schwarzacher, S	1997	95	1863	Circulation	HCAPLUS
Tsao, P	1996	94	1682	Circulation	HCAPLUS
Tsao, P	1997	96	934	Circulation	HCAPLUS
Vallance, P	1992	20	560	J Cardiovasc Pharmac	
Vives, E	1997	272	16010	J Biol Chem	HCAPLUS
Wang, Q	1999	288	270	J Pharmacol Exp Ther	HCAPLUS
Weeks, K	1990	249	1281	Science	HCAPLUS
Yang, Z	1993	14	193	Eur Heart J	

L57 ANSWER 10 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:880980 HCAPLUS
DN 134:37025
TI Method and composition using an amino acid polymer for inhibiting cardiovascular cell proliferation
IN Cooke, John P.; Fathman, Garrison C.; **Rothbard, Jonathan B.**; Uemura, Shiro; Robbins, Robert C.
PA The Board of Trustees of the Leland Stanford Junior University, USA
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000074701	A2	20001214	WO 2000-US40125	20000605 <--
	WO 2000074701	A3	20010830		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2376375	AA	20001214	CA 2000-2376375	20000605 <--
	EP 1189623	A2	20020327	EP 2000-947622	20000605 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2003501393	T2	20030114	JP 2001-501235	20000605 <--
	AU 774185	B2	20040617	AU 2000-61195	20000605 <--
	EP 1656945	A1	20060517	EP 2005-77503	20000605 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	US 2006159719	A1	20060720	US 2005-316304	20051220 <--
	US 2006167402	A1	20060727	US 2005-316519	20051220 <--
PRAI	US 1999-137826P	P	19990605 <--		
	EP 2000-947622	A3	20000605 <--		
	US 2000-587647	A1	20000605 <--		
	WO 2000-US40125	W	20000605 <--		
	US 2003-442671	A1	20030520		

AB Cardiovascular cell proliferation in a blood vessel subjected to trauma, e.g. angioplasty, vascular graft, anastomosis, or organ transplant, can be inhibited by contacting the vessel with a polymer consisting of from 6 to about 30 amino acid subunits, where at least 50% of the subunits are arginine, and the polymer contains at least six contiguous arginine subunits. Exemplary polymers for this purpose include arginine homopolymers 7 to 15 subunits in length.

IT **143413-47-2 165893-48-1 312691-24-0**
312691-25-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid polymer for inhibiting cardiovascular cell proliferation)

IT **165893-48-1D**, biotinylated **216584-13-3D**, biotinylated
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(amino acid polymer for inhibiting cardiovascular cell proliferation)

IT **143413-47-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid polymer for inhibiting cardiovascular cell proliferation)

RN 143413-47-2 HCAPLUS

CN L-Arginine, L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-A



L57 ANSWER 11 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:846954 HCAPLUS

DN 134:183382
TI The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters
AU **Wender, Paul A.**; Mitchell, Dennis J.; Pattabiraman, Kanaka; Pelkey, Erin T.; Steinman, Lawrence; **Rothbard, Jonathan B.**
CS Department of Chemistry, Stanford University, Stanford, CA, 94305-5080, USA
SO Proceedings of the National Academy of Sciences of the United States of America (**2000**), 97(24), 13003-13008
CODEN: PNASA6; ISSN: 0027-8424
PB National Academy of Sciences
DT Journal
LA English
AB Certain proteins contain subunits that enable their active translocation across the plasma membrane into cells. In the specific case of HIV-1, this subunit is the basic domain Tat49-57 (RKKRRQRRR). To establish the optimal structural requirements for this translocation process, and thereby to develop improved mol. transporters that could deliver agents into cells, a series of analogs of Tat49-57 were prepared and their cellular uptake into Jurkat cells was determined by flow cytometry. All truncated and alanine-substituted analogs exhibited diminished cellular uptake, suggesting that the cationic residues of Tat49-57 play a principal role in its uptake. Charge alone, however, is insufficient for transport as oligomers of several cationic amino acids (histidine, lysine, and ornithine) are less effective than Tat49-57 in cellular uptake. In contrast, a 9-mer of L-arginine (R9) was 20-fold more efficient than Tat49-57 at cellular uptake as determined by Michaelis-Menton kinetic anal. The D-arginine oligomer (r9) exhibited an even greater uptake rate enhancement (>100-fold). Collectively, these studies suggest that the guanidinium groups of Tat49-57 play a greater role in facilitating cellular uptake than either charge or backbone structure. Based on this anal., we designed and synthesized a class of polyguanidine peptoid derivs. Remarkably, the subset of peptoid analogs containing a six-methylene space between the guanidine head group and backbone (N-hxg), exhibited significantly enhanced cellular uptake compared to Tat49-57 and even to r9. Overall, a transporter has been developed that is superior to Tat49-57, protease resistant, and more readily and economically prepared
IT **123251-89-8**
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(design, synthesis, and evaluation of peptoid mol. transporters that enable or enhance cellular uptake)
IT **123251-89-8**
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(design, synthesis, and evaluation of peptoid mol. transporters that enable or enhance cellular uptake)
RN 123251-89-8 HCAPLUS
CN L-Arginine, L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anderson, D	1993	194	876	Biochem Biophys Res	HCAPLUS
Atherton, E	1989			Solid-Phase Peptide	
Bernatowicz, M	1992	57	2497	J Org Chem	HCAPLUS
Buschle, M	1997	94	3256	Proc Natl Acad Sci U	HCAPLUS
Derossi, D	1998	8	84	Trends Cell Biol	HCAPLUS
Elliott, G	1997	88	223	Cell	HCAPLUS
Emi, N	1997	231	421	Biochem Biophys Res	HCAPLUS
Fawell, S	1994	91	664	Proc Natl Acad Sci U	HCAPLUS
Feichtinger, K	1998	63	8432	J Org Chem	HCAPLUS
Frankel, A	1988	55	1189	Cell	HCAPLUS
Ghosh, A	1996	3	1011	Chem Biol	HCAPLUS
Gius, D	1999	59	2577	Cancer Res	HCAPLUS
Green, M	1988	55	1179	Cell	HCAPLUS
Hamy, F	1997	94	3548	Proc Natl Acad Sci U	HCAPLUS

Heizmann, G	1994	7	328	Peptide Res	HCAPLUS
Jeang, K	1999	274	28837	J Biol Chem	HCAPLUS
Kim, D	1997	159	1666	J Immunol	HCAPLUS
Kono, K	1999	10	1115	Bioconjugate Chem	HCAPLUS
Kruijtzer, J	1998	4	1570	Chem Eur J	HCAPLUS
Leonetti, J	1990	1	149	Bioconjugate Chem	HCAPLUS
Lin, Y	1995	270	14255	J Biol Chem	HCAPLUS
Lindgren, M	2000	21	99	Trends Pharmacol Sci	HCAPLUS
Mann, D	1991	10	1733	EMBO J	HCAPLUS
Miller, S	1994	4	2657	Bioorg Med Chem Lett	HCAPLUS
Mitchell, D	2000	55		to be published in J	
Mulders, P	1998	58	956	Cancer Res	HCAPLUS
Murphy, J	1998	95	1517	Proc Natl Acad Sci U	HCAPLUS
Nagahara, H	1998	4	1449	Nat Med	HCAPLUS
Pepinsky, R	1994	13	1011	DNA Cell Biol	HCAPLUS
Pons, J	1998		853	Eur J Org Chem	HCAPLUS
Pooga, M	1998	12	67	FASEB J	HCAPLUS
Rait, A	2000	11	153	Bioconjugate Chem	HCAPLUS
Rui, Y	1998	120	11213	J Am Chem Soc	HCAPLUS
Ryser, H	1967	215	934	Nature (London)	HCAPLUS
Ryser, H	1978	75	3867	Proc Natl Acad Sci U	HCAPLUS
Sandvig, K	1982	257	7504	J Biol Chem	HCAPLUS
Schwarze, S	1999	285	1569	Science	HCAPLUS
Shen, W	1978	75	1872	Proc Natl Acad Sci U	HCAPLUS
Simon, R	1992	89	9367	Proc Natl Acad Sci U	HCAPLUS
Tamilarasu, N	1999	121	1597	J Am Chem Soc	HCAPLUS
Terwogt, J	1997	23	87	Cancer Treat Rev	HCAPLUS
Vives, E	1997	272	16010	J Biol Chem	HCAPLUS
Vives, E	1994	68	3343	J Virol	HCAPLUS
Vives, E	1997	4	429	Lett Pept Sci	HCAPLUS
Vocero-Akbani, A	1999	5	29	Nat Med	HCAPLUS
Zuckermann, R	1992	114	10646	J Am Chem Soc	HCAPLUS

L57 ANSWER 12 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:802976 HCAPLUS
DN 134:152475
TI Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation
AU **Rothbard, Jonathan B.**; Garlington, Sarah; Lin, Qun; Kirschberg, Thorsten; **Kreider, Erik**; McGrane, Leo P.; **Wender, Paul A.**; Khavari, Paul A.
CS CellGate, Sunnyvale, CA, 94086, USA
SO Nature Medicine (New York) (**2000**), 6(11), 1253-1257
CODEN: NAMEFI; ISSN: 1078-8956
PB Nature America Inc.
DT Journal
LA English
AB Many systemically effective drugs such as cyclosporin A are ineffective topically because of their poor penetration into skin. To surmount this problem, we conjugated a heptamer of arginine to cyclosporin A through a pH-sensitive linker to produce R7-CsA. In contrast to unmodified cyclosporin A, which fails to penetrate skin, topically applied R7-CsA was efficiently transported into cells in mouse and human skin. R7-CsA reached dermal T lymphocytes and inhibited cutaneous inflammation. These data establish a general strategy for enhancing delivery of poorly absorbed drugs across tissue barriers and provide a new topical approach to the treatment of inflammatory skin disorders.
IT **165893-48-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(conjugation of arginine oligomers to cyclosporin A facilitates topical

delivery and inhibition of inflammation)

IT **165893-48-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation)

RN 165893-48-1 HCAPLUS

CN L-Arginine, L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bach, M	1998	46	1	Eur J Pharm Biopharm	HCAPLUS
Baumann, L	1999		2713	Topical Glucocortico	
Berth-Jones, J	1996	135	775	Br J Dermatol	MEDLINE
Berth-Jones, J	1997	136	76	Br J Dermatol	HCAPLUS
Berti, J	1995	70	581	Mayo Clinic Proc	MEDLINE
Choate, K	1996	2	1263	Nature Med	HCAPLUS
de Prost, Y	1986	2	803	Lancet	MEDLINE
De Rie, M	1991	71	452	Acta Derm Venereol	MEDLINE
Derossi, D	1994	269	10444	J Biol Chem	HCAPLUS
Doering, T	1999	274	11038	J Biol Chem	HCAPLUS

Duncan, J	1993	73	84	Acta Derm Venereol	MEDLINE
Furlanut, M	1996	33	349	Pharmacol Res	HCAPLUS
Ghadially, R	1995	95	2281	J Clin Invest	HCAPLUS
Gilbertson, E	1998	38	318	J Am Acad Dermatol	MEDLINE
Gilhar, A	1989	69	252	Acta Derm Venereol	MEDLINE
Hadgraft, J	1998	3	131	J Invest Dermatol Sy	HCAPLUS
Handschumacher, R	1984	226	544	Science	HCAPLUS
Ho, V	1999	141	283	Br J Dermatol	HCAPLUS
Kim, D	1997	159	1666	J Immunol	HCAPLUS
Klemm, J	1998	16	569	Annu Rev Immunol	HCAPLUS
Koo, J	1998	139	88	Br J Dermatol	HCAPLUS
Miyachi, Y	1982	118	451	Arch Dermatol	MEDLINE
Mrowietz, U	1992	72	321	Acta Derm Venereol	MEDLINE
Naeyaert, J	1999	198	145	Dermatology	HCAPLUS
Nagahara, H	1998	4	1449	Nature Med	HCAPLUS
Oikarinen, A	1998	139	1106	Br J Dermatol	HCAPLUS
Powles, A	1998	138	443	Br J Dermatol	HCAPLUS
Prochiantz, A	2000	12	400	Curr Opin Cell Biol	HCAPLUS
Proksch, E	1993	128	473	Br J Dermatol	HCAPLUS
Ranade, V	1991	31	401	J Clin Pharmacol	MEDLINE
Roberts, M	1997	24	874	Clin Exp Pharmacol P	HCAPLUS
Schmook, F	1993	6	116	Skin Pharmacol	HCAPLUS
Schwarze, S	2000	10	290	Trends Cell Biol	HCAPLUS
Sieg, P	1995	132	790	Br J Dermatol	MEDLINE
Simpson, J	1998	20	294	Ther Drug Monit	HCAPLUS
Sowden, J	1991	338	137	Lancet	MEDLINE
Surber, C	1992	26	116	Contact Dermatitis	MEDLINE
Wiskocil, R	1985	134	1599	J Immunol	HCAPLUS

L57 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:785678 HCAPLUS
DN 134:113485
TI Polyarginine enters cells more efficiently than other polycationic homopolymers
AU Mitchell, D. J.; Kim, D. T.; Steinman, L.; Fathman, C. G.; **Rothbard, J. B.**
CS Department of Neurology, Stanford University, Stanford, CA, USA
SO Journal of Peptide Research (**2000**), 56(5), 318-325
CODEN: JPERFA; ISSN: 1397-002X
PB Munksgaard International Publishers Ltd.
DT Journal
LA English
AB Homopolymers or peptides containing a high percentage of cationic amino acids have been shown to have a unique ability to cross the plasma membrane of cells, and consequently have been used to facilitate the uptake of a variety of biopolymers and small mols. To investigate whether the polycationic character of these mols., or some other structural feature, was the mol. basis for the effect, the ability of a variety of homopolymers to enter cells was assayed by confocal microscopy and flow cytometry. Polymers of L- or D-arginine containing six or more amino acids entered cells far more effectively than polymers of equal length composed of lysine, ornithine and histidine. Peptides of fewer than six amino acids were ineffective. The length of the arginine side-chain could be varied without significant loss of activity. These data combined with the inability of polymers of citrulline to enter cells demonstrated that the guanidine headgroup of arginine was the critical structural component responsible for the biol. activity. Cellular uptake could be inhibited by pre-incubation of the cells with sodium azide, but not by low temperature (3°C), indicating that the process was energy dependent, but did not involve endocytosis.

IT **143413-47-2 153127-44-7 165893-48-1**
216584-13-3 320351-21-1 320616-11-3
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(polyarginine uptake by cell membrane and intracellular transport)

IT **143413-47-2**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(polyarginine uptake by cell membrane and intracellular transport)

RN 143413-47-2 HCAPLUS

CN L-Arginine, L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-A



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Arnold, L	1979	76	3246	Proc Natl Acad Sci U	HCAPLUS
Bernatowicz, M	1992	57	2497	J Org Chem	HCAPLUS
Brugidou, J	1995	214	685	Biochem Biophys Res	HCAPLUS
Curiel, D	1994	716	36	Ann NY Acad Sci	HCAPLUS
Frankel, A	1988	55	1189	Cell	HCAPLUS
Gordon, A	1972			The Chemist's Compan	
Green, M	1988	55	1179	Cell	HCAPLUS
Harrison, J	1998	26	3136	Nucleic Acids Res	HCAPLUS
Hill, C	1994	152	2890	J Immunol	HCAPLUS
Hwang, P	1998	76	235	Biochem Cell Biol	HCAPLUS
Laurent, N	1999	443	61	FEBS Lett	HCAPLUS
Mahato, R	1997	14	133	Crit Rev Ther Drug C	HCAPLUS
Midoux, P	1998	9	260	Bioconjugate Chem	HCAPLUS
Phillips, S	1995	23	13	Biologicals	MEDLINE
Ryser, H	1989			US 4847240	HCAPLUS
Ryser, H	1982	113	167	J Cell Physiol	HCAPLUS
Ryser, H	1967	215	934	Nature	HCAPLUS
Ryser, H	1978	75	3867	Proc Natl Acad Sci U	HCAPLUS
Ryser, H	1965	150	501	Science	MEDLINE
Shen, W	1978	75	1872	Proc Natl Acad Sci U	HCAPLUS
Uemura, S				to be published in C	
Wagner, E	1990	87	3410	Proc Natl Acad Sci U	HCAPLUS
Wu, G	1991	3	87	Biothera	HCAPLUS

L57 ANSWER 14 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:789054 HCAPLUS
DN 130:57169
TI Polymer conjugates for enhancing drug transport across biological membranes
IN **Rothbard, Jonathan B.; Wender, Paul A.**
PA The Board of Trustees of the Leland Stanford Junior University, USA
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9852614	A2	19981126	WO 1998-US10571	19980521 <--
	WO 9852614	A3	19990318		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW

```
        RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
            FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
            CM, GA, GN, ML, MR, NE, SN, TD, TG
    CA 2291074          AA    19981126    CA 1998-2291074        19980521 <--
    AU 9875938          A1    19981211    AU 1998-75938          19980521 <--
    AU 734827           B2    20010621
    EP 975370           A2    20000202    EP 1998-923711         19980521 <--
    EP 975370           B1    20031015
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
    GB 2341390          A1    20000315    GB 1999-23841          19980521 <--
    GB 2341390          B2    20001108
    BR 9809138          A     20010828    BR 1998-9138           19980521 <--
    US 6306993          B1    20011023    US 1998-83259          19980521 <--
    JP 2002502376       T2    20020122    JP 1998-550716         19980521 <--
    EP 1304122          A2    20030423    EP 2003-75137          19980521 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL
    AT 251913           E     20031115    AT 1998-923711         19980521 <--
    ES 2210761          T3    20040701    ES 1998-923711         19980521 <--
    US 6495663          B1    20021217    US 1999-396195         19990914 <--
    US 2002131965       A1    20020919    US 2001-957161         20010919 <--
    US 2003162719       A1    20030828    US 2003-338348         20030107 <--
    US 2006111274       A1    20060525    US 2006-335007         20060118 <--
PRAI US 1997-47345P     P     19970521  <--
    EP 1998-923711      A3    19980521  <--
    US 1998-83259       A1    19980521  <--
    WO 1998-US10571     W     19980521  <--
    US 1999-396194      B1    19990914  <--
    US 1999-396195      A1    19990914  <--
    US 2003-338348      A1    20030107
```

AB Methods and compns. for transporting drugs and macromols. across biol. membranes are disclosed. In one embodiment, the invention includes a method for enhancing transport of a selected compound across a biol. membrane, wherein a biol. membrane is contacted with a conjugate containing a biol. active agent that is covalently attached to a transport polymer. In one embodiment, the polymer consists of from 6 to 25 subunits, at least 50 % of which contain a guanidino or amidino side-chain moiety. The polymer is effective to impart to the attached agent a rate of trans-membrane transport across a biol. membrane that is greater than the rate of trans-membrane transport of the agent in non-conjugated form.

IT **123251-89-8 143413-47-2 153127-44-7**
165893-48-1 216584-13-3
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(polymer conjugates for enhancing drug transport across biol. membranes)

IT **123251-89-8**
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(polymer conjugates for enhancing drug transport across biol. membranes)

RN 123251-89-8 HCAPLUS

CN L-Arginine, L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L57 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:534575 HCAPLUS
DN 127:246793
TI Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide
AU Kim, Dewey T.; Mitchell, Dennis J.; Brockstedt, Dirk G.; Fong, Lawrence; Nolan, Garry P.; Fathman, C. Garrison; Engleman, Edgar G.; **Rothbard, Jonathan B.**
CS Dep. Med., Neurology, Pharmacology, and Pathology, Stanford Univ. Sch. Med., Stanford, CA, 94305, USA
SO Journal of Immunology (**1997**), 159(4), 1666-1668
CODEN: JOIMA3; ISSN: 0022-1767
PB American Association of Immunologists
DT Journal
LA English
AB Protection against most intracellular pathogens requires T cells that recognize pathogen-derived peptides in association with MHC class I mols. on

the surface of infected cells. However, because exogenous proteins do not ordinarily enter the cytosol and access the MHC class I-processing pathway, protein-based vaccines that induce class I-restricted CTL responses have proved difficult to design. The authors addressed this problem by conjugating proteins, such as OVA, to a short cationic peptide derived from HIV-1 tat (residues 49-57). When APC were exposed in vitro to such protein conjugates, they processed and presented the peptides in association with MHC class I mols. and stimulated CD8+ antigen (Ag)-specific T cells. Moreover, Ag-specific CTLs were generated in vivo by immunizing mice with histocompatible dendritic cells that had been exposed to protein-tat conjugates.

IT **123251-89-8**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soluble proteins introduction into MHC class I pathway by conjugation to HIV tat peptide)

IT **123251-89-8**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soluble proteins introduction into MHC class I pathway by conjugation to HIV tat peptide)

RN 123251-89-8 HCAPLUS

CN L-Arginine, L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Allsopp, C	1996	26	1951	Eur J Immunol	HCAPLUS
Carbone, F	1988	167	1767	J Exp Med	HCAPLUS
Carbone, F	1989	169	603	J Exp Med	HCAPLUS
Cresswell, P	1994	12	259	Annu Rev Immunol	HCAPLUS
Elbe, A	1995	378	341	Adv Exp Med Biol	HCAPLUS
Fawell, S	1994	91	664	Proc Natl Acad Sci U	HCAPLUS
Flamand, V	1994	24	605	Eur J Immunol	MEDLINE
Frankel, A	1988	55	1189	Cell	HCAPLUS
Germain, R	1995	754	114	Ann NY Acad Sci	HCAPLUS
Heemels, M	1995	64	463	Annu Rev Biochem	HCAPLUS
Hill, C	1994	152	2890	J Immunol	HCAPLUS
Hsu, F	1996	2	52	Nat Med	HCAPLUS
Kalish, R	1995	32	640	J Am Acad Dermatol	MEDLINE
Kim, D	1996	156	2737	J Immunol	HCAPLUS
Mayordomo, J	1995	I	1297	Nat Med	
Mehta-Damani, A	1994	153	996	J Immunol	HCAPLUS
Monaco, J	1995	57	543	J Leukocyte Biol	HCAPLUS
Moore, M	1988	54	777	Cell	HCAPLUS
Nonacs, R	1992	176	519	J Exp Med	HCAPLUS
Norbury, C	1995	3	783	Immunity	HCAPLUS
Paglia, P	1996	183	317	J Exp Med	HCAPLUS
Pepinsky, R	1994	13	1011	DNA Cell Biol	HCAPLUS
Porgador, A	1995	182	255	J Exp Med	HCAPLUS
Powis, S	1991	354	528	Nature	HCAPLUS
Rotzschke, O	1991	21	2891	Eur J Immunol	MEDLINE
Zitvogel, L	1996	183	87	J Exp Med	HCAPLUS

=> d l59 bib abs hitrn fhitstr retable tot

L59 ANSWER 1 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:740582 HCAPLUS
DN 145:180963
TI Membrane-permeable fusion proteins of tat and anti-apoptopic proteins for treatment of sepsis
IN Hotchkiss, Richard; Piwnica-Worms, David; Mcdunn, Jonathan
PA USA
SO U.S. Pat. Appl. Publ., 56 pp., Cont.-in-part of U.S. Ser. No. 374,035.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	US 2006166881	A1	20060727	US 2005-286920	20051123 <--
	US 6348185	B1	20020219	US 1999-336093	19990618 <--
	US 6589503	B1	20030708	US 2000-557465	20000425 <--
	US 2003219375	A1	20031127	US 2003-368280	20030218 <--
	US 2003219378	A1	20031127	US 2003-374035	20030225 <--
PRAI	US 1998-90087P	P	19980620 <--		
	US 1999-336093	A2	19990618 <--		
	US 2000-557465	A3	20000425 <--		
	US 2003-368280	A2	20030218		
	US 2003-374035	A2	20030225		

AB Membrane permeable fusion proteins of anti-apoptopic proteins of the Bcl-2 family with cell membrane-penetrating peptide of the tat protein of human immunodeficiency virus are described for use in the prevention of large-scale apoptosis in the treatment of sepsis. Fusion proteins of the same tat peptide and a peptide complex with technetium99m are described for use in diagnostic imaging. Preparation of the fusion proteins, either by chem synthesis or expression of the corresponding gene is described. Fusion proteins of the tat peptide and the BH4 domain of Bcl-Xl improved survival in the rat cecal ligation and puncture model of sepsis and also promoted the survival of lymphocytes in vivo and in vitro.

IT **143413-47-2 627881-61-2**
RL: PRP (Properties)
(unclaimed sequence; membrane-permeable fusion proteins of tat and anti-apoptopic proteins for treatment of sepsis)

IT **143413-47-2**
RL: PRP (Properties)
(unclaimed sequence; membrane-permeable fusion proteins of tat and anti-apoptopic proteins for treatment of sepsis)

RN 143413-47-2 HCAPLUS

CN L-Arginine, L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-A



L59 ANSWER 2 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1224630 HCAPLUS
DN 143:476398
TI Antibodies that immunospecifically bind to B lymphocyte stimulator and their use in diagnosis and treatment of autoimmune disease
IN Ruben, Steven M.; Barash, Steven C.; Choi, Gil H.; Vaughan, Tristan; Hilbert, David
PA USA
SO U.S. Pat. Appl. Publ., 240 pp., Cont.-in-part of Ser. No. US 2002-293418, filed on 14 Nov 2002 whichCont.-in-pa
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 19

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005255532	A1	20051117	US 2005-54515	20050210 <--
	EP 1577391	A1	20050921	EP 2005-12261	19961025 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 2003059937	A1	20030327	US 2001-880748	20010615 <--
	AU 2001054180	A5	20020725	AU 2001-54180	20010703 <--
	AU 779750	B2	20050210		
	US 2003223996	A1	20031204	US 2002-293418	20021114 <--
	JP 2004129667	A2	20040430	JP 2003-362615	20031022 <--
	US 2006062789	A1	20060323	US 2005-266444	20051104 <--
PRAI	US 2000-212210P	P	20000616 <--		
	US 2000-240816P	P	20001017 <--		
	US 2001-276248P	P	20010316 <--		

US 2001-277379P	P	20010321	<--
US 2001-293499P	P	20010525	<--
US 2001-880748	A2	20010615	<--
US 2001-331469P	P	20011116	<--
US 2001-340817P	P	20011219	<--
US 2002-293418	A2	20021114	
US 2004-543296P	P	20040211	
US 2004-580347P	P	20040618	
AU 1996-76745	A3	19961025	<--
EP 1996-939612	A3	19961025	<--
JP 1998-520411	A3	19961025	<--

AB The present invention relates to 2128 VH and VL domains of single-chain antibodies and related mols. that immunospecifically bind to B Lymphocyte Stimulator (BLyS). The present invention also relates to methods and compns. for detecting or diagnosing a disease or disorder associated with aberrant BLyS expression or inappropriate function of BLyS comprising antibodies or fragments or variants thereof or related mols. that immunospecifically bind to BLyS. The present invention further relates to methods and compns. for preventing, treating or ameliorating a disease or disorder associated with aberrant BLyS expression or inappropriate BLyS function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related mols. that immunospecifically bind to BLyS.

IT **389116-42-1**
RL: PRP (Properties)
(unclaimed protein sequence; antibodies that immunospecifically bind to B lymphocyte stimulator and their use in diagnosis and treatment of autoimmune disease)

IT **389116-42-1**
RL: PRP (Properties)
(unclaimed protein sequence; antibodies that immunospecifically bind to B lymphocyte stimulator and their use in diagnosis and treatment of autoimmune disease)

RN 389116-42-1 HCAPLUS

CN L-Arginine, L-arginyl-L-leucyl-L-isoleucyl-L-arginyl-L-lysyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L59 ANSWER 3 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:238548 HCAPLUS
DN 142:294256
TI Use of HIV Tat peptides complexed with semiconductor nanocrystals for enhancing transport across cell membranes and their use in high throughput drug screening assays
IN Bruchez, Marcel P.; Daniels, R. Hugh; Dias, Jennifer; Mattheakis, Larry C.; Liu, Hongjian; Burt, Aquanette M.; Christoffer, Berndt; Ly, Danith H.
PA Quantum Dot Corporation, USA
SO U.S. Pat. Appl. Publ., 60 pp., Cont.-in-part of U.S. Ser. No. 972,744.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005059031	A1	20050317	US 2003-735608	20031212 <--
US 2002155507	A1	20021024	US 2001-972744	20011005 <--
US 2004023261	A1	20040205	US 2003-374652	20030226 <--
CA 2550151	AA	20050909	CA 2004-2550151	20041206
WO 2005081721	A2	20050909	WO 2004-US41045	20041206
WO 2005081721	A3	20060316		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-238677P P 20001006 <--
US 2001-312558P P 20010815 <--
US 2001-972744 A2 20011005 <--
US 2003-735608 A 20031212
WO 2004-US41045 W 20041206

AB The present invention relates to use of HIV Tat peptides complexed with semiconductor nanocrystals for enhancing transport across cell membranes and their use in high throughput drug screening assays. The methods are particularly useful in multiplex settings where a plurality of encoded cells are to be assayed. Kits comprising reagents for performing such methods are also provided.

IT **123251-89-8**
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(Tat peptide sequence; use of HIV Tat peptides complexed with semiconductor nanocrystals for enhancing transport across cell membranes and their use in high throughput drug screening assays)

IT **123251-89-8**
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(Tat peptide sequence; use of HIV Tat peptides complexed with semiconductor nanocrystals for enhancing transport across cell membranes and their use in high throughput drug screening assays)

RN 123251-89-8 HCAPLUS

CN L-Arginine, L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L59 ANSWER 4 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:207840 HCAPLUS
DN 142:274073
TI Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
IN Turley, Eva A.; Cruz, Tony F.
PA Can.
SO U.S., 115 pp., Cont.-in-part of U.S. Ser. No. 541,522, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6864235	B1	20050308	US 2000-685010	20001005 <--
	US 2003100490	A1	20030529	US 2001-978309	20011015 <--
	US 6911429	B2	20050628		
	US 2005058646	A1	20050317	US 2004-898675	20041129 <--
	US 2005065085	A1	20050324	US 2004-892831	20041129 <--
PRAI	US 1999-127457P	P	19990401 <--		
	US 2000-541522	B2	20000403 <--		
	US 2000-685010	A2	20001005 <--		
	US 2001-978309	A3	20011015 <--		

AB The present invention provides compns. and methods for treating a tissue disorder associated with a response-to-injury process or proliferating cells in a mammal. The tissue disorders include fibrosis, inflammation, degeneration and invasive disorders such as those occur in cancerous cells. The invention provides methods for detecting hyaluronic acid in a sample comprising: incubating the sample with RHAMM polypeptide and with RHAMM-binding protein and detecting the complex formed by using antibody. The methods provided herein include administering to the mammal, an effective amount of a composition that alters the activity of transition mols. within a cell. Transition mols. are shown to be comprised of hyaladherins, hyaluronans and associated mols. that regulate the transitional phenotype.

IT **410521-18-5 410521-34-5 410521-35-6**
410521-42-5
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synthetic peptide; compns. and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans)

IT **410521-18-5**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synthetic peptide; compns. and methods for treating cellular response

to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans)

RN 410521-18-5 HCAPLUS

CN L-Arginine, L-arginylglycylglycylglycyl-L-arginylglycyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Agrafiotis	1995			US 5463564 A	
Alting-Mees	1990	3	1	Strategies in Molecu	
Anon	1989			WO 8901973	HCAPLUS
Anon	1990			WO 9002809	HCAPLUS
Anon	1990			WO 9007862	
Anon	1990			WO 9007936	HCAPLUS
Anon	1991			EP 0415731 A2	HCAPLUS
Anon	1991			EP 0440219 A1	HCAPLUS
Anon	1991			WO 9100285	HCAPLUS
Anon	1992			WO 9215677	HCAPLUS
Anon	1992			WO 9215679	HCAPLUS
Anon	1993			WO 9310218	HCAPLUS
Anon	1993			WO 9311230	HCAPLUS
Anon	1993			WO 9312227	HCAPLUS
Anon	1993			WO 9320242	HCAPLUS
Anon	1993			WO 9321312	HCAPLUS
Anon	1993			WO 9321312	HCAPLUS
Anon	1993			WO 9325234	HCAPLUS
Anon	1993			WO 9325698	HCAPLUS
Anon	1994			EP 0612844 A2	HCAPLUS
Anon	1994			WO 9206693	HCAPLUS
Anon	1994			WO 9403622	HCAPLUS
Anon	1995			WO 9502566	HCAPLUS
Anon	1995			WO 9504277	HCAPLUS
Anon	1995			WO 9510607	HCAPLUS
Anon	1995			WO 9512387	HCAPLUS
Anon	1995			WO 9516209	HCAPLUS
Anon	1995			WO 9516712	HCAPLUS
Anon	1995			WO 9516918	HCAPLUS
Anon	1995			WO 9524186	HCAPLUS
Anon	1995			WO 9524929	HCAPLUS
Anon	1995			WO 9530642	HCAPLUS
Anon	1996			EP 0360257 B1	HCAPLUS
Anon	1996			EP 0721012	HCAPLUS
Anon	1996			WO 9600148	HCAPLUS
Anon	1997			WO 9738098	HCAPLUS
Anon	1997			WO 9738098	HCAPLUS
Anon	1999			EP 0950708	HCAPLUS

Anon	1999			WO 9901164	HCAPLUS
Anon	2000			WO 0001841	HCAPLUS
Anon	2000			WO 0029447	HCAPLUS
Anon	2000			WO 0039166	HCAPLUS
Anon	2001			WO 0180899	HCAPLUS
Anon	2002			WO 0213848	HCAPLUS
Anon	2002			WO 0228415	HCAPLUS
Anon	2001			PCT/I00/01534	
Assmann, V	1999	112	3943	J Cell Sci	HCAPLUS
Barber	1997			US 5591624 A	HCAPLUS
Barber	1998			US 5716832 A	HCAPLUS
Bauer	1985	37	73	Gene	HCAPLUS
Bird	1988	242	423	Science	HCAPLUS
Bosselman	1992			US 5162215 A	HCAPLUS
Brinster	1985	82	4438	PNAS	HCAPLUS
Byrne	1993			US 5221778 A	HCAPLUS
Cech	1991			US 4987071 A	HCAPLUS
Chao	1996	174	299	Gene	
Cheung, W	1999		135	Biochemical Society	HCAPLUS
Chothia	1985	186	651	Journal of Molecular	HCAPLUS
Cleeland	1977			US 4018884 A	HCAPLUS
Cook	1994			US 5359051 A	HCAPLUS
Cordell	1995			US 5387742 A	HCAPLUS
Craik	1985	3	12	BioTechniques	HCAPLUS
Curiel	1992	3	147	Human Gene Therapy	MEDLINE
David	1983			US 4376110 A	HCAPLUS
David	1984			US 4486530 A	HCAPLUS
Day, A	2002	277	4585	J Biol Chem	HCAPLUS
Deboer	1985			US 4551433 A	HCAPLUS
Deboer	1997			US 5633076 A	HCAPLUS
Deboer	1998			US 5741957 A	HCAPLUS
Dillon	1995			US 5395750 A	HCAPLUS
Drinkwater	1986	83	3402	PNAS	HCAPLUS
Dubensky	1998			US 5789245 A	HCAPLUS
Dubensky	1998			US 5814482 A	HCAPLUS
Dubensky	1998			US 5843723 A	HCAPLUS
Ellman	1994			US 5288514 A	HCAPLUS
Evans	1989			US 4870009 A	HCAPLUS
Felgner	1996			US 5580859 A	HCAPLUS
Fell	1993			US 5204244 A	HCAPLUS
Fell	1996			US 5482856 A	HCAPLUS
Fernandez-Pol	1993			US 5243041 A	HCAPLUS
Fisher-Hoch	1989	86	317	PNAS	HCAPLUS
Flexner	1990	8	17	Vaccine	MEDLINE
Forster	1987	49	211	Cell	HCAPLUS
Frackelton	1985			US 4543439 A	HCAPLUS
Fritzberg	1990			US 4897255 A	HCAPLUS
Gerlach	1987	328	802	Nature	HCAPLUS
Gillis	1983			US 4411993 A	HCAPLUS
Gruber	1998			US 5716826 A	
Guber	1998			US 5716613 A	HCAPLUS
Guber	1998			US 5851529 A	HCAPLUS
Gunner Von, H	1985	184	99	Journal of Molecular	
Hamilton	1998			US 5770380 A	HCAPLUS
Hammer	1985	315	680	Nature	HCAPLUS
Haseloff	1993			US 5254678 A	HCAPLUS
Haseloff	1988	334	585	Nature	HCAPLUS
Hew	1996			US 5545808 A	HCAPLUS
Hirashima	1987		401	Molecular Biology of	
Hopp	1989			US 4851341 A	HCAPLUS

Hopp	1988	6	1204	BioTechnology	HCAPLUS
Horwitz	1989	3	112	Genome	
Huang	1993			US 5217879 A	HCAPLUS
Huse	1989	246	1275	Science	HCAPLUS
Inman	1974	34	30	Methods in Enzymolog	HCAPLUS
Jean	2001	268	544	European Journal of	HCAPLUS
Jones	1986	321	522	Nature	HCAPLUS
Karatzas	1998			US 5780009 A	HCAPLUS
Kit, S	1989	215	219	Adv Exp Med Biol	
Kohler	1975	256	495	Nature	MEDLINE
Krimpenfort	1992			US 5175384 A	HCAPLUS
Kuhns, W	1998	195	216	Biol Bull	HCAPLUS
Kyte	1982	157	105	Journal of Molecular	HCAPLUS
Leder	1988			US 4736866 A	HCAPLUS
Leder	1992			US 5087571 A	HCAPLUS
Leder	1992			US 5175383 A	HCAPLUS
Liao	1990	88	107	Gene	HCAPLUS
Little	1998			US 5840479 A	HCAPLUS
Look	1996	6	707	Biorganic and Medici	HCAPLUS
Luytjes	1989	59	1107	Cell	HCAPLUS
McMichael	1983	309	13	The New England Jour	MEDLINE
Miller	1993			US 5219740 A	HCAPLUS
Morgan	1992			US 5106951 A	HCAPLUS
Morrison	1984	81	6851	PNAS	HCAPLUS
Mosbach	1992			US 5110833 A	HCAPLUS
Moss	1989	569	86	Annals of the New Yo	MEDLINE
Mulligan	1979	277	108	Nature	HCAPLUS
Ngo	1994			US 5328834 A	HCAPLUS
Novotny	1985	82	4592	PNAS	HCAPLUS
Palese	1992			US 5166057 A	HCAPLUS
Palmiter	1985	41	343	Cell	HCAPLUS
Palmiter	1983	222	809	Science	HCAPLUS
Paoletti	1986			US 4603112 A	HCAPLUS
Paoletti	1988			US 4769330 A	HCAPLUS
Pavanasasivam	1988			US 4744981 A	HCAPLUS
Phillips	1996	37	4887	Tet Letters	HCAPLUS
Pieczenik	1982			US 4359535 A	HCAPLUS
Pieczenik	1985			US 4528266 A	HCAPLUS
Poznansky	1991	65	532	Journal of Virology	HCAPLUS
Presta	1992	2	593	Current Op Struct Bi	HCAPLUS
Queen	1997			US 5693761 A	HCAPLUS
Queen	1997			US 5693762 A	HCAPLUS
Reisner	1998			US 5849288 A	HCAPLUS
Riechmann	1988	332	323	Nature	HCAPLUS
Robinson	1997			US 5698435 A	HCAPLUS
Roizman	1994			US 5288641 A	HCAPLUS
Ruhland	1996	118	253	J Am Chem Soc	HCAPLUS
Sastry	1989	86	5728	PNAS	HCAPLUS
Savani	1995	XVII	141	Inc J Tiss Reac	
Scatchard	1949	51	660	Annals of The New Yo	
Schlesinger	1992			US 5091309 A	HCAPLUS
Smith	1988			US 4745051 A	HCAPLUS
Smith	1981	3	1	Genetic Engineering	
Snyder	1989			US 4816597 A	HCAPLUS
Sorge	1994			US 5347075 A	HCAPLUS
Srinivasan	1991			US 4988496 A	HCAPLUS
Stein	1993	261	1004	Science	HCAPLUS
Stunnenberg	1991			US 5017487 A	HCAPLUS
Summers	1992			US 5169784 A	HCAPLUS
Summerton	1996			US 5506337 A	HCAPLUS

Tomalski	1993			US 5266317 A	HCAPLUS
Turkey	2000			U S Patent applicati	
Turley	2001			US 6271344 B1	HCAPLUS
Tykocinski	1993			US 5242687 A	HCAPLUS
Volker	1998	111	1685	J Cell Science	
Wagner	1989			US 4873191 A	HCAPLUS
Wakabayashi	1990			US 4902614 A	HCAPLUS
Walbot	1988	334	196	Nature	
Walder	1986	42	133	Gene	HCAPLUS
Wang	1999			US 5872005 A	HCAPLUS
Wang	1998	4	567	Clinical Cancer Rese	MEDLINE
Wigler	1998			US 5780225 A	HCAPLUS
Wilchek	1988	171	1	Analytical Biochemis	HCAPLUS
Winter	1993			US 5225539 A	HCAPLUS
Wu	1989	264	16985	The Journal of Biolo	HCAPLUS
Yap	1978	273	238	Nature	MEDLINE
Yee	1998			US 5817491 A	HCAPLUS
Zhao	1996			US 5567607 A	HCAPLUS
Zimmerman	1985			US 32011 E	HCAPLUS

L59 ANSWER 5 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:1060835 HCAPLUS
DN 142:1728
TI Branched compounds containing bioactive molecules and targeting moieties for cellular delivery
IN Vargeese, Chandra; Haeberli, Peter; Wang, Weimin; Chen, Tongqian
PA Sirna Therapeutics, Inc., USA
SO U.S. Pat. Appl. Publ., 143 pp., Cont.-in-part of U.S. Ser. No. 427,160.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 238

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004249178	A1	20041209	US 2004-780447	20040213
	AU 9851819	A1	19980611	AU 1998-51819	19980112 <--
	AU 729657	B2	20010208		
	AU 9939188	A1	19990916	AU 1999-39188	19990713 <--
	AU 769175	B2	20040115	AU 2000-56616	20000911 <--
	US 2004110296	A1	20040610	US 2003-427160	20030430
	WO 2004111237	A1	20041223	WO 2004-US11848	20040416
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005032733	A1	20050210	US 2004-826966	20040416
	WO 2005041859	A2	20050512	WO 2004-US13456	20040430
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

```
    RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
        AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
        EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
        SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
        SN, TD, TG
EP 1622572          A2    20060208    EP 2004-775924          20040430
    R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
        IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
AU 2004266311       A1    20050303    AU 2004-266311          20040524
CA 2526831          AA    20050303    CA 2004-2526831         20040524
EP 1627061          A2    20060222    EP 2004-776102          20040524
    R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
        IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
WO 2005045034       A2    20050519    WO 2004-US17630         20040603
WO 2005045034       A3    20050811
    W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
        CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
        GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
        LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
        NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
        TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
    RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
        AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
        EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
        SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
        SN, TD, TG
US 2005137155       A1    20050623    US 2004-861060          20040603
EP 1675948          A2    20060705    EP 2004-754277          20040603
    R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
        IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
US 2005143333       A1    20050630    US 2004-863973          20040609 <--
US 2005171040       A1    20050804    US 2004-864044          20040609 <--
US 2005119211       A1    20050602    US 2004-869638          20040616 <--
US 2005119212       A1    20050602    US 2004-871222          20040618 <--
CA 2528963          AA    20050113    CA 2004-2528963         20040625
WO 2005003350       A2    20050113    WO 2004-US20516         20040625
WO 2005003350       C1    20050519
WO 2005003350       A3    20050804
    W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
        CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
        GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
        LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
        NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
        TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
    RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
        AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
        EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
        SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
        SN, TD, TG
US 2005209179       A1    20050922    US 2004-877889          20040625 <--
EP 1644498          A2    20060412    EP 2004-756160          20040625
    R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
        IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
US 2005124566       A1    20050609    US 2004-879867          20040628 <--
US 2005130181       A1    20050616    US 2004-881118          20040630 <--
US 2006142225       A1    20060629    US 2004-881580          20040630 <--
US 2005124567       A1    20050609    US 2004-883218          20040701 <--
WO 2005007859       A2    20050127    WO 2004-US22247         20040709
WO 2005007859       A3    20051201
    W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
```

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

US 2005124568 A1 20050609 US 2004-888226 20040709 <--
WO 2005007855 A2 20050127 WO 2004-US22658 20040714
WO 2005007855 A3 20050324
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

US 2005124569 A1 20050609 US 2004-892922 20040716 <--
US 2005164224 A1 20050728 US 2004-893010 20040716 <--
US 2005070497 A1 20050331 US 2004-894475 20040719 <--
US 2005176663 A1 20050811 US 2004-897902 20040723 <--
US 2005196765 A1 20050908 US 2004-898660 20040723 <--
US 2005277608 A1 20051215 US 2004-898311 20040723 <--
US 2005182006 A1 20050818 US 2004-903128 20040730 <--
WO 2005014811 A2 20050217 WO 2004-US25589 20040806
WO 2005014811 A3 20051222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

US 2005159378 A1 20050721 US 2004-915896 20040811 <--
US 2005159379 A1 20050721 US 2004-916030 20040811 <--
US 2005158735 A1 20050721 US 2004-916095 20040811 <--
US 2005153914 A1 20050714 US 2004-918969 20040816 <--
US 2005164966 A1 20050728 US 2004-918896 20040816 <--
US 2005203040 A1 20050915 US 2004-918987 20040816 <--
US 2005176664 A1 20050811 US 2004-919866 20040817 <--
US 2005176665 A1 20050811 US 2004-919964 20040817 <--
US 2005233997 A1 20051020 US 2004-919584 20040817 <--
AU 2004288143 A1 20050519 AU 2004-288143 20040818
CA 2541643 AA 20050519 CA 2004-2541643 20040818
WO 2005045036 A2 20050519 WO 2004-US27042 20040818
WO 2005045036 A3 20060302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

EP 1675950 A2 20060705 EP 2004-781674 20040818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

CA 2543030 AA 20050519 CA 2004-2543030 20040819

WO 2005045032 A2 20050519 WO 2004-US26941 20040819

WO 2005045032 A3 20060302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

WO 2005045041 A2 20050519 WO 2004-US27404 20040819

WO 2005045041 A3 20050818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

US 2005136436 A1 20050623 US 2004-923640 20040819 <--

US 2005153915 A1 20050714 US 2004-922544 20040819 <--

US 2005159380 A1 20050721 US 2004-922626 20040819 <--

US 2005159382 A1 20050721 US 2004-923580 20040819 <--

US 2005164967 A1 20050728 US 2004-922034 20040819 <--

US 2006142226 A1 20060629 US 2004-921554 20040819 <--

EP 1675951 A2 20060705 EP 2004-781983 20040819
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

US 2005079610 A1 20050414 US 2004-923115 20040820 <--

WO 2005035759 A2 20050421 WO 2004-US27294 20040820

WO 2005035759 C1 20060202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,

SN, TD, TG
WO 2005040379 A2 20050506 WO 2004-US27333 20040820
WO 2005040379 A3 20060302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2542527 AA 20050519 CA 2004-2542527 20040820
CA 2542835 AA 20050519 CA 2004-2542835 20040820
CA 2543013 AA 20050519 CA 2004-2543013 20040820
CA 2543029 AA 20050519 CA 2004-2543029 20040820
WO 2005045035 A2 20050519 WO 2004-US26930 20040820
WO 2005045035 A3 20051208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2005045037 A2 20050519 WO 2004-US27169 20040820
WO 2005045037 A3 20051103
WO 2005045037 B1 20051229
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2005045038 A2 20050519 WO 2004-US27231 20040820
WO 2005045038 C1 20050714
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2005045039 A2 20050519 WO 2004-US27366 20040820
WO 2005045039 C2 20050721

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

WO 2005045040 A2 20050519 WO 2004-US27367 20040820
WO 2005045040 A3 20060223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

WO 2005044981 A2 20050519 WO 2004-US27403 20040820
WO 2005044981 A3 20050922

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

US 2005153916 A1 20050714 US 2004-923330 20040820 <--
US 2005159381 A1 20050721 US 2004-923522 20040820 <--
US 2005164968 A1 20050728 US 2004-923329 20040820 <--
US 2005170371 A1 20050804 US 2004-922340 20040820 <--
US 2005176666 A1 20050811 US 2004-923182 20040820 <--
US 2005176024 A1 20050811 US 2004-923354 20040820 <--
US 2005176025 A1 20050811 US 2004-923516 20040820 <--
US 2005182007 A1 20050818 US 2004-922675 20040820 <--
US 2005182008 A1 20050818 US 2004-923142 20040820 <--
US 2005182009 A1 20050818 US 2004-923201 20040820 <--
US 2005187174 A1 20050825 US 2004-923181 20040820 <--
US 2005191618 A1 20050901 US 2004-923473 20040820 <--
US 2005196767 A1 20050908 US 2004-923380 20040820 <--
US 2005227935 A1 20051013 US 2004-923470 20040820 <--
US 2005227936 A1 20051013 US 2004-923475 20040820 <--
US 2005233344 A1 20051020 US 2004-923270 20040820 <--
US 2005239731 A1 20051027 US 2004-923379 20040820 <--
US 2005256068 A1 20051117 US 2004-923451 20040820 <--
US 2005267058 A1 20051201 US 2004-922761 20040820 <--
US 2005288242 A1 20051229 US 2004-923476 20040820 <--
EP 1675949 A2 20060705 EP 2004-781588 20040820

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

```
EP 1675953          A2    20060705    EP 2004-816819          20040820
    R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
        IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
EP 1682660          A2    20060726    EP 2004-781956          20040820
    R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
        IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
EP 1682661          A2    20060726    EP 2004-781982          20040820
    R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
        IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
EP 1694838          A2    20060830    EP 2004-781836          20040820
    R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
        IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
WO 2005028650       A2    20050331    WO 2004-US31012         20040915
WO 2005028650       A3    20051229
    W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
        CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
        GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
        LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
        NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
        TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
    RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
        AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
        EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
        SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
        SN, TD, TG
US 2005209180       A1    20050922    US 2004-942560          20040915 <--
EP 1670915          A2    20060621    EP 2004-816223          20040915
    R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
        IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
AU 2004274951       A1    20050331    AU 2004-274951          20040916
CA 2537085          AA    20050331    CA 2004-2537085         20040916
WO 2005028649       A1    20050331    WO 2004-US30488         20040916
    W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
        CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
        GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
        LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
        NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
        TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
    RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
        AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
        EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
        SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
        SN, TD, TG
US 2005233998       A1    20051020    US 2004-944611          20040916 <--
EP 1664299          A1    20060607    EP 2004-784372          20040916
    R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
        IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
US 2005222066       A1    20051006    US 2004-962898          20041012 <--
US 2005261219       A1    20051124    US 2004-1347            20041201 <--
US 2005196781       A1    20050908    US 2004-14373           20041215 <--
US 2006019913       A1    20060126    US 2005-31668           20050106 <--
US 2006025361       A1    20060202    US 2005-35813           20050114 <--
US 2005287128       A1    20051229    US 2005-54047           20050209 <--
US 2005260620       A1    20051124    US 2005-58582           20050215 <--
US 2005277133       A1    20051215    US 2005-63415           20050222 <--
US 2005282188       A1    20051222    US 2005-98303           20050404 <--
US 2006019917       A1    20060126    US 2005-140328          20050527 <--
US 2006148743       A1    20060706    US 2005-217936          20050901 <--
PRAI US 2003-427160 A2    20030430
    AU 1995-26422   A3    19950518  <--
```

US 1996-623891	A	19960325	<--
AU 1996-76662	A3	19961025	<--
US 2000-181797P	P	20000211	<--
US 2001-780533	B2	20010209	<--
WO 2001-US4273	A2	20010209	<--
US 2001-827395	B2	20010405	<--
US 2001-292217P	P	20010518	<--
US 2001-294140P	P	20010529	<--
US 2001-296249P	P	20010606	<--
US 2001-306883P	P	20010720	<--
US 2001-916466	B1	20010725	<--
US 2001-311865P	P	20010813	<--
US 2001-930423	B2	20010815	<--
US 2001-318471P	P	20010910	<--
US 2001-334461P	P	20011130	<--
US 2002-358580P	P	20020220	
US 2002-362016P	P	20020306	
US 2002-363124P	P	20020311	
WO 2002-US9187	A2	20020326	
WO 2002-US10512	A2	20020403	
US 2002-374722P	P	20020422	
US 2002-151116	A2	20020517	
WO 2002-US15876	A2	20020520	
US 2002-157580	A2	20020529	
WO 2002-US16840	A2	20020529	
WO 2002-US17674	A1	20020529	
US 2002-163552	A2	20020606	
US 2002-386782P	P	20020606	
US 2002-393796P	P	20020703	
US 2002-393924P	P	20020703	
US 2002-396600P	P	20020717	
US 2002-396905P	P	20020718	
US 2002-201394	A2	20020722	
US 2002-398036P	P	20020723	
US 2002-205309	A2	20020725	
US 2002-206705	A2	20020726	
US 2002-399348P	P	20020729	
US 2002-401093P	P	20020805	
US 2002-401104P	P	20020805	
US 2002-404039P	P	20020815	
US 2002-225023	A2	20020821	
US 2002-406784P	P	20020829	
US 2002-408378P	P	20020905	
US 2002-409293P	P	20020909	
US 2002-409493P	P	20020909	
US 2002-238700	A2	20020910	
US 2002-409785P	P	20020911	
US 2002-411275P	P	20020917	
US 2002-411707P	P	20020918	
US 2002-251117	A2	20020919	
US 2002-412304P	P	20020920	
US 2002-413714P	P	20020926	
US 2002-418655P	P	20021015	
US 2002-277494	B2	20021021	
US 2002-287949	A2	20021104	
US 2002-425559P	P	20021112	
US 2002-427467P	P	20021119	
US 2002-306747	A2	20021127	
US 2002-429359P	P	20021128	
US 2002-431105P	P	20021205	

US 2003-439922P	P	20030114
US 2003-440129P	P	20030115
WO 2003-US2510	A2	20030128
WO 2003-US3473	A2	20030205
WO 2003-US3662	A2	20030206
WO 2003-US4034	A2	20030211
WO 2003-US4088	A2	20030211
WO 2003-US4123	A2	20030211
WO 2003-US4347	A2	20030211
WO 2003-US4566	A2	20030211
WO 2003-US7273	A2	20030211
WO 2003-US4250	A2	20030213
WO 2003-US4317	A2	20030213
WO 2003-US4397	A2	20030213
WO 2003-US4402	A2	20030213
WO 2003-US4448	A2	20030213
WO 2003-US4710	A2	20030218
WO 2003-US4738	A2	20030218
WO 2003-US4907	A2	20030218
WO 2003-US4908	A2	20030218
WO 2003-US4909	A2	20030218
WO 2003-US4741	A2	20030220
WO 2003-US4951	A2	20030220
WO 2003-US5022	A2	20030220
WO 2003-US5028	A2	20030220
WO 2003-US5043	A2	20030220
WO 2003-US5044	A2	20030220
WO 2003-US5045	A2	20030220
WO 2003-US5162	A2	20030220
WO 2003-US5190	A	20030220
WO 2003-US5234	A2	20030220
WO 2003-US5326	A2	20030220
WO 2003-US5346	A2	20030220
US 2003-417012	A	20030416
US 2003-420194	A2	20030422
WO 2003-US12626	A2	20030422
US 2003-422704	A	20030424
US 2003-424339	A2	20030425
US 2003-430882	A2	20030506
US 2003-444853	A	20030523
US 2003-607933	A	20030627
US 2003-486729P	P	20030711
US 2003-487214P	P	20030714
US 2003-493561P	P	20030808
US 2003-496655P	P	20030820
US 2003-652791	A	20030829
US 2003-664767	A	20030916
US 2003-665255	A	20030916
US 2003-667271	A	20030916
US 2003-670011	A	20030923
US 2003-683990	A2	20031010
US 2003-512701P	P	20031020
US 2003-693059	A	20031023
US 2003-698311	A	20031031
US 2003-712633	A2	20031113
US 2003-720448	A	20031124
US 2003-724270	A2	20031126
US 2003-726236	A2	20031202
US 2003-727780	A2	20031203
US 2003-738128	A2	20031218

US 2004-757803	A	20040114
US 2004-764957	A	20040126
US 2004-543480P	P	20040210
US 2004-780447	A	20040213
US 2004-798090	A2	20040311
US 2004-800487	A2	20040315
US 2004-824036	A2	20040414
US 2004-825485	A2	20040415
US 2004-826966	A	20040416
WO 2004-US11848	A2	20040416
US 2004-830569	A2	20040423
US 2004-831620	A	20040423
WO 2004-US12517	A2	20040423
US 2004-832522	A2	20040426
WO 2004-US13456	W	20040430
US 2004-570086P	P	20040511
US 2004-844076	A	20040511
US 2004-844072	A	20040512
US 2004-16390	A	20040524
WO 2004-US16390	W	20040524
WO 2004-US17630	W	20040603
US 2004-863973	A2	20040609
US 2004-864044	A	20040609
WO 2004-US20516	W	20040625
US 2004-894475	A2	20040719
US 2004-919866	A	20040817
WO 2004-US27042	W	20040818
WO 2004-US27404	W	20040819
US 2004-922675	A2	20040820
US 2004-923475	A2	20040820
US 2004-923536	A2	20040820
WO 2004-US26930	W	20040820
WO 2004-US27231	W	20040820
WO 2004-US27333	W	20040820
WO 2004-US27367	W	20040820
WO 2004-US27403	W	20040820
WO 2004-US31012	W	20040915
US 2004-944611	A2	20040916
WO 2004-US30488	W	20040916
US 2005-31668	A1	20050106
US 2005-39680	A2	20050118
WO 2005-US4270	A2	20050209
US 2005-98303	A2	20050404

OS MARPAT 142:1728

AB Branched compds. comprising **conjugates** of bioactive mols. (such as ribozymes or siRNA's) and targeting moieties are disclosed. Thus, siRNA **conjugated** to branched structures containing cholesterol or fatty alkyl group were prepared These siRNA **conjugates** exhibited vastly improved liver pharmacokinetics in mice relative to the **unconjugated** siRNAs.

IT **123251-89-8**
RL: PRP (Properties)
(unclaimed sequence; branched compds. containing bioactive mols. and targeting moieties for cellular delivery)

IT **123251-89-8**
RL: PRP (Properties)
(unclaimed sequence; branched compds. containing bioactive mols. and targeting moieties for cellular delivery)

RN 123251-89-8 HCAPLUS

CN L-Arginine, L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-

arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L59 ANSWER 6 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:936107 HCAPLUS
DN 141:389814
TI Ionic complexes of macromolecules for transdermal delivery of therapeutic nucleic acids or proteins
IN Waugh, Jacob; Dake, Michael
PA Essentia Biosystems, Inc., USA
SO U.S. Pat. Appl. Publ., 48 pp., Cont.-in-part of U.S. Ser. No. 910,432.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI US 2004220100 A1 20041104 US 2004-793138 20040303 <--
US 2003229034 A1 20031211 US 2001-910432 20010720 <--
WO 2005084361 A2 20050915 WO 2005-US6930 20050303
WO 2005084361 A3 20060316
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI US 2000-220244P P 20000721 <--
US 2001-910432 A2 20010720 <--
US 2004-793138 A 20040303

AB Methods of delivering therapeutic nucleic acids across the skin are described. The complexes have a core component that is pos. charged at physiol. pH. This forms a complex with neg. charged moieties that may include: an imaging agent; a targeting agent; a nucleic acid such as a ribozyme, an antisense nucleic acid, or an expression cassette; an expression cassette for a persistence factor gene that maintains the nucleic acid as an episome; or some other therapeutic agent. The compns. can be prepared with components useful for targeting the delivery of the compns. as well as imaging components. Use of a C- and N-terminal modified polylysine (150000 mol. weight) to deliver plasmids to aortic smooth muscle cells is demonstrated. Similar carriers were used to deliver the cosmetic protein Botox.

IT **123251-89-8D**, N- and C-terminal glycine addition derivs.
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(complexes with nucleic acids; ionic complexes of macromols. for transdermal delivery of therapeutic nucleic acids)

IT **123251-89-8D**, N- and C-terminal glycine addition derivs.
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(complexes with nucleic acids; ionic complexes of macromols. for transdermal delivery of therapeutic nucleic acids)

RN 123251-89-8 HCAPLUS
CN L-Arginine, L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L59 ANSWER 7 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:817391 HCAPLUS
DN 141:320008
TI Chimeric fibroblast growth factor 2 with increased cell-penetrating activity and therapeutic uses thereof
IN Olwin, Bradley B.; Rosenthal, Richard Scott
PA The Regents of the University of Colorado, USA
SO U.S., 42 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6800286	B1	20041005	US 1999-377675	19990819 <--
PRAI US 1998-97160P	P	19980819 <--		

AB A chimeric fibroblast growth factor protein and recombinant nucleic acid

mol. encoding the same are disclosed. The chimeric fibroblast growth factor protein is characterized by: fibroblast growth factor biol. activity in the absence of heparan sulfate and, entry into a living cell in the absence of a receptor that binds to FGF. Also disclosed are a method of making the chimeric fibroblast growth factor protein and methods of using the chimeric fibroblast growth factor protein to promote fibroblast growth factor activity in a cell and to enhance a biol. process associated with fibroblast growth factor activity.

IT **123251-89-8**
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence; chimeric fibroblast growth factor 2 with increased cell-penetrating activity and therapeutic uses thereof)

IT **123251-89-8**
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence; chimeric fibroblast growth factor 2 with increased cell-penetrating activity and therapeutic uses thereof)

RN 123251-89-8 HCAPLUS

CN L-Arginine, L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1991			WO 9118981	HCAPLUS
Anon	1997			WO 9712912	HCAPLUS
Derossi	1994	269	10444	J Biol Chem	HCAPLUS
Femig	1994	5	353	Progress in Growth F	
Fiddes	1997			US 5604293 A	HCAPLUS
Frankel	1998			US 5804604 A	HCAPLUS
Joliot	1999			US 5888762 A	HCAPLUS
Perez	1992	102	717	J Cell Sci	HCAPLUS

L59 ANSWER 8 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:802546 HCAPLUS
DN 141:319980
TI RNA interference-mediated inhibition of gene expression using chemically modified short interfering nucleic acids
IN Mcswiggen, James; Chowrira, Bharat; Beigelman, Leonid; Macejak, Dennis; Zinnen, Shawn; Pavco, Pamela; Haeberli, Peter; Morrissey, David; Fosnaugh, Kathy; Jamison, Sharon; Usman, Nassim; Thompson, James; Vargeese, Chandra; Wang, Weimin; Chen, Tongqian; Vaish, Narendra
PA USA
SO U.S. Pat. Appl. Publ., 407 pp., Cont.-in-part of U.S. Ser. No. 427,160.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 238

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 2004192626	A1	20040930	US 2003-444853	20030523	
	AU 9851819	A1	19980611	AU 1998-51819	19980112	<--
	AU 729657	B2	20010208			
	AU 9939188	A1	19990916	AU 1999-39188	19990713	<--
	AU 769175	B2	20040115	AU 2000-56616	20000911	<--
	WO 2003070918	A2	20030828	WO 2003-US5346	20030220	
	WO 2003070918	A3	20040708			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	WO 2003074654	A2	20030912	WO 2003-US5028	20030220	

```
WO 2003074654        A3    20040205
    W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
        CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
        GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
        LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
        PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
        UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
    RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
        KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
        FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
        BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2004110296        A1    20040610    US 2003-427160          20030430
WO 2003106476        A1    20031224    WO 2003-US18911         20030616
WO 2003106476        C1    20040610
    W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
        CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
        GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
        LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
        PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR,
        TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
    RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
        KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
        FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
        BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003245512        A1    20031231    AU 2003-245512          20030616
US 2005106726        A1    20050519    US 2003-652791          20030829
US 2004209831        A1    20041021    US 2003-667271          20030916
US 2005080031        A1    20050414    US 2003-724270          20031126 <--
US 2005233329        A1    20051020    US 2003-727780          20031203
US 2005096284        A1    20050505    US 2004-783128          20040220
US 2005014172        A1    20050120    US 2004-798090          20040311
US 2005048529        A1    20050303    US 2004-800487          20040315
WO 2004092383        A2    20041028    WO 2004-US11320         20040413
WO 2004092383        A3    20050210
    W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
        CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
        GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
        LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
        NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
        TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
    RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
        BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
        ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
        SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
        TD, TG
US 2005191638        A1    20050901    US 2004-824036          20040414
US 2006160757        A1    20060720    US 2004-825485          20040415
WO 2004111237        A1    20041223    WO 2004-US11848         20040416
    W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
        CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
        GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
        LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
        NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
        TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
    RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
        BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
        ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
        SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
        TD, TG
US 2005032733        A1    20050210    US 2004-826966          20040416
```

```
WO 2004097020        A2    20041111    WO 2004-US12517        20040423
WO 2004097020        A3    20060105
    W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
        CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
        GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
        LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
        NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
        TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
    RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
        BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
        ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
        SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
        TD, TG
US 2005054598        A1    20050310    US 2004-830569         20040423
US 2005148530        A1    20050707    US 2004-831620         20040423
US 2005233996        A1    20051020    US 2004-832522         20040426
US 2005137153        A1    20050623    US 2004-840731         20040506
US 2005171039        A1    20050804    US 2004-844076         20040511
US 2005159376        A1    20050721    US 2004-844072         20040512
AU 2004266311        A1    20050303    AU 2004-266311         20040524
CA 2526831           AA    20050303    CA 2004-2526831        20040524
WO 2005019453        A2    20050303    WO 2004-US16390        20040524
WO 2005019453        A3    20050623
    W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
        CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
        GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
        LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
        NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
        TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
    RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
        AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
        EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
        SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
        SN, TD, TG
EP 1627061           A2    20060222    EP 2004-776102         20040524
    R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
        IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
US 2005137155        A1    20050623    US 2004-861060         20040603
US 2005143333        A1    20050630    US 2004-863973         20040609 <--
US 2005171040        A1    20050804    US 2004-864044         20040609 <--
US 2005119211        A1    20050602    US 2004-869638         20040616 <--
US 2005119212        A1    20050602    US 2004-871222         20040618 <--
US 2005209179        A1    20050922    US 2004-877889         20040625 <--
US 2005124566        A1    20050609    US 2004-879867         20040628 <--
US 2005130181        A1    20050616    US 2004-881118         20040630 <--
US 2006142225        A1    20060629    US 2004-881580         20040630 <--
US 2005124567        A1    20050609    US 2004-883218         20040701 <--
US 2005124568        A1    20050609    US 2004-888226         20040709 <--
US 2005222064        A1    20051006    US 2004-888269         20040709
US 2005124569        A1    20050609    US 2004-892922         20040716 <--
US 2005164224        A1    20050728    US 2004-893010         20040716 <--
US 2005070497        A1    20050331    US 2004-894475         20040719 <--
US 2005176663        A1    20050811    US 2004-897902         20040723 <--
US 2005196765        A1    20050908    US 2004-898660         20040723 <--
US 2005277608        A1    20051215    US 2004-898311         20040723 <--
US 2005182006        A1    20050818    US 2004-903128         20040730 <--
US 2005159378        A1    20050721    US 2004-915896         20040811 <--
US 2005159379        A1    20050721    US 2004-916030         20040811 <--
US 2005158735        A1    20050721    US 2004-916095         20040811 <--
US 2005153914        A1    20050714    US 2004-918969         20040816 <--
```

	US 2005164966	A1	20050728	US 2004-918896	20040816 <--
	US 2005203040	A1	20050915	US 2004-918987	20040816 <--
	US 2005176664	A1	20050811	US 2004-919866	20040817 <--
	US 2005176665	A1	20050811	US 2004-919964	20040817 <--
	US 2005233997	A1	20051020	US 2004-919584	20040817 <--
	US 2005136436	A1	20050623	US 2004-923640	20040819 <--
	US 2005153915	A1	20050714	US 2004-922544	20040819 <--
	US 2005159380	A1	20050721	US 2004-922626	20040819 <--
	US 2005159382	A1	20050721	US 2004-923580	20040819 <--
	US 2005164967	A1	20050728	US 2004-922034	20040819 <--
	US 2006142226	A1	20060629	US 2004-921554	20040819 <--
	US 2005079610	A1	20050414	US 2004-923115	20040820 <--
	US 2005153916	A1	20050714	US 2004-923330	20040820 <--
	US 2005159381	A1	20050721	US 2004-923522	20040820 <--
	US 2005164968	A1	20050728	US 2004-923329	20040820 <--
	US 2005170371	A1	20050804	US 2004-922340	20040820 <--
	US 2005176666	A1	20050811	US 2004-923182	20040820 <--
	US 2005176024	A1	20050811	US 2004-923354	20040820 <--
	US 2005176025	A1	20050811	US 2004-923516	20040820 <--
	US 2005182007	A1	20050818	US 2004-922675	20040820 <--
	US 2005182008	A1	20050818	US 2004-923142	20040820 <--
	US 2005182009	A1	20050818	US 2004-923201	20040820 <--
	US 2005187174	A1	20050825	US 2004-923181	20040820 <--
	US 2005191618	A1	20050901	US 2004-923473	20040820 <--
	US 2005196767	A1	20050908	US 2004-923380	20040820 <--
	US 2005227935	A1	20051013	US 2004-923470	20040820 <--
	US 2005227936	A1	20051013	US 2004-923475	20040820 <--
	US 2005233344	A1	20051020	US 2004-923270	20040820 <--
	US 2005239731	A1	20051027	US 2004-923379	20040820 <--
	US 2005256068	A1	20051117	US 2004-923451	20040820 <--
	US 2005267058	A1	20051201	US 2004-922761	20040820 <--
	US 2005288242	A1	20051229	US 2004-923476	20040820 <--
	US 2005209180	A1	20050922	US 2004-942560	20040915 <--
	US 2005233998	A1	20051020	US 2004-944611	20040916 <--
	US 2005222066	A1	20051006	US 2004-962898	20041012 <--
	US 2005261219	A1	20051124	US 2004-1347	20041201 <--
	US 2005209182	A1	20050922	US 2004-11913	20041214
	US 2005196781	A1	20050908	US 2004-14373	20041215 <--
	US 2006019913	A1	20060126	US 2005-31668	20050106 <--
	US 2006025361	A1	20060202	US 2005-35813	20050114 <--
	US 2005287128	A1	20051229	US 2005-54047	20050209 <--
	US 2005260620	A1	20051124	US 2005-58582	20050215 <--
	US 2005277133	A1	20051215	US 2005-63415	20050222 <--
	US 2005282188	A1	20051222	US 2005-98303	20050404 <--
	US 2006019917	A1	20060126	US 2005-140328	20050527 <--
	US 2006148743	A1	20060706	US 2005-217936	20050901 <--
PRAI	WO 2003-US5028	A2	20030220		
	WO 2003-US5346	A2	20030220		
	US 2003-417012	A1	20030416		
	US 2003-422704	A2	20030424		
	US 2003-427160	A2	20030430		
	AU 1995-26422	A3	19950518	<--	
	US 1996-623891	A	19960325	<--	
	AU 1996-76662	A3	19961025	<--	
	US 2000-181797P	P	20000211	<--	
	US 2001-780533	B2	20010209	<--	
	WO 2001-US4273	A2	20010209	<--	
	US 2001-827395	B2	20010405	<--	
	US 2001-292217P	P	20010518	<--	
	US 2001-294140P	P	20010529	<--	

US 2001-296249P	P	20010606	<--
US 2001-306883P	P	20010720	<--
US 2001-916466	B1	20010725	<--
US 2001-311865P	P	20010813	<--
US 2001-930423	B2	20010815	<--
US 2001-318471P	P	20010910	<--
US 2001-334461P	P	20011130	<--
US 2002-358580P	P	20020220	
US 2002-362016P	P	20020306	
US 2002-363124P	P	20020311	
WO 2002-US9187	A2	20020326	
WO 2002-US10512	A2	20020403	
US 2002-374722P	P	20020422	
US 2002-151116	A2	20020517	
WO 2002-US15876	A2	20020520	
US 2002-157580	A2	20020529	
WO 2002-US16840	A2	20020529	
WO 2002-US17674	A2	20020529	
US 2002-163552	A2	20020606	
US 2002-386782P	P	20020606	
US 2002-389198P	P	20020617	
US 2002-393796P	P	20020703	
US 2002-393924P	P	20020703	
US 2002-396600P	P	20020717	
US 2002-396905P	P	20020718	
US 2002-201394	A2	20020722	
US 2002-398036P	P	20020723	
US 2002-205309	A2	20020725	
US 2002-206705	A2	20020726	
US 2002-399348P	P	20020729	
US 2002-401093P	P	20020805	
US 2002-401104P	P	20020805	
US 2002-404039P	P	20020815	
US 2002-225023	A2	20020821	
US 2002-406784P	P	20020829	
US 2002-408378P	P	20020905	
US 2002-409293P	P	20020909	
US 2002-409493P	P	20020909	
US 2002-238700	A2	20020910	
US 2002-409785P	P	20020911	
US 2002-411275P	P	20020917	
US 2002-411707P	P	20020918	
US 2002-251117	A2	20020919	
US 2002-412304P	P	20020920	
US 2002-413714P	P	20020926	
US 2002-418655P	P	20021015	
US 2002-277494	B2	20021021	
US 2002-287949	A2	20021104	
US 2002-425559P	P	20021112	
US 2002-427467P	P	20021119	
US 2002-306747	A2	20021127	
US 2002-429359P	P	20021128	
US 2002-431105P	P	20021205	
US 2003-439922P	P	20030114	
US 2003-440129P	P	20030115	
WO 2003-US2510	A2	20030128	
WO 2003-US3473	A2	20030205	
WO 2003-US3662	A2	20030206	
WO 2003-US4034	A2	20030211	
WO 2003-US4088	A2	20030211	

WO 2003-US4123	A2	20030211
WO 2003-US4347	A2	20030211
WO 2003-US4566	A2	20030211
WO 2003-US7273	A2	20030211
WO 2003-US4250	A2	20030213
WO 2003-US4317	A2	20030213
WO 2003-US4397	A2	20030213
WO 2003-US4402	A2	20030213
WO 2003-US4448	A2	20030213
WO 2003-US4710	A2	20030218
WO 2003-US4738	A2	20030218
WO 2003-US4907	A2	20030218
WO 2003-US4908	A2	20030218
WO 2003-US4909	A2	20030218
WO 2003-US4741	A2	20030220
WO 2003-US4951	A2	20030220
WO 2003-US5022	A2	20030220
WO 2003-US5043	A2	20030220
WO 2003-US5044	A2	20030220
WO 2003-US5045	A2	20030220
WO 2003-US5162	A2	20030220
WO 2003-US5190	A	20030220
WO 2003-US5234	A2	20030220
WO 2003-US5326	A2	20030220
US 2003-462874P	P	20030415
US 2003-420194	A2	20030422
WO 2003-US12626	A2	20030422
US 2003-424339	A	20030425
US 2003-430882	A2	20030506
US 2003-444853	A	20030523
WO 2003-US18911	W	20030616
US 2003-607933	A2	20030627
US 2003-485667P	P	20030709
US 2003-486729P	P	20030711
US 2003-652791	A2	20030829
US 2003-664767	B2	20030916
US 2003-665255	A2	20030916
US 2003-667271	A2	20030916
US 2003-664668	A2	20030918
US 2003-665951	A2	20030918
US 2003-670011	A2	20030923
US 2003-683990	A2	20031010
US 2003-512701P	P	20031020
US 2003-693059	A2	20031023
US 2003-698311	A2	20031031
US 2003-712633	A2	20031113
US 2003-720448	A2	20031124
US 2003-724270	A2	20031126
US 2003-726236	A2	20031202
US 2003-727780	A2	20031203
US 2003-738128	A2	20031218
US 2004-758155	A2	20040112
US 2004-757803	A2	20040114
US 2004-764957	A2	20040126
US 2004-543480P	P	20040210
US 2004-780447	A	20040213
US 2004-783128	A2	20040220
US 2004-798090	A2	20040311
US 2004-800487	A2	20040315
US 2004-824036	A2	20040414

US 2004-825485	A2	20040415
US 2004-826966	A2	20040416
WO 2004-US11848	A2	20040416
US 2004-830569	A2	20040423
US 2004-831620	A2	20040423
WO 2004-US12517	A2	20040423
US 2004-832522	A2	20040426
WO 2004-US13456	A2	20040430
US 2004-570086P	P	20040511
US 2004-844076	A2	20040511
US 2004-844072	A2	20040512
WO 2004-US16390	W	20040524
US 2004-863973	A2	20040609
US 2004-864044	A2	20040609
US 2004-894475	A2	20040719
US 2004-922675	A2	20040820
US 2004-923475	A2	20040820
US 2004-923536	A2	20040820
US 2004-944611	A2	20040916
US 2005-31668	A1	20050106
US 2005-39680	A2	20050118
WO 2005-US4270	A2	20050209
US 2005-98303	A2	20050404

AB The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemical modified small nucleic acid mols., such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) mols. capable of mediating RNA interference (RNAi) against target nucleic acid sequences. Introduction of chemical modified nucleotides into nucleic acid mols. provides a powerful tool in overcoming potential limitations of in vivo stability and bioavailability inherent to native RNA mols. Unlike native unmodified siRNA, chemical modified siNA can also minimize the possibility of activating interferon activity in humans. Modifications are described including pyrimidine or purine nucleotides with 2'-deoxy-2'-fluoro or 2'-O-Me groups, phosphorothioate backbone modification, terminal residues comprising inverted deoxy thymidine or inverted deoxy abasic moieties, linking the sense and antisense strands with glyceryl succinate or dodecanoic acid or other linkers, and **conjugation** of targeting ligands (N-acetylgalactosamine, pteroic acid, peptides, or phospholipids) to the oligonucleotide termini. Thus, the serum stability of siNA constructs consisting of all RNA nucleotides containing two thymidine nucleotide overhangs have a half-life in human serum of 15 s, whereas chemical modified siNA constructs remained stable in serum for 1 to 3 days depending on the extent of modification. The small nucleic acid mols. are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism. Three nuclease-resistant siNA mols. targeting site 1580 of hepatitis B virus RNA are designed using Stab 7/8 chemical and a 5'-terminal **conjugate** moiety (a branched cholesterol **conjugate**, a branched phospholipid **conjugate**, and a polyethylene glycol **conjugate**) showed significant stability in human and mouse serum (t1/2 = 10-408 h) and human liver extract (t1/2 = 28-43 h); the most stable siNA with all purine positions in the antisense strand with 2'-O-Me nucleotides had a half-life of 816 h in human liver extract

IT **123251-89-8**
RL: PRP (Properties)
(unclaimed sequence; rNA interference-mediated inhibition of gene

expression using chemical modified short interfering nucleic acids)

IT **123251-89-8**
RL: PRP (Properties)
(unclaimed sequence; rNA interference-mediated inhibition of gene expression using chemical modified short interfering nucleic acids)

RN 123251-89-8 HCAPLUS

CN L-Arginine, L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L59 ANSWER 9 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:473253 HCAPLUS

DN 141:34630

TI Branched compounds containing bioactive molecules and targeting moieties for cellular delivery

IN Vargeese, Chandra; Haeberli, Peter; Wang, Weimin; Chen, Tongqian

PA Ribozyme Pharmaceuticals, Inc., USA

SO U.S. Pat. Appl. Publ., 142 pp., Cont.-in-part of WO 2003 70,918.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 238

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 2004110296	A1	20040610	US 2003-427160	20030430	
	AU 9851819	A1	19980611	AU 1998-51819	19980112	<--
	AU 729657	B2	20010208			
	AU 9939188	A1	19990916	AU 1999-39188	19990713	<--
	AU 769175	B2	20040115	AU 2000-56616	20000911	<--
	WO 2002094185	A2	20021128	WO 2002-US15876	20020520	<--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	WO 2003070918	A2	20030828	WO 2003-US5346	20030220	
	WO 2003070918	A3	20040708			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	WO 2003074654	A2	20030912	WO 2003-US5028	20030220	
	WO 2003074654	A3	20040205			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	US 2004192626	A1	20040930	US 2003-444853	20030523	
	US 2005080031	A1	20050414	US 2003-724270	20031126	<--
	US 2004249178	A1	20041209	US 2004-780447	20040213	
	US 2005096284	A1	20050505	US 2004-783128	20040220	
	US 2005014172	A1	20050120	US 2004-798090	20040311	
	US 2005048529	A1	20050303	US 2004-800487	20040315	
	WO 2004092383	A2	20041028	WO 2004-US11320	20040413	
	WO 2004092383	A3	20050210			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

US 2005191638 A1 20050901 US 2004-824036 20040414
US 2006160757 A1 20060720 US 2004-825485 20040415
WO 2004111237 A1 20041223 WO 2004-US11848 20040416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

US 2005032733 A1 20050210 US 2004-826966 20040416
WO 2004097020 A2 20041111 WO 2004-US12517 20040423
WO 2004097020 A3 20060105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

US 2005054598 A1 20050310 US 2004-830569 20040423
US 2005148530 A1 20050707 US 2004-831620 20040423
US 2005233996 A1 20051020 US 2004-832522 20040426
WO 2005041859 A2 20050512 WO 2004-US13456 20040430
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

EP 1622572 A2 20060208 EP 2004-775924 20040430
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

US 2005137153 A1 20050623 US 2004-840731 20040506
US 2005171039 A1 20050804 US 2004-844076 20040511
US 2005159376 A1 20050721 US 2004-844072 20040512
US 2005137155 A1 20050623 US 2004-861060 20040603
US 2005143333 A1 20050630 US 2004-863973 20040609 <--
US 2005171040 A1 20050804 US 2004-864044 20040609 <--
US 2005119211 A1 20050602 US 2004-869638 20040616 <--
US 2005119212 A1 20050602 US 2004-871222 20040618 <--
US 2005209179 A1 20050922 US 2004-877889 20040625 <--

US 2005124566	A1	20050609	US 2004-879867	20040628 <--
US 2005130181	A1	20050616	US 2004-881118	20040630 <--
US 2006142225	A1	20060629	US 2004-881580	20040630 <--
US 2005124567	A1	20050609	US 2004-883218	20040701 <--
US 2005124568	A1	20050609	US 2004-888226	20040709 <--
US 2005124569	A1	20050609	US 2004-892922	20040716 <--
US 2005164224	A1	20050728	US 2004-893010	20040716 <--
US 2005070497	A1	20050331	US 2004-894475	20040719 <--
US 2005176663	A1	20050811	US 2004-897902	20040723 <--
US 2005196765	A1	20050908	US 2004-898660	20040723 <--
US 2005277608	A1	20051215	US 2004-898311	20040723 <--
US 2005182006	A1	20050818	US 2004-903128	20040730 <--
US 2005159378	A1	20050721	US 2004-915896	20040811 <--
US 2005159379	A1	20050721	US 2004-916030	20040811 <--
US 2005158735	A1	20050721	US 2004-916095	20040811 <--
US 2005153914	A1	20050714	US 2004-918969	20040816 <--
US 2005164966	A1	20050728	US 2004-918896	20040816 <--
US 2005203040	A1	20050915	US 2004-918987	20040816 <--
US 2005176664	A1	20050811	US 2004-919866	20040817 <--
US 2005176665	A1	20050811	US 2004-919964	20040817 <--
US 2005233997	A1	20051020	US 2004-919584	20040817 <--
US 2005136436	A1	20050623	US 2004-923640	20040819 <--
US 2005153915	A1	20050714	US 2004-922544	20040819 <--
US 2005159380	A1	20050721	US 2004-922626	20040819 <--
US 2005159382	A1	20050721	US 2004-923580	20040819 <--
US 2005164967	A1	20050728	US 2004-922034	20040819 <--
US 2006142226	A1	20060629	US 2004-921554	20040819 <--
US 2005079610	A1	20050414	US 2004-923115	20040820 <--
US 2005153916	A1	20050714	US 2004-923330	20040820 <--
US 2005159381	A1	20050721	US 2004-923522	20040820 <--
US 2005164968	A1	20050728	US 2004-923329	20040820 <--
US 2005170371	A1	20050804	US 2004-922340	20040820 <--
US 2005176666	A1	20050811	US 2004-923182	20040820 <--
US 2005176024	A1	20050811	US 2004-923354	20040820 <--
US 2005176025	A1	20050811	US 2004-923516	20040820 <--
US 2005182007	A1	20050818	US 2004-922675	20040820 <--
US 2005182008	A1	20050818	US 2004-923142	20040820 <--
US 2005182009	A1	20050818	US 2004-923201	20040820 <--
US 2005187174	A1	20050825	US 2004-923181	20040820 <--
US 2005191618	A1	20050901	US 2004-923473	20040820 <--
US 2005196767	A1	20050908	US 2004-923380	20040820 <--
US 2005227935	A1	20051013	US 2004-923470	20040820 <--
US 2005227936	A1	20051013	US 2004-923475	20040820 <--
US 2005233344	A1	20051020	US 2004-923270	20040820 <--
US 2005239731	A1	20051027	US 2004-923379	20040820 <--
US 2005256068	A1	20051117	US 2004-923451	20040820 <--
US 2005267058	A1	20051201	US 2004-922761	20040820 <--
US 2005288242	A1	20051229	US 2004-923476	20040820 <--
US 2005209180	A1	20050922	US 2004-942560	20040915 <--
US 2005233998	A1	20051020	US 2004-944611	20040916 <--
US 2005222066	A1	20051006	US 2004-962898	20041012 <--
US 2005261219	A1	20051124	US 2004-1347	20041201 <--
US 2005196781	A1	20050908	US 2004-14373	20041215 <--
US 2006019913	A1	20060126	US 2005-31668	20050106 <--
US 2006025361	A1	20060202	US 2005-35813	20050114 <--
US 2005287128	A1	20051229	US 2005-54047	20050209 <--
US 2005260620	A1	20051124	US 2005-58582	20050215 <--
US 2005277133	A1	20051215	US 2005-63415	20050222 <--
US 2005282188	A1	20051222	US 2005-98303	20050404 <--
US 2006019917	A1	20060126	US 2005-140328	20050527 <--

	US 2006148743	A1	20060706	US 2005-217936	20050901 <--
PRAI	WO 2002-US15876	A2	20020520		
	US 2002-386782P	P	20020606		
	US 2002-406784P	P	20020829		
	US 2002-408378P	P	20020905		
	US 2002-409293P	P	20020909		
	US 2003-440129P	P	20030115		
	WO 2003-US5028	A2	20030220		
	WO 2003-US5346	A2	20030220		
	AU 1995-26422	A3	19950518	<--	
	US 1996-623891	A	19960325	<--	
	AU 1996-76662	A3	19961025	<--	
	US 2000-181797P	P	20000211	<--	
	US 2001-780533	B2	20010209	<--	
	WO 2001-US4273	A2	20010209	<--	
	US 2001-827395	B2	20010405	<--	
	US 2001-292217P	P	20010518	<--	
	US 2001-294140P	P	20010529	<--	
	US 2001-296249P	P	20010606	<--	
	US 2001-306883P	P	20010720	<--	
	US 2001-916466	B1	20010725	<--	
	US 2001-311865P	P	20010813	<--	
	US 2001-930423	B2	20010815	<--	
	US 2001-318471P	P	20010910	<--	
	US 2001-334461P	P	20011130	<--	
	US 2002-358580P	P	20020220		
	US 2002-362016P	P	20020306		
	US 2002-363124P	P	20020311		
	WO 2002-US9187	A2	20020326		
	WO 2002-US10512	A2	20020403		
	US 2002-374722P	P	20020422		
	US 2002-151116	A2	20020517		
	US 2002-157580	A2	20020529		
	WO 2002-US16840	A2	20020529		
	WO 2002-US17674	A2	20020529		
	US 2002-163552	A2	20020606		
	US 2002-393796P	P	20020703		
	US 2002-393924P	P	20020703		
	US 2002-396600P	P	20020717		
	US 2002-396905P	P	20020718		
	US 2002-201394	A2	20020722		
	US 2002-398036P	P	20020723		
	US 2002-205309	A2	20020725		
	US 2002-206705	A2	20020726		
	US 2002-399348P	P	20020729		
	US 2002-401093P	P	20020805		
	US 2002-401104P	P	20020805		
	US 2002-404039P	P	20020815		
	US 2002-225023	A2	20020821		
	US 2002-409493P	P	20020909		
	US 2002-238700	A2	20020910		
	US 2002-409785P	P	20020911		
	US 2002-411275P	P	20020917		
	US 2002-411707P	P	20020918		
	US 2002-251117	A2	20020919		
	US 2002-412304P	P	20020920		
	US 2002-413714P	P	20020926		
	US 2002-418655P	P	20021015		
	US 2002-277494	B2	20021021		
	US 2002-287949	A2	20021104		

US 2002-425559P	P	20021112
US 2002-427467P	P	20021119
US 2002-306747	A2	20021127
US 2002-429359P	P	20021128
US 2002-431105P	P	20021205
US 2003-439922P	P	20030114
WO 2003-US2510	A2	20030128
WO 2003-US3473	A2	20030205
WO 2003-US3662	A2	20030206
WO 2003-US4034	A2	20030211
WO 2003-US4088	A2	20030211
WO 2003-US4123	A2	20030211
WO 2003-US4347	A2	20030211
WO 2003-US4566	A2	20030211
WO 2003-US7273	A2	20030211
WO 2003-US4250	A2	20030213
WO 2003-US4317	A2	20030213
WO 2003-US4397	A2	20030213
WO 2003-US4402	A2	20030213
WO 2003-US4448	A2	20030213
WO 2003-US4710	A2	20030218
WO 2003-US4738	A2	20030218
WO 2003-US4907	A2	20030218
WO 2003-US4908	A2	20030218
WO 2003-US4909	A2	20030218
WO 2003-US4741	A2	20030220
WO 2003-US4951	A2	20030220
WO 2003-US5022	A2	20030220
WO 2003-US5043	A2	20030220
WO 2003-US5044	A2	20030220
WO 2003-US5045	A2	20030220
WO 2003-US5162	A2	20030220
WO 2003-US5190	A	20030220
WO 2003-US5234	A2	20030220
WO 2003-US5326	A2	20030220
US 2003-462874P	P	20030415
US 2003-417012	A1	20030416
US 2003-420194	A2	20030422
WO 2003-US12626	A2	20030422
US 2003-422704	A2	20030424
US 2003-424339	A	20030425
US 2003-427160	A2	20030430
US 2003-430882	A2	20030506
US 2003-444853	A2	20030523
US 2003-607933	A2	20030627
US 2003-486729P	P	20030711
US 2003-652791	A2	20030829
US 2003-664767	B2	20030916
US 2003-665255	A2	20030916
US 2003-667271	A2	20030916
US 2003-664668	A2	20030918
US 2003-665951	A2	20030918
US 2003-670011	A2	20030923
US 2003-683990	A2	20031010
US 2003-512701P	P	20031020
US 2003-693059	A2	20031023
US 2003-698311	A2	20031031
US 2003-712633	A2	20031113
US 2003-720448	A2	20031124
US 2003-724270	A2	20031126

US 2003-726236	A2	20031202
US 2003-727780	A2	20031203
US 2003-738128	A2	20031218
US 2004-758155	A2	20040112
US 2004-757803	A2	20040114
US 2004-764957	A2	20040126
US 2004-543480P	P	20040210
US 2004-780447	A	20040213
US 2004-783128	A2	20040220
US 2004-798090	A2	20040311
US 2004-800487	A2	20040315
US 2004-824036	A2	20040414
US 2004-825485	A2	20040415
US 2004-826966	A2	20040416
WO 2004-US11848	A2	20040416
US 2004-830569	A2	20040423
US 2004-831620	A2	20040423
WO 2004-US12517	A2	20040423
US 2004-832522	A2	20040426
WO 2004-US13456	W	20040430
US 2004-570086P	P	20040511
US 2004-844076	A2	20040511
US 2004-844072	A2	20040512
WO 2004-US16390	A2	20040524
US 2004-863973	A2	20040609
US 2004-864044	A2	20040609
US 2004-894475	A2	20040719
US 2004-922675	A2	20040820
US 2004-923475	A2	20040820
US 2004-923536	A2	20040820
US 2004-944611	A2	20040916
US 2005-31668	A1	20050106
US 2005-39680	A2	20050118
WO 2005-US4270	A2	20050209
US 2005-98303	A2	20050404

OS MARPAT 141:34630

AB Branched compds. comprising **conjugates** of bioactive mols. (such as ribozymes or siRNA's) and targeting moieties are disclosed. Thus, siRNA **conjugated** to branched structures containing cholesterol or fatty alkyl group were prepared These siRNA **conjugates** exhibited vastly improved liver pharmacokinetics in mice relative to the **unconjugated** siRNAs.

IT **123251-89-8**
RL: PRP (Properties)
(unclaimed sequence; branched compds. containing bioactive mols. and targeting moieties for cellular delivery)

IT **123251-89-8**
RL: PRP (Properties)
(unclaimed sequence; branched compds. containing bioactive mols. and targeting moieties for cellular delivery)

RN 123251-89-8 HCAPLUS

CN L-Arginine, L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L59 ANSWER 10 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:310820 HCAPLUS
DN 140:332504
TI Fusion proteins comprising IF1 peptides for regulating endogenous inhibitor of ATP synthase, and methods of treatment of diabetes
IN Anderson, Christen M.; Clevenger, William
PA USA
SO U.S. Pat. Appl. Publ., 72 pp., Cont.-in-part of U.S. Ser. No. 709,189, abandoned.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004072739	A1	20040415	US 2001-796076	20010227 <--
	WO 2002068680	A2	20020906	WO 2002-US6090	20020227 <--

WO 2002068680 A3 20031016
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2003026781 A1 20030206 US 2002-83815 20020227 <--
PRAI US 1999-164622P P 19991110 <--
US 2000-709189 B2 20001110 <--
US 2001-796076 A 20010227 <--

AB The present invention provides compns. and methods for altering mitochondrial ATP metabolism, including compns. having fusion proteins comprising IF1 (ATPase F1 inhibitor)-derived sequences, as well as binding and functional assays exploiting IF1 interactions with ATP synthase. Also disclosed are methods for screening assays for a compound capable of reducing mitochondrial ATP hydrolysis and/or increasing mitochondrial ATP synthesis, including pharmaceutical compns. identified by such methods. The invention also provides methods for treating diabetes, and in particular, type 2 diabetes mellitus, using an agent identified according to the disclosed methods. An IF1 fusion protein containing a His tag sequence, a tat cell transport sequence, a mitochondrial targeting sequence and a peptide of rat IF1 was prepared and tested in INS-1 cells. The fusion protein induced glucose stimulated insulin secretion in a dose dependent manner.

IT **455876-60-5**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(cell transport sequence, in IF1 fusion protein; fusion proteins comprising IF1 peptides for regulating endogenous inhibitor of ATP synthase, and methods of treatment of diabetes)

IT **455876-60-5**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(cell transport sequence, in IF1 fusion protein; fusion proteins comprising IF1 peptides for regulating endogenous inhibitor of ATP synthase, and methods of treatment of diabetes)

RN 455876-60-5 HCAPLUS
CN L-Arginine, L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L59 ANSWER 11 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:950457 HCAPLUS
DN 140:26909
TI Antibodies that immunospecifically bind to BLyS and their use in diagnosis and treatment of autoimmune disease
IN Ruben, Steven M.; Barash, Steven C.; Choi, Gil H.; Vaughan, Tristan; Hilbert, David
PA USA
SO U.S. Pat. Appl. Publ., 186 pp., Cont.-in-part of U.S. Ser. No. 880,748.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 19

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	US 2003223996	A1	20031204	US 2002-293418	20021114 <--
	EP 1577391	A1	20050921	EP 2005-12261	19961025 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 2003059937	A1	20030327	US 2001-880748	20010615 <--
	AU 2001054180	A5	20020725	AU 2001-54180	20010703 <--
	AU 779750	B2	20050210		
	JP 2004129667	A2	20040430	JP 2003-362615	20031022 <--
	US 2005255532	A1	20051117	US 2005-54515	20050210 <--
	US 2006062789	A1	20060323	US 2005-266444	20051104 <--
PRAI	US 2000-212210P	P	20000616 <--		
	US 2000-240816P	P	20001017 <--		
	US 2001-276248P	P	20010316 <--		
	US 2001-277379P	P	20010321 <--		
	US 2001-293499P	P	20010525 <--		
	US 2001-880748	A2	20010615 <--		
	US 2001-331469P	P	20011116 <--		
	US 2001-340817P	P	20011219 <--		
	AU 1996-76745	A3	19961025 <--		
	EP 1996-939612	A3	19961025 <--		
	JP 1998-520411	A3	19961025 <--		
	US 2002-293418	A2	20021114		
	US 2004-543296P	P	20040211		
	US 2004-580347P	P	20040618		

AB The present invention relates to antibodies and related mols. that immunospecifically bind to BLyS (B lymphocyte stimulator). The present invention also relates to methods and compns. for detecting or diagnosing a disease or disorder associated with aberrant BLyS expression or inappropriate function of BLyS comprising antibodies or fragments or variants thereof or related mols. that immunospecifically bind to BLyS. The present invention further relates to methods and compns. for preventing, treating or ameliorating a disease or disorder associated with aberrant BLyS expression or inappropriate BLyS function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related mols. that immunospecifically bind to BLyS.

IT **389116-42-1**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; antibodies that immunospecifically bind to BLyS and their use in diagnosis and treatment of autoimmune disease)

IT **389116-42-1**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; antibodies that immunospecifically bind to BLyS and their use in diagnosis and treatment of autoimmune disease)

RN 389116-42-1 HCAPLUS

CN L-Arginine, L-arginyl-L-leucyl-L-isoleucyl-L-arginyl-L-lysyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L59 ANSWER 12 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:930859 HCAPLUS
DN 140:14513
TI Identification and therapeutic use of peptides that facilitate uptake and cytoplasmic and nuclear transport of proteins, DNA and viruses
IN Robbins, Paul D.; Mi, Zhibao; Frizzell, Raymond; Glorioso, Joseph C.; Gambotto, Andrea; Mai, Jeffrey C.
PA USA
SO U.S. Pat. Appl. Publ., 140 pp., Cont.-in-part of U.S. Ser. No. 75,869.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003219826	A1	20031127	US 2003-366493	20030212 <--
	US 6881825	B1	20050419	US 2000-653182	20000831 <--
	US 2003104622	A1	20030605	US 2002-75869	20020213 <--
PRAI	US 1999-151980P	P	19990901 <--		
	US 2000-188944P	P	20000313 <--		
	US 2000-653182	A2	20000831 <--		
	US 2002-75869	A2	20020213		

AB The present invention relates to internalizing peptides which facilitate the uptake and transport of cargo into the cytoplasm and nuclei of cells as well as methods for the identification of such peptides. The internalizing peptides of the present invention are selected for their ability to efficiently internalize cargo into a wide variety of cell types both in vivo and in vitro. The method for identification of the internalizing peptides of the present invention comprises incubating a target cell with a peptide display library, isolating peptides with internalization characteristics and determining the ability of said peptide to internalize cargo into a cell. The peptides of the invention are useful in therapeutic applications, such as: stimulating the immune response in a

subject; selectively inducing apoptosis in cells, such as cancer and arthritic cells; facilitatating transfer of proteins and peptides to the lung for treatment of cystic fibrosis, lung inflammation or injury.

IT **148796-87-6P**

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); BUU (Biological use, unclassified); CST (Combinatorial study, unclassified); PRP (Properties); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(identification and therapeutic use of peptides that facilitate uptake and cytoplasmic and nuclear transport of proteins, DNA and viruses)

IT **148796-87-6P**

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); BUU (Biological use, unclassified); CST (Combinatorial study, unclassified); PRP (Properties); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(identification and therapeutic use of peptides that facilitate uptake and cytoplasmic and nuclear transport of proteins, DNA and viruses)

RN 148796-87-6 HCAPLUS

CN L-Arginine, L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L59 ANSWER 13 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:930717 HCAPLUS
DN 140:8758
TI Membrane-permeant peptide complexes for medical imaging, diagnostics, and therapy
IN Piwnica-Worms, David
PA USA
SO U.S. Pat. Appl. Publ., 48 pp., Cont.-in-part of U.S. Ser. No. 557,465.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003219378	A1	20031127	US 2003-374035	20030225 <--
	US 6348185	B1	20020219	US 1999-336093	19990618 <--
	US 6589503	B1	20030708	US 2000-557465	20000425 <--
	AU 2004212997	A1	20040902	AU 2004-212997	20040218
	CA 2516282	AA	20040902	CA 2004-2516282	20040218
	WO 2004073640	A2	20040902	WO 2004-US4752	20040218
	WO 2004073640	A3	20050303		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	GB 2413076	A1	20051019	GB 2005-16702	20040218
	US 2006166881	A1	20060727	US 2005-286920	20051123 <--
PRAI	US 1998-90087P	P	19980620 <--		
	US 1999-336093	A2	19990618 <--		

US 2000-557465 A2 20000425 <--
US 2003-368280 A 20030218
US 2003-374035 A 20030225
WO 2004-US4752 A 20040218

AB Methods and compns. for medical imaging, evaluating intracellular processes and components, radiotherapy of intracellular targets, and drug delivery by the use of novel cell membrane-permeant peptide **conjugate** coordination and covalent complexes having target cell specificity are provided. Kits for **conjugating** radionuclides and other metals to peptide coordination complexes are also provided. Examples are provided of 99cTc-labeled Tat peptide chelate **conjugates**, their preparation, uptake by human tumor cells, and applications in imaging.

IT **143413-47-2 627881-61-2 627881-75-8D**, biotinylated
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(membrane-permeant peptide complexes for medical imaging, diagnostics, and therapy)

IT **143413-47-2**
RL: DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(membrane-permeant peptide complexes for medical imaging, diagnostics, and therapy)

RN 143413-47-2 HCAPLUS

CN L-Arginine, L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-A



L59 ANSWER 14 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:696307 HCAPLUS
DN 139:235379
TI Histidine copolymer for drug delivery
IN Mixson, A. James
PA USA
SO U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S. Ser. No. 18,103.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003165567	A1	20030904	US 2002-131909	20020425 <--
	US 7070807	B2	20060704		
	WO 2001047496	A1	20010705	WO 2000-US34603	20001220 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2003045465	A1	20030306	US 2001-18103	20011105 <--
	WO 2003090719	A1	20031106	WO 2003-US12890	20030424
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				

PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	AU 2003263165	A1	20031110	AU 2003-263165	20030424
PRAI	US 1999-173576P	P	19991229	<--	
	WO 2000-US34603	W	20001220	<--	
	US 2001-18103	A2	20011105	<--	
	US 2002-131909	A	20020425		
	WO 2003-US12890	W	20030424		

AB The invention provides a branched transport polymer characterized as having at least 10 amino acids and a ratio of histidine to non-histidine amino acids greater than 1.5, said branched transport polymer comprising one or more backbones, one or more terminal branches, and optionally, one or more non-terminal branches. The branched transport polymer may be associated with a pharmaceutical agent to form a pharmaceutical agent delivery composition useful for in vivo therapies based on local injection.

IT **349451-29-2**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histidine copolymer for drug delivery)

IT **349451-29-2**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histidine copolymer for drug delivery)

RN 349451-29-2 HCAPLUS

CN L-Arginine, L-arginyl-L-histidyl-L-arginyl-L-histidyl-L-arginyl-L-histidyl-L-arginyl-L-histidyl-L-arginylglycyl-L-arginyl-L-histidyl-L-arginyl-L-histidyl-L-arginyl-L-histidyl-L-arginyl-L-histidyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



L59 ANSWER 15 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:532743 HCAPLUS
DN 139:99852

TI Human anti-BLyS antibodies for diagnosis, prognosis and therapy of autoimmune, inflammatory, infectious and proliferative diseases

IN Ruben, Steven M.; Barash, Steven C.; Choi, Gil H.; Vaughan, Tristan J.; Hilbert, David

PA Human Genome Sciences, Inc., USA

SO PCT Int. Appl., 3099 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 19

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003055979	A2	20030710	WO 2002-US36496	20021114 <--
	WO 2003055979	A3	20031218		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1577391	A1	20050921	EP 2005-12261	19961025 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	AU 2001054180	A5	20020725	AU 2001-54180	20010703 <--
	AU 779750	B2	20050210		
	CA 2467521	AA	20030710	CA 2002-2467521	20021114 <--
	AU 2002364954	A1	20030715	AU 2002-364954	20021114 <--
	EP 1456347	A2	20040915	EP 2002-802570	20021114 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2004129667	A2	20040430	JP 2003-362615	20031022 <--
PRAI	US 2001-331469P	P	20011116 <--		
	US 2001-340817P	P	20011219 <--		
	AU 1996-76745	A3	19961025 <--		
	EP 1996-939612	A3	19961025 <--		
	JP 1998-520411	A3	19961025 <--		
	WO 2002-US36496	W	20021114		

AB The present invention relates to antibodies and related mols. that immunospecifically bind to BLyS or B lymphocyte stimulator. The present invention also relates to methods and compns. for detecting or diagnosing a disease or disorder associated with aberrant BLyS expression or inappropriate function of BLyS comprising antibodies or fragments or variants thereof or related mols. that immunospecifically bind to BLyS. The present invention further relates to methods and compns. for preventing, treating or ameliorating a disease or disorder associated with aberrant BLyS expression or inappropriate BLyS function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related mols. that immunospecifically bind to BLyS.

IT **389116-42-1**
RL: PRP (Properties)
(unclaimed sequence; human anti-BLyS antibodies for diagnosis, prognosis and therapy of autoimmune, inflammatory, infectious and proliferative diseases)

IT **389116-42-1**
RL: PRP (Properties)

(unclaimed sequence; human anti-BLyS antibodies for diagnosis, prognosis and therapy of autoimmune, inflammatory, infectious and proliferative diseases)
RN 389116-42-1 HCAPLUS
CN L-Arginine, L-arginyl-L-leucyl-L-isoleucyl-L-arginyl-L-lysyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L59 ANSWER 16 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:511956 HCAPLUS
DN 139:65738
TI Methods of detecting a cell
IN Tse, Eric; Rabbitts, Terence
PA UK
SO U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of Appl. No. PCT/GB/01540.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003124629	A1	20030703	US 2002-265002	20021004 <--
	WO 2001075453	A2	20011011	WO 2001-GB1540	20010404 <--
	WO 2001075453	A3	20020606		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2000-8254 A 20000404 <--
GB 2000-8256 A 20000404 <--
WO 2001-GB1540 A2 20010404 <--

AB We describe a method of inducing a cell to generate a detectable signal. The method comprises the steps of providing a cell comprising an entity and providing a first reporter and a second reporter, in which a stable interaction of the first reporter with the second reporter leads to generation of a detectable signal. The first reporter and the second reporter are allowed to bind to the entity, such that binding of the reporters to the entity leads to stable interaction of the first reporter with the second reporter and generation of a signal. The signal is preferably the activation of a cell killing mechanism.

IT **123251-89-8**
RL: PRP (Properties)
(unclaimed sequence; methods of detecting a cell)

IT **123251-89-8**
RL: PRP (Properties)
(unclaimed sequence; methods of detecting a cell)

RN 123251-89-8 HCAPLUS

CN L-Arginine, L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L59 ANSWER 17 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:454824 HCAPLUS
DN 139:30852
TI Cell-permeable peptide inhibitors of the JNK signal transduction pathway
IN Bonny, Christophe
PA Switz.
SO U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Ser. No. 503,954.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003108539	A1	20030612	US 2002-165250	20020607 <--
US 6610820	B1	20030826	US 2000-503954	20000214 <--
CA 2471762	AA	20030717	CA 2003-2471762	20030109
WO 2003057725	A2	20030717	WO 2003-IB332	20030109
WO 2003057725	A3	20041007		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003201733	A1	20030724	AU 2003-201733	20030109
US 2003175920	A1	20030918	US 2003-340458	20030109
EP 1487870	A2	20041222	EP 2003-700434	20030109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005106695	A1	20050519	US 2003-500804	20030109
JP 2005525096	T2	20050825	JP 2003-558039	20030109
CA 2488695	AA	20031218	CA 2003-2488695	20030609
WO 2003103698	A1	20031218	WO 2003-IB3094	20030609
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

	AU 2003274820	A1	20031222	AU 2003-274820	20030609
	US 2004082509	A1	20040429	US 2003-457614	20030609 <--
	EP 1511507	A1	20050309	EP 2003-740977	20030609
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006501165	T2	20060112	JP 2004-510817	20030609
	US 2005043241	A1	20050224	US 2004-924028	20040823 <--
PRAI	US 2000-503954	A2	20000214 <--		
	US 2002-347062P	P	20020109		
	US 1999-158774P	P	19991012 <--		
	US 2001-970515	A1	20011003 <--		
	US 2002-165250	A	20020607		
	WO 2003-IB332	W	20030109		
	WO 2003-IB3094	W	20030609		

AB The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells. The peptides, referred to herein as JNK peptide inhibitors, decrease the downstream cell-proliferative effects of c-Jun amino terminal kinase (JNK). The JNK inhibitor peptides can be present as polymers of L-amino acids or D-amino acids. The invention includes a method of treating a pathophysiol. associated with activation of JNK in a cell or cells. The invention further provides a method of preventing or treating hearing loss in a subject. The method includes administering to the subject a cell-permeable bioactive peptide which prevents damage to the hair cell stereocilia, hair cell apoptosis, or neuronal apoptosis. He invention also contemplates a method of inhibiting pancreatic islet cell death, where the method includes contacting a pancreatic islet cell with a cell-permeable bioactive peptide such that pancreatic cell death is inhibited.

IT **123251-89-8 448950-42-3**
RL: PRP (Properties)
(Unclaimed; cell-permeable peptide inhibitors of the JNK signal transduction pathway)

IT **123251-89-8**
RL: PRP (Properties)
(Unclaimed; cell-permeable peptide inhibitors of the JNK signal transduction pathway)

RN 123251-89-8 HCAPLUS

CN L-Arginine, L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L59 ANSWER 18 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:435239 HCAPLUS
DN 139:32886
TI Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
IN Robbins, Paul D.; Mi, Zhibao; Frizzell, Raymond; Glorioso, Joseph C.; Gambotto, Andrea
PA USA
SO U.S. Pat. Appl. Publ., 110 pp., Cont.-in-part of U.S. Ser. No. 653,182.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003104622	A1	20030605	US 2002-75869	20020213 <--
	US 6881825	B1	20050419	US 2000-653182	20000831 <--

WO 2003068942 A2 20030821 WO 2003-US4632 20030212
WO 2003068942 A3 20040701
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003216289 A1 20030904 AU 2003-216289 20030212
US 2003219826 A1 20031127 US 2003-366493 20030212 <--
US 2005074884 A1 20050407 US 2004-926893 20040826 <--
PRAI US 1999-151980P P 19990901 <--
US 2000-188944P P 20000313 <--
US 2000-653182 A2 20000831 <--
US 2002-75869 A 20020213
WO 2003-US4632 W 20030212

AB The present invention relates to internalizing peptides which facilitate the uptake and transport of cargo into the cytoplasm and nuclei of cells as well as methods for the identification of such peptides. The internalizing peptides of the present invention are selected for their ability to efficiently internalize cargo into a wide variety of cell types both in vivo and in vitro. The method for identification of the internalizing peptides of the present invention comprises incubating a target cell with a peptide display library, isolating peptides with internalization characteristics and determining the ability of said peptide to internalize cargo into a cell. Various cells and cell lines were panned with a phage display library for internalizing peptides. Internalizing peptides PTD-5 and Airway peptide were prepared and coupled to β-galactosidase. PTD-5 achieved more efficient uptake of β-gal in comparison to Airway peptide in Calu3 cells, but the Airway peptide demonstrated greater specificity for Calu3 cells. PTD-5 indiscriminately facilitates uptake in multiple cell types in the murine lung, whereas Airway peptide facilitates uptake specifically into lung epithelia. NF-κB-mediated apoptosis in islet cells was inhibited with a peptide containing PTD-5 and IκB.

IT **148796-87-6**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(effect on β-galactosidase uptake; identification and use of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses)

IT **148796-87-6**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(effect on β-galactosidase uptake; identification and use of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses)

RN 148796-87-6 HCAPLUS
CN L-Arginine, L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L59 ANSWER 19 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:118585 HCAPLUS
DN 138:158767

TI Intracellular delivery of biological effectors
IN Bonny, Christophe
PA Universite De Lausanne, Switz.
SO U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U. S. Ser. No. 977,831.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003032594	A1	20030213	US 2002-165015	20020607 <--
	US 7033597	B2	20060425		
	US 2002120100	A1	20020829	US 2001-977831	20011015 <--
	US 6960648	B2	20051101		
	CA 2488716	AA	20031218	CA 2003-2488716	20030606
	WO 2003103718	A2	20031218	WO 2003-IB3097	20030606
	WO 2003103718	A3	20041125		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003274822	A1	20031222	AU 2003-274822	20030606
	EP 1511763	A2	20050309	EP 2003-740980	20030606
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006500917	T2	20060112	JP 2004-510837	20030606
	US 2006178310	A1	20060810	US 2006-408396	20060421 <--
PRAI	US 2000-240315P	P	20001013	<--	
	US 2001-977831	A2	20011015	<--	
	US 2002-165015	A	20020607		
	WO 2003-IB3097	W	20030606		

OS MARPAT 138:158767
AB The invention relates to sequences of amino acids with the capacity to facilitate transport of an effector across a biol. membrane. More specifically, the present invention relates to novel peptide transporters that specifically target certain cell types for the intracellular delivery of drugs and therapeutic agents.
IT **412271-64-8**
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(intracellular delivery of biol. effectors)
IT **412271-64-8**
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(intracellular delivery of biol. effectors)
RN 412271-64-8 HCAPLUS
CN L-Arginine, L-arginylglycyl-L-asparaginyl-L-arginylglycyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ammendrup	2000	49	1468	Diabetes	HCAPLUS
Anderson	1989	53	S63	Clin. Immun. and Imm	HCAPLUS
Anon	1993			CA 2094658	HCAPLUS
Anon	1994			WO 9423751	HCAPLUS
Anon	1998			WO 9851325	HCAPLUS
Anon	1998			WO 9851825	HCAPLUS
Anon	1999			FR 2767323	HCAPLUS
Anon	1999			WO 9907414	HCAPLUS
Anon	2000			WO 0012587	HCAPLUS
Anon	2001			WO 0164738	HCAPLUS
Anon	2002			WO 0231109 A2	HCAPLUS
Anon	2002			International Search	
Anon	2004			International Search	
Avrameas	1998	95	5601	Proc. Natl. Acad. Sc	HCAPLUS
Bleich	1999	103	1431	J. Clin. Inves	HCAPLUS
Bonner-Weir	1994	49	91	Recent Prog. Hormone	HCAPLUS
Bonny	2001	50	77	Diabetes	HCAPLUS
Bonny	1998	273	1843	J. Biol. Che	HCAPLUS
Bonny	2000	275	16466	J. Biol. Che	HCAPLUS
Breeman	1999	81	658	Int. J. Cancer	HCAPLUS
Brugidou	1995	214	685	Biochem. Biophys. Re	HCAPLUS
Burns	1998	273	12203	J. Biol. Che	HCAPLUS
Cabibbo	1995	167	41	Gene	HCAPLUS
Carithers	1996	3	537	Chem. Biol.	
Chen	2000	49	562	Diabetes	HCAPLUS
Damke	1996	389	48	FEBS Letters	HCAPLUS
De Jong	1999	40	2081	J. Nucl. Med.	HCAPLUS
Dupraz	1999	6	1160	Gene Therapy	HCAPLUS

Efrat	1988	85	9037	Proc. Natl. Acad. Sc	HCAPLUS
Flodstrom	1999	48	706	Diabetes	HCAPLUS
Giannoukakis	1999	48	1730	Diabetes	HCAPLUS
Gibbs	1994	79	193	Cell	HCAPLUS
Gibbs	2000	287	1969	Science	HCAPLUS
Gotoh	1987	43	725	Transplantati	MEDLINE
Hawiger	1999	3	89	Current Opinion Chem	HCAPLUS
Hofland	1999	111	63	Proc. Assoc. Am. Phy	HCAPLUS
Hoorens	1996	98	1568	J. Clin. Inves	HCAPLUS
Ivanenkov	1999	1448	450	Biochem. Biophys. Ac	HCAPLUS
Ivanenkov	1999	1448	463	Biochem. Biophys. Ac	HCAPLUS
Iwahashi	1998	4	45	Cell Mol. Ther.	MEDLINE
Iwahashi	1996	39	530	Diabetologia	HCAPLUS
Kato	1997	14	287	Critical Rev Thera.	HCAPLUS
Kim	2000	20	439	Anticancer Res.	HCAPLUS
Larsen	1998	273	15294	J. Biol. Che	HCAPLUS
Lin	1995	270	14255	J. Biol. Che	HCAPLUS
Lund	1990	265	15713	J. Biol. Che	
Mahato	1997	14	133	Critical Rev. Thera	HCAPLUS
Mahato	1997	4	337	J. Drug Targeti	HCAPLUS
Mandrup-Poulsen	1998	316	1221	BMJ	MEDLINE
Mandrup-Poulsen	1996	39	1005	Diabetologia	HCAPLUS
Mukherjee	1997	77	759	Physiol. Rev	HCAPLUS
Negri	2000	64	324	Genomics	HCAPLUS
Nerup	1988	11	16	Diabetes Care	
Oehlke	1998	1414	127	Biochem. Biophys. Ac	HCAPLUS
Offord	1997	287	348	Meth. Enzymol.	HCAPLUS
Pasqualini	1996	1	423	Mol. Psychiatry	MEDLINE
Pasquallini	1996	380	364	Nature	
Peralta	1990	127	595	Endocrino	
Rabinovitch	1999	48	1223	Diabetes	HCAPLUS
Renschler	1994	91	3623	Proc. Natl. Acad. Sc	HCAPLUS
Roitt	1991		65	Essential Immunology	
Rose	1999	121	7034	J. Am. Chem Soc.	HCAPLUS
Rothbard	2000	6	1253	Nature Med	HCAPLUS
Rouquet	1996	6	1192	Curr. Bio	HCAPLUS
Scharfmann	1996	22	223	Diabetes and Metabol	MEDLINE
Schwarze	1999	285	1569	Science	HCAPLUS
Scott	1990	249	386	Science	HCAPLUS
Sela	1997	11	449	FASEB J.	HCAPLUS
Sela	1997	11	449	FASEB J.	HCAPLUS
Sjoholm	1998	5	461	Cell Death Diff.	HCAPLUS
Smith	1988	58	613	Laboratory Inves	HCAPLUS
Smith	1993	217	228	Meth. Enzymol.	HCAPLUS
Stephens	1999	140	3219	Endocrino	HCAPLUS
Stephens	1997	10	293	J. Autoimmunity	MEDLINE
Suzuki	2002	277	2437	J. Biol Che	HCAPLUS
Terskikh	1997	94	1663	Proc. Natl. Acad. Sc	HCAPLUS
Thorens	1992	89	8641	Proc. Natl. Acad. Sc	HCAPLUS
Torgerson	1998	161	6084	J. Immunology	MEDLINE
Ulbrich	2000	64	63	J. Controlled Rel.	HCAPLUS
Usami	1998	55	185	Biochem Pharmacol	HCAPLUS
Volz	1995	373	23	FEBS Letters	HCAPLUS
Wang	1999	140	1200	Endocrino	HCAPLUS
Welsh	1999	5	169	Mol. Med.	HCAPLUS
Widmann	1995	315	203	Biochem J.	
Yamada	1999	48	478	Diabetes	HCAPLUS
Yamato	1997	29	56	Horm. Metab. Res.	HCAPLUS
Yoon	1999	284	1183	Science	HCAPLUS
York	1999	274	1164	J. Biol Che	HCAPLUS

Zacher	1980	9	127	Gene	HCAPLUS
Zeng	1996	2	66	J. Peptide Sci.	HCAPLUS
Zwick	1998	9	427	Curr. Opin. Biotech.	HCAPLUS

L59 ANSWER 20 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:97803 HCAPLUS
DN 138:147741
TI Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
IN Anderson, Christen Marie; Clevenger, William
PA Mitokor, USA
SO U.S. Pat. Appl. Publ., 79 pp., Cont.-in-part of U.S. Ser. No. 796,076.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003026781	A1	20030206	US 2002-83815	20020227 <--
	US 2004072739	A1	20040415	US 2001-796076	20010227 <--
PRAI	US 1999-164622P	P	19991110 <--		
	US 2000-709189	A2	20001110 <--		
	US 2001-796076	A2	20010227 <--		

AB The present invention provides compns. and methods for altering mitochondrial ATP metabolism, including compns. having fusion proteins comprising IF1 polypeptide-derived sequences, as well as binding and functional assays exploiting IF1 interactions with ATP synthase. Also disclosed are methods for identifying an agent capable of reducing mitochondrial ATP hydrolysis and/or increasing mitochondrial ATP synthesis, including pharmaceutical compns. identified by such methods. The invention also provides methods for treating diabetes, and in particular, type 2 DM, using an agent identified according to the disclosed methods. An IF1 fusion protein containing a His tag sequence, a tat cell transport sequence, a mitochondrial targeting sequence and a peptide of rat IF1 was prepared and tested in INS-1 cells. The fusion protein induced glucose stimulated insulin secretion in a dose dependent manner.

IT **455876-60-5**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(cell transport sequence in IF1 fusion protein; compns. and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes)

IT **455876-60-5**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(cell transport sequence in IF1 fusion protein; compns. and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes)

RN 455876-60-5 HCAPLUS
CN L-Arginine, L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L59 ANSWER 21 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:905731 HCAPLUS
DN 138:14152
TI Preparation of enzymic ribonucleic acid peptide **conjugates** as antitumor and antiviral agents and compositions for cellular delivery
IN Beigelman, Leonid; Matulic-Adamic, Jasenka; Vargeese, Chandra; Karpeisky, Alexander; Blatt, Lawrence; Shaffer, Christopher
PA Ribozyme Pharmaceuticals, Inc, USA
SO PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 238

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2002094185	A2	20021128	WO 2002-US15876	20020520 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 9851819	A1	19980611	AU 1998-51819	19980112 <--
	AU 729657	B2	20010208		
	AU 9939188	A1	19990916	AU 1999-39188	19990713 <--
	AU 769175	B2	20040115	AU 2000-56616	20000911 <--
	EP 1572067	A2	20050914	EP 2002-746413	20020517 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CA 2447161	AA	20021128	CA 2002-2447161	20020520 <--
	JP 2005505504	T2	20050224	JP 2002-590906	20020520 <--
	US 2004110296	A1	20040610	US 2003-427160	20030430
	US 2005080031	A1	20050414	US 2003-724270	20031126 <--
	US 2005096284	A1	20050505	US 2004-783128	20040220
	US 2005014172	A1	20050120	US 2004-798090	20040311
	US 2005048529	A1	20050303	US 2004-800487	20040315
	US 2005191638	A1	20050901	US 2004-824036	20040414
	US 2006160757	A1	20060720	US 2004-825485	20040415
	US 2005054598	A1	20050310	US 2004-830569	20040423
	US 2005148530	A1	20050707	US 2004-831620	20040423
	US 2005233996	A1	20051020	US 2004-832522	20040426
	US 2005137153	A1	20050623	US 2004-840731	20040506
	US 2005171039	A1	20050804	US 2004-844076	20040511
	US 2005159376	A1	20050721	US 2004-844072	20040512
	US 2005137155	A1	20050623	US 2004-861060	20040603
	US 2005143333	A1	20050630	US 2004-863973	20040609 <--
	US 2005171040	A1	20050804	US 2004-864044	20040609 <--
	US 2005119211	A1	20050602	US 2004-869638	20040616 <--
	US 2005119212	A1	20050602	US 2004-871222	20040618 <--
	US 2005209179	A1	20050922	US 2004-877889	20040625 <--
	US 2005124566	A1	20050609	US 2004-879867	20040628 <--
	US 2005130181	A1	20050616	US 2004-881118	20040630 <--
	US 2006142225	A1	20060629	US 2004-881580	20040630 <--
	US 2005124567	A1	20050609	US 2004-883218	20040701 <--
	US 2005124568	A1	20050609	US 2004-888226	20040709 <--
	US 2005124569	A1	20050609	US 2004-892922	20040716 <--
	US 2005164224	A1	20050728	US 2004-893010	20040716 <--
	US 2005070497	A1	20050331	US 2004-894475	20040719 <--
	US 2005176663	A1	20050811	US 2004-897902	20040723 <--
	US 2005196765	A1	20050908	US 2004-898660	20040723 <--
	US 2005277608	A1	20051215	US 2004-898311	20040723 <--
	US 2005182006	A1	20050818	US 2004-903128	20040730 <--
	US 2005159378	A1	20050721	US 2004-915896	20040811 <--
	US 2005159379	A1	20050721	US 2004-916030	20040811 <--
	US 2005158735	A1	20050721	US 2004-916095	20040811 <--
	US 2005153914	A1	20050714	US 2004-918969	20040816 <--
	US 2005164966	A1	20050728	US 2004-918896	20040816 <--
	US 2005203040	A1	20050915	US 2004-918987	20040816 <--
	US 2005176664	A1	20050811	US 2004-919866	20040817 <--
	US 2005176665	A1	20050811	US 2004-919964	20040817 <--
	US 2005233997	A1	20051020	US 2004-919584	20040817 <--

	US 2005136436	A1	20050623	US 2004-923640	20040819 <--
	US 2005153915	A1	20050714	US 2004-922544	20040819 <--
	US 2005159380	A1	20050721	US 2004-922626	20040819 <--
	US 2005159382	A1	20050721	US 2004-923580	20040819 <--
	US 2005164967	A1	20050728	US 2004-922034	20040819 <--
	US 2006142226	A1	20060629	US 2004-921554	20040819 <--
	US 2005079610	A1	20050414	US 2004-923115	20040820 <--
	US 2005153916	A1	20050714	US 2004-923330	20040820 <--
	US 2005159381	A1	20050721	US 2004-923522	20040820 <--
	US 2005164968	A1	20050728	US 2004-923329	20040820 <--
	US 2005170371	A1	20050804	US 2004-922340	20040820 <--
	US 2005176666	A1	20050811	US 2004-923182	20040820 <--
	US 2005176024	A1	20050811	US 2004-923354	20040820 <--
	US 2005176025	A1	20050811	US 2004-923516	20040820 <--
	US 2005182007	A1	20050818	US 2004-922675	20040820 <--
	US 2005182008	A1	20050818	US 2004-923142	20040820 <--
	US 2005182009	A1	20050818	US 2004-923201	20040820 <--
	US 2005187174	A1	20050825	US 2004-923181	20040820 <--
	US 2005191618	A1	20050901	US 2004-923473	20040820 <--
	US 2005196767	A1	20050908	US 2004-923380	20040820 <--
	US 2005227935	A1	20051013	US 2004-923470	20040820 <--
	US 2005227936	A1	20051013	US 2004-923475	20040820 <--
	US 2005233344	A1	20051020	US 2004-923270	20040820 <--
	US 2005239731	A1	20051027	US 2004-923379	20040820 <--
	US 2005256068	A1	20051117	US 2004-923451	20040820 <--
	US 2005267058	A1	20051201	US 2004-922761	20040820 <--
	US 2005288242	A1	20051229	US 2004-923476	20040820 <--
	US 2005209180	A1	20050922	US 2004-942560	20040915 <--
	US 2005233998	A1	20051020	US 2004-944611	20040916 <--
	US 2005222066	A1	20051006	US 2004-962898	20041012 <--
	US 2005261219	A1	20051124	US 2004-1347	20041201 <--
	US 2005196781	A1	20050908	US 2004-14373	20041215 <--
	US 2006019913	A1	20060126	US 2005-31668	20050106 <--
	US 2006025361	A1	20060202	US 2005-35813	20050114 <--
	US 2005287128	A1	20051229	US 2005-54047	20050209 <--
	US 2005260620	A1	20051124	US 2005-58582	20050215 <--
	US 2005277133	A1	20051215	US 2005-63415	20050222 <--
	US 2005282188	A1	20051222	US 2005-98303	20050404 <--
	US 2006019917	A1	20060126	US 2005-140328	20050527 <--
	US 2006148743	A1	20060706	US 2005-217936	20050901 <--
PRAI	US 2001-292217P	P	20010518 <--		
	US 2001-306883P	P	20010720 <--		
	US 2001-311865P	P	20010813 <--		
	US 2002-362016P	P	20020306		
	AU 1995-26422	A3	19950518 <--		
	US 1996-623891	A	19960325 <--		
	AU 1996-76662	A3	19961025 <--		
	US 2000-181797P	P	20000211 <--		
	US 2001-780533	B2	20010209 <--		
	WO 2001-US4273	A2	20010209 <--		
	US 2001-827395	B2	20010405 <--		
	US 2001-294140P	P	20010529 <--		
	US 2001-296249P	P	20010606 <--		
	US 2001-916466	B1	20010725 <--		
	US 2001-930423	B2	20010815 <--		
	US 2001-318471P	P	20010910 <--		
	US 2001-334461P	P	20011130 <--		
	US 2002-358580P	P	20020220		
	US 2002-363124P	P	20020311		
	WO 2002-US9187	A2	20020326		

WO 2002-US10512	A2	20020403
US 2002-374722P	P	20020422
US 2002-151116	A2	20020517
WO 2002-US15876	W	20020520
US 2002-157580	A2	20020529
WO 2002-US16840	A2	20020529
WO 2002-US17674	A2	20020529
US 2002-163552	A2	20020606
US 2002-386782P	P	20020606
US 2002-393796P	P	20020703
US 2002-393924P	P	20020703
US 2002-396600P	P	20020717
US 2002-396905P	P	20020718
US 2002-201394	A2	20020722
US 2002-398036P	P	20020723
US 2002-205309	A2	20020725
US 2002-206705	A2	20020726
US 2002-399348P	P	20020729
US 2002-401093P	P	20020805
US 2002-401104P	P	20020805
US 2002-404039P	P	20020815
US 2002-225023	A2	20020821
US 2002-406784P	P	20020829
US 2002-408378P	P	20020905
US 2002-409293P	P	20020909
US 2002-409493P	P	20020909
US 2002-238700	A2	20020910
US 2002-409785P	P	20020911
US 2002-411275P	P	20020917
US 2002-411707P	P	20020918
US 2002-251117	A2	20020919
US 2002-412304P	P	20020920
US 2002-413714P	P	20020926
US 2002-418655P	P	20021015
US 2002-277494	B2	20021021
US 2002-287949	A2	20021104
US 2002-425559P	P	20021112
US 2002-427467P	P	20021119
US 2002-306747	A2	20021127
US 2002-429359P	P	20021128
US 2002-431105P	P	20021205
US 2003-439922P	P	20030114
US 2003-440129P	P	20030115
WO 2003-US2510	A2	20030128
WO 2003-US3473	A2	20030205
WO 2003-US3662	A2	20030206
WO 2003-US4034	A2	20030211
WO 2003-US4088	A2	20030211
WO 2003-US4123	A2	20030211
WO 2003-US4347	A2	20030211
WO 2003-US4566	A2	20030211
WO 2003-US7273	A2	20030211
WO 2003-US4250	A2	20030213
WO 2003-US4317	A2	20030213
WO 2003-US4397	A2	20030213
WO 2003-US4402	A2	20030213
WO 2003-US4448	A2	20030213
WO 2003-US4710	A2	20030218
WO 2003-US4738	A2	20030218
WO 2003-US4907	A2	20030218

WO 2003-US4908	A2	20030218
WO 2003-US4909	A2	20030218
WO 2003-US4741	A2	20030220
WO 2003-US4951	A2	20030220
WO 2003-US5022	A2	20030220
WO 2003-US5028	A2	20030220
WO 2003-US5043	A2	20030220
WO 2003-US5044	A2	20030220
WO 2003-US5045	A2	20030220
WO 2003-US5162	A2	20030220
WO 2003-US5190	A	20030220
WO 2003-US5234	A2	20030220
WO 2003-US5326	A2	20030220
WO 2003-US5346	A2	20030220
US 2003-417012	B2	20030416
US 2003-420194	A2	20030422
WO 2003-US12626	A2	20030422
US 2003-422704	B2	20030424
US 2003-424339	A2	20030425
US 2003-427160	A2	20030430
US 2003-430882	A2	20030506
US 2003-444853	A2	20030523
US 2003-607933	A2	20030627
US 2003-486729P	P	20030711
US 2003-652791	A2	20030829
US 2003-664767	B2	20030916
US 2003-665255	A2	20030916
US 2003-667271	A2	20030916
US 2003-664668	A2	20030918
US 2003-665951	A2	20030918
US 2003-670011	A2	20030923
US 2003-683990	A2	20031010
US 2003-512701P	P	20031020
US 2003-693059	A2	20031023
US 2003-698311	A2	20031031
US 2003-712633	A2	20031113
US 2003-720448	A2	20031124
US 2003-724270	A2	20031126
US 2003-726236	A2	20031202
US 2003-727780	A2	20031203
US 2003-738128	A2	20031218
US 2004-758155	A2	20040112
US 2004-757803	A2	20040114
US 2004-764957	A2	20040126
US 2004-543480P	P	20040210
US 2004-780447	A2	20040213
US 2004-783128	A2	20040220
US 2004-798090	A2	20040311
US 2004-800487	A2	20040315
US 2004-824036	A2	20040414
US 2004-825485	A2	20040415
US 2004-826966	A2	20040416
WO 2004-US11848	A2	20040416
US 2004-830569	A2	20040423
US 2004-831620	A2	20040423
WO 2004-US12517	A2	20040423
US 2004-832522	A2	20040426
WO 2004-US13456	A2	20040430
US 2004-570086P	P	20040511
US 2004-844076	A2	20040511

US 2004-844072	A2	20040512
WO 2004-US16390	A2	20040524
US 2004-863973	A2	20040609
US 2004-864044	A2	20040609
US 2004-894475	A2	20040719
US 2004-922675	A2	20040820
US 2004-923475	A2	20040820
US 2004-923536	A2	20040820
US 2004-944611	A2	20040916
US 2005-31668	A1	20050106
US 2005-39680	A2	20050118
WO 2005-US4270	A2	20050209
US 2005-98303	A2	20050404

GI



I

AB This invention features peptide nucleotide **conjugates** I wherein each R1-R8 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, or a protecting group, each "n" is independently an integer from 0 to about 200, R9 is a straight or branched chain alkyl, substituted alkyl, aryl, or substituted aryl, and R2 is a phosphorus containing group, nucleoside, nucleotide, small mol., nucleic acid, or a solid support comprising a linker., degradable linkers, compns., methods of synthesis, and applications thereof, including folate, galactose, galactosamine, N-acetyl galactosamine, PEG, phospholipid, peptide and human serum albumin (HAS) derived **conjugates** of biol. active compds., including antibodies, antivirals, chemotherapeutics, peptides, proteins, hormones nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymic nucleic acids, DNAzymes, allozymes, antisense, dsRNA, siRNA, triplex oligonucleotides, 2,5-A chimeras, decoys and aptamers. Thus, 1-O-(4-monomethoxytrityl)-N-(12'-hydroxydodecanoyl-2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-3-D-galactopyranose)-D-threoninol 3-O-(2-cyanoethyl,N,N-diisopropylphosphorami-dite) was prepared and incorporated into RNA. A method of treating a cancer patient, comprising contacting cells of patient wherein said cancer is breast cancer, lung cancer, colorectal cancer, brain cancer, esophageal cancer, stomach cancer, bladder cancer, pancreatic cancer, cervical cancer, head and neck cancer, ovarian cancer, melanoma, lymphoma, glioma, or multidrug resistant cancers and/or viral infections including HIV, HBV, HCV, CMV, RSV, HSV, poliovirus, influenza, rhinovirus, west nile virus, Ebola virus, foot and mouth virus, and papilloma.

IT **123251-89-8**
RL: PRP (Properties)
(unclaimed sequence; preparation of enzymic RNA peptide **conjugates** as antitumor and antiviral agents and compns. for cellular delivery)

IT **123251-89-8**

RL: PRP (Properties)
(unclaimed sequence; preparation of enzymic RNA peptide **conjugates** as antitumor and antiviral agents and compns. for cellular delivery)
RN 123251-89-8 HCAPLUS
CN L-Arginine, L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L59 ANSWER 22 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:857449 HCAPLUS
DN 137:380978
TI Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
IN Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.
PA Agensys, Inc., USA
SO PCT Int. Appl., 1021 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 30

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002083921	A2	20021024	WO 2002-XH11654	20020410 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2002083921	A2	20021024	WO 2002-US11654	20020410 <--
	WO 2002083921	C1	20051215		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2005227253	A1	20051013	US 2004-990137	20041115 <--
	US 2006018917	A1	20060126	US 2004-989767	20041115 <--
	US 2005214211	A1	20050929	US 2005-73349	20050303 <--
PRAI	US 2001-282739P	P	20010410 <--		
	US 2001-283112P	P	20010410 <--		
	US 2001-286630P	P	20010425 <--		
	WO 2002-US11654	A	20020410		
	US 2000-227098P	P	20000822 <--		
	US 2001-300373P	P	20010622 <--		
	US 2001-935430	A1	20010822 <--		
	US 2002-120835	A3	20020409		

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstract record is one of 16 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT **473327-31-0 473328-45-9 474817-05-5**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT **473327-31-0**

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

RN 473327-31-0 HCAPLUS

CN L-Arginine, L-arginyl-L-alanyl-L-α-glutamyl-L-leucyl-L-arginyl-L-α-glutamyl-L-α-aspartyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L59 ANSWER 23 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:857447 HCAPLUS

DN 137:380976

TI Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers

IN Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.

PA Agensys, Inc., USA

SO PCT Int. Appl., 1021 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 30

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002083921	A2	20021024	WO 2002-XF11654	20020410 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2002083921	A2	20021024	WO 2002-US11654	20020410 <--
	WO 2002083921	C1	20051215		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2005227253	A1	20051013	US 2004-990137	20041115 <--
	US 2006018917	A1	20060126	US 2004-989767	20041115 <--
	US 2005214211	A1	20050929	US 2005-73349	20050303 <--
PRAI	US 2001-282739P	P	20010410 <--		
	US 2001-283112P	P	20010410 <--		
	US 2001-286630P	P	20010425 <--		
	WO 2002-US11654	A	20020410		
	US 2000-227098P	P	20000822 <--		
	US 2001-300373P	P	20010622 <--		
	US 2001-935430	A1	20010822 <--		
	US 2002-120835	A3	20020409		

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAsd corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstract record is one of 16 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT **473328-45-9**

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT **473328-45-9**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

RN 473328-45-9 HCAPLUS

CN L-Arginine, L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-L-arginyl-L-asparaginyl-L-phenylalanyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A

PAGE 2-B

L59 ANSWER 24 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:814341 HCAPLUS
DN 137:334071
TI Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
IN Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.
PA Agensys, Inc., USA
SO PCT Int. Appl., 1021 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 30

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002083921	A2	20021024	WO 2002-US11654	20020410 <--
	WO 2002083921	C1	20051215		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

CA 2443123 AA 20021024 CA 2002-2443123 20020410 <--

WO 2002083921 A2 20021024 WO 2002-XA11654 20020410 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002083921 A2 20021024 WO 2002-XB11654 20020410 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002083921 A2 20021024 WO 2002-XC11654 20020410 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002083921 A2 20021024 WO 2002-XD11654 20020410 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002083921 A2 20021024 WO 2002-XE11654 20020410 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-XF11654 20020410 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-XG11654 20020410 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-XH11654 20020410 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-XI11654 20020410 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-XJ11654 20020410 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-XK11654 20020410 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-XL11654 20020410 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-XM11654 20020410 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-XN11654 20020410 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-XO11654 20020410 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2003109470 A1 20030612 US 2002-121019 20020410 <--
EP 1573024 A2 20050914 EP 2002-747813 20020410 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2005227253 A1 20051013 US 2004-990137 20041115 <--
US 2006018917 A1 20060126 US 2004-989767 20041115 <--
US 2005214211 A1 20050929 US 2005-73349 20050303 <--
PRAI US 2001-282739P P 20010410 <--
US 2001-283112P P 20010410 <--
US 2001-286630P P 20010425 <--
US 2000-227098P P 20000822 <--
US 2001-300373P P 20010622 <--
US 2001-935430 A1 20010822 <--
US 2002-120835 A3 20020409
WO 2002-US11654 W 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that

are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstract record is one of 16 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT **473327-31-0 473327-74-1 473328-45-9**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT **473327-31-0**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

RN 473327-31-0 HCAPLUS

CN L-Arginine, L-arginyl-L-alanyl-L-α-glutamyl-L-leucyl-L-arginyl-L-α-glutamyl-L-α-aspartyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L59 ANSWER 25 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:676220 HCAPLUS
DN 137:210960
TI Compositions and methods for regulating endogenous inhibitor of ATP synthase, including a treatment for diabetes
IN Anderson, Christen M.; Clevenger, William
PA Mitokor, USA
SO PCT Int. Appl., 184 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002068680	A2	20020906	WO 2002-US6090	20020227 <--
	WO 2002068680	A3	20031016		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004072739	A1	20040415	US 2001-796076	20010227 <--
PRAI	US 2001-796076	A	20010227 <--		
	US 1999-164622P	P	19991110 <--		
	US 2000-709189	B2	20001110 <--		

AB The present invention provides compns. and methods for altering mitochondrial ATP metabolism, including compns. having fusion proteins comprising IF1 polypeptide-derived sequences, as well as binding and functional assays exploiting IF1 interactions with ATP synthase. Also disclosed are methods for identifying an agent capable of reducing mitochondrial ATP hydrolysis and/or increasing mitochondrial ATP synthesis, including pharmaceutical compns. identified by such methods. The invention also provides methods for treating diabetes, and in particular, type 2 DM, using an agent identified according to the disclosed methods.
IT **455876-60-5**
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(unclaimed sequence; compns. and methods for regulating endogenous

inhibitor of ATP synthase, including a treatment for diabetes)

IT **455876-60-5**
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(unclaimed sequence; compns. and methods for regulating endogenous inhibitor of ATP synthase, including a treatment for diabetes)

RN 455876-60-5 HCAPLUS

CN L-Arginine, L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L59 ANSWER 26 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:615447 HCAPLUS

DN 137:190698

TI Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents

IN Paranjp, Pankaj; Stein, Stanley; Leibowitz, Michael J.; Sinko, Patrick J.; Minko, Tamara; Williams, Gregory C.; Zhang, Goubao; Pooyan, Shahrair; Park, Seong Hee; Qiu, Bo; Ramanathan, Srinivasan; Pooyan, Shahrair; et al.

PA University of Medicine and Dentistry of New Jersey, USA; Rutgers, the State University of New Jersey

SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062396	A2	20020815	WO 2002-US3819	20020208 <--
	WO 2002062396	A3	20040318		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002240312	A1	20020819	AU 2002-240312	20020208 <--
	US 2003091640	A1	20030515	US 2002-72657	20020208 <--
	US 2006029667	A1	20060209	US 2005-170652	20050629 <--
PRAI	US 2001-267396P	P	20010208	<--	
	US 2002-72657	B1	20020208		
	WO 2002-US3819	W	20020208		

OS MARPAT 137:190698

AB The invention is directed to pharmaceutical compns. and methods for delivery of a therapeutic or diagnostic agent from one body compartment to one or more other body compartment by administering one of the following **conjugates**: a polymer having multiple functional groups at least one of which is covalently bound to a therapeutic or diagnostic agent, and at least one cell uptake promoter covalently bound to the therapeutic or diagnostic agent; or a polymer and at lest one cell uptake promoter bound thereto; the polymer further comprising multiple functional groups at least one of which is covalently bound a therapeutic or diagnostic agent.

IT **448950-42-3**
RL: PRP (Properties)
(unclaimed sequence; enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents)

IT **448950-42-3**
RL: PRP (Properties)
(unclaimed sequence; enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents)

RN 448950-42-3 HCAPLUS

CN L-Arginine, L-arginyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L59 ANSWER 27 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:595029 HCAPLUS
DN 137:174885
TI Targeting delivery of apoptosis-regulating proteins affecting the permeability transition pore complex using fusion proteins with cell-specific antibodies
IN Edelman, Lena; Jacotot, Etienne; Briand, Jean-Paul
PA Institut Pasteur, Fr.; Centre National De La Recherche
SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002061105	A2	20020808	WO 2002-EP1633	20020201 <--
	WO 2002061105	C2	20021031		
	WO 2002061105	A3	20031106		
	WO 2002061105	C1	20040521		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003077826	A1	20030424	US 2002-59261	20020131	<--
CA 2436281	AA	20020808	CA 2002-2436281	20020201	<--
EP 1379672	A2	20040114	EP 2002-722084	20020201	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004532005	T2	20041021	JP 2002-561659	20020201	<--
US 2004265300	A1	20041230	US 2003-627649	20030728	<--
PRAI US 2001-265594P	P	20010202	<--		
WO 2002-EP1633	W	20020201			

AB Fusion proteins of an apoptosis-regulating protein and a cell surface protein-specific antibody are used to target the apoptosis regulating protein to a specific cell type. The apoptosis regulating protein is preferably the Vpr peptide of HIV-1 or a fragment containing the amino acid motif H(F/S)RIG that interacts with mitochondrial inner membrane, adenine nucleotide translocation (ANT) protein of a cell. Binding of the fusion protein to the cell is followed by uptake of the protein and induction or inhibition of apoptosis of the cell. A vector encoding a fusion protein and a host cell carrying the vector are provided. The fusion proteins are useful for the targeted killing of cells such as cancer cells. The preparation of peptides inducing mitochondrial swelling (apoptosis-inducing) or inhibiting atractyloside-induced swelling (apoptosis-inhibiting) is demonstrated.

IT **123251-89-8D**, fusion products, **conjugates**, retroverso analogs
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as apoptosis inhibitor; targeting delivery of apoptosis-regulating proteins affecting permeability transition pore complex using fusion proteins with cell-specific antibodies)

IT **123251-89-8**
RL: PRP (Properties)
(unclaimed sequence; targeting delivery of apoptosis-regulating proteins affecting the permeability transition pore complex using fusion proteins with cell-specific antibodies)

IT **123251-89-8D**, fusion products, **conjugates**, retroverso analogs
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as apoptosis inhibitor; targeting delivery of apoptosis-regulating proteins affecting permeability transition pore complex using fusion proteins with cell-specific antibodies)

RN 123251-89-8 HCAPLUS

CN L-Arginine, L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L59 ANSWER 28 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:521462 HCAPLUS
DN 137:88442
TI Incensole and furanogermacrens and compounds in treatment for inhibiting neoplastic lesions and microorganisms
IN Shanahan-Pendergast, Elisabeth
PA Ire.
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002053138	A2	20020711	WO 2002-IE1	20020102 <--
WO 2002053138	A3	20020919		

W: AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD,

UA, UG, US, VN, YU, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI, ML, MR, NE, SN, TD, TG

AU 2002219472 A1 20020716 AU 2002-219472 20020102 <--
EP 1351678 A2 20031015 EP 2002-727007 20020102 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2004092583 A1 20040513 US 2004-250535 20040102 <--
PRAI IE 2001-2 A 20010102 <--
WO 2002-IE1 W 20020102
OS MARPAT 137:88442
AB The invention discloses the use of incensole and/or furanogermacrens, derivs. metabolites and precursors thereof in the treatment of neoplasia, particularly resistant neoplasia and immunodysregulatory disorders. These compds. can be administered alone or in combination with conventional chemotherapeutic, antiviral, antiparasite agents, radiation and/or surgery. Incensole and furanogermacren and their mixture showed antitumor activity against various human carcinomas and melanomas and antimicrobial activity against Staphylococcus aureus and Enterococcus faecalis.
IT **153127-49-2**, ALX40-4C
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulation further containing; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
IT **153127-49-2**, ALX40-4C
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulation further containing; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
RN 153127-49-2 HCAPLUS
CN D-Argininamide, N2-acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-, nonaacetate (9CI) (CA INDEX NAME)

CM 1

CRN 143413-49-4
CMF C56 H113 N37 O10

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



CM 2

CRN 64-19-7
CMF C2 H4 O2



L59 ANSWER 29 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:293810 HCAPLUS

DN 136:330522
TI Intracellular delivery of biological effectors
IN Bonny, Christophe
PA University of Lausanne, Switz.
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002031109	A2	20020418	WO 2001-IB2423	20011015 <--
	WO 2002031109	A3	20030116		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2425610	AA	20020418	CA 2001-2425610	20011015 <--
	AU 2002020979	A5	20020422	AU 2002-20979	20011015 <--
	EP 1345956	A2	20030924	EP 2001-986713	20011015 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004511494	T2	20040415	JP 2002-534479	20011015 <--
	US 2004110690	A1	20040610	US 2003-399127	20031204 <--
	US 7034109	B2	20060425		
PRAI	US 2000-240315P	P	20001013	<--	
	WO 2001-IB2423	W	20011015	<--	

AB The invention relates to a sequence of amino acids with the capacity to facilitate transport of an effector across a biol. membrane. More specifically, the present invention relates to novel peptide transporters that specifically target certain cell types for the intracellular delivery of drugs and therapeutic agents.

IT **412271-64-8**
RL: BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(intracellular delivery of biol. effectors with peptide transporters)

IT **412271-64-8**
RL: BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(intracellular delivery of biol. effectors with peptide transporters)

RN 412271-64-8 HCAPLUS
CN L-Arginine, L-arginylglycyl-L-asparaginyl-L-arginylglycyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L59 ANSWER 30 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:185291 HCAPLUS
DN 136:242900
TI Site-specific DNA recombination with cell-permeable Cre recombinase fusion proteins containing a membrane translocation sequence or nuclear localization signal
IN Ruley, H. Earl; Jo, Daewoong
PA Vanderbilt University, USA
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002020737	A2	20020314	WO 2001-US28209	20010907 <--
	WO 2002020737	A3	20020829		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001088955	A5	20020322	AU 2001-88955	20010907 <--
	US 2003027335	A1	20030206	US 2001-948193	20010907 <--
PRAI	US 2000-230690P	P	20000907 <--		
	WO 2001-US28209	W	20010907 <--		

AB The present invention provides site-specific DNA recombinase fusion

proteins containing a membrane translocation sequence, cDNAs, and uses in effecting site-specific DNA recombination in cells and in animals. Also provided are methods of determining the efficiency of protein transduction into cells; methods of detecting whether site-specific DNA recombination has occurred within a cell; methods of identifying compds. that modulate nuclear metabolism or protein trafficking, uptake, and/or excretion; and methods of identifying peptides that act as membrane translocation signals or that act as nuclear localization signals or other types of protein targeting signals. In the present study, recombinant fusion proteins bearing the 12 amino acid membrane translocation sequence (MTS) from the Kaposi fibroblast growth factor (FGF-4) were used to transduce enzymically active Cre proteins directly into mammalian cells. High levels of recombination were observed in a variety of cultured cell types and in all tissues examined in mice following i.p. administration. This represents the first use of protein transduction to induce the enzymic conversion of a substrate in living cells and animals and provides a rapid and efficient means to manipulate mammalian gene structure and function.

IT **136268-89-8**
RL: PRP (Properties)
(unclaimed sequence; site-specific DNA recombination with cell-permeable Cre recombinase fusion proteins containing a membrane translocation sequence or nuclear localization signal)

IT **136268-89-8**
RL: PRP (Properties)
(unclaimed sequence; site-specific DNA recombination with cell-permeable Cre recombinase fusion proteins containing a membrane translocation sequence or nuclear localization signal)

RN 136268-89-8 HCAPLUS

CN L-Arginine, L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

NH_2

PAGE 2-A



L59 ANSWER 31 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:142874 HCAPLUS
DN 136:195329
TI Nucleic acid and corresponding protein sequences of human PHOR1-A11 and PHOR1-F5D6 useful in treatment and detection of cancer
IN Hubert, Rene S.; Raitano, Arthur B.; Faris, Mary; Challita-Eid, Pia M.; Ge, Wangmao; Jakobovits, Aya
PA Agensys, Inc., USA
SO PCT Int. Appl., 250 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002014501	A2	20020221	WO 2001-US25862	20010817 <--
	WO 2002014501	A3	20030130		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001086541	A5	20020225	AU 2001-86541	20010817 <--
PRAI	US 2000-226241P	P	20000817 <--		
	WO 2001-US25862	W	20010817 <--		

AB The present invention relates to novel genes, designated PHOR1-A11 and PHOR1-F5D6, that are over-expressed in prostate, ovarian, bladder, and kidney cancers. A degenerate oligo PCR strategy was utilized to identify these two family members of the G-protein coupled receptors. Northern blot anal. of PHOR1-A11 and PHOR1-F5D6 gene expression in normal tissues shows a restricted expression pattern in adult tissues. The nucleotide and amino acid sequences of PHOR1-A11 and PHOR1-F5D6 are provided. PHOR1-A11 has the highest homol. to a Marmota olfactory receptor with 83% identity and 92% similarity over the entire Marmota 237 amino acid sequence; PHOR1-F5D6 has 100% amino acid homol. to an olfactory receptor protein predicted from PAC clone RP5-988G15. PHOR1-A11 is localized to human chromosome 1q43, suggesting that it is a candidate gene for hereditary prostate cancer, whereas PHOR1-F5D6 is localized to 7q33-q35, a region frequently amplified or rearranged in cancer. The tissue-related profile of PHOR1-A11 and PHOR1-F5D6 in normal adult tissues, combined with the over-expression observed in prostate and other tumors, shows that PHOR1-A11 and PHOR1-F5D6 is aberrantly over-expressed in at least some cancers, and thus serves as a useful diagnostic and/or therapeutic target for cancers of tissues such as prostate. The PHOR1-A11 or PHOR1-F5D6 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.

IT **398467-75-9**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunogenic peptide; nucleic acid and corresponding protein sequences of human PHOR1-A11 and PHOR1-F5D6 useful in treatment and detection of cancer)

IT **398467-75-9**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunogenic peptide; nucleic acid and corresponding protein sequences of human PHOR1-A11 and PHOR1-F5D6 useful in treatment and detection of cancer)

RN 398467-75-9 HCAPLUS

CN L-Arginine, L-arginyl-L-α-glutamyl-L-valyl-L-glutaminyl-L-arginyl-L-lysyl-L-alanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

PAGE 2-A



L59 ANSWER 32 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:142749 HCAPLUS
DN 136:195323
TI Nucleic acid and corresponding protein sequences of human 83P2H3 and CaTrF2E11 useful in treatment and detection of cancer
IN Raitano, Arthur B.; Challita-Eid, Pia M.; Faris, Mary; Saffran, Douglas C.; Afar, Daniel E. H.; Levin, Elana; Hubert, Rene S.; Ge, Wangmao; Jakobovits, Aya
PA Agensys, Inc., USA
SO PCT Int. Appl., 270 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002014361	A2	20020221	WO 2001-US25782	20010817 <--
	WO 2002014361	A3	20030925		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001085018	A5	20020225	AU 2001-85018	20010817 <--
	US 2003134784	A1	20030717	US 2001-932165	20010817 <--
PRAI	US 2000-226329P	P	20000817 <--		
	WO 2001-US25782	W	20010817 <--		

AB The present invention relates to novel genes, designated 83P2H3 and CaTrF2E11, that are over-expressed in prostate, ovarian, bladder, kidney, and lung cancers. A degenerate oligo PCR strategy was utilized to identify these two family members of the calcium transporters. Northern blot anal. of 83P2H3 and CaTrF2E11 gene expression in normal tissues shows a restricted expression pattern in adult tissues. The nucleotide and amino acid sequences of 83P2H3 and CaTrF2E11 are provided. 83P2H3 is localized to human chromosome 7q34, whereas CaTrF2E11 is localized to 12q24.1. The tissue-related profile of 83P2H3 and CaTrF2E11 in normal adult tissues, combined with the over-expression observed in prostate and other tumors, shows that 83P2H3 and CaTrF2E11 is aberrantly over-expressed in at least some cancers, and thus serves as a useful diagnostic and/or therapeutic target for cancers of tissues such as prostate. The 83P2H3 or CaTrF2E11 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.

IT **399540-45-5**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunogenic peptide; nucleic acid and corresponding protein sequences of human 83P2H3 and CaTrF2E11 useful in treatment and detection of cancer)

IT **399540-45-5**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunogenic peptide; nucleic acid and corresponding protein sequences of human 83P2H3 and CaTrF2E11 useful in treatment and detection of cancer)

RN 399540-45-5 HCAPLUS
CN L-Arginine, L-arginyl-L-threonyl-L-asparaginyl-L-asparaginyl-L-arginyl-L-threonyl-L-seryl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L59 ANSWER 33 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:107056 HCAPLUS
DN 136:166049
TI Molecular vaccine linking intercellular spreading protein to an antigen
IN Wu, Tzyy-Choou; Hung, Chien-Fu
PA The Johns Hopkins University, USA
SO PCT Int. Appl., 102 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002009645	A2	20020207	WO 2001-US23966	20010801 <--
	WO 2002009645	A3	20021017		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001090520	A5	20020213	AU 2001-90520	20010801 <--
	US 2004028693	A1	20040212	US 2003-343719	20030808 <--
PRAI	US 2000-222185P	P	20000801 <--		
	US 2001-268575P	P	20010215 <--		
	US 2001-281004P	P	20010404 <--		
	WO 2001-US23966	W	20010801 <--		

AB Superior mol. vaccines comprise nucleic acids, including naked DNA and replicon RNA, that encode a fusion polypeptide that includes an antigenic peptide or polypeptide against which an immune response is desired. Fused to the antigenic peptide is an intercellular spreading protein, in particular a herpes virus protein VP22 or a homolog or functional derivative thereof. Preferred spreading proteins are VP22 from HSV-1 and Marek's disease virus. The nucleic acid can encode any antigenic epitope of interest, preferably an epitope that is processed and presented by MHC class I proteins. Antigens of pathogenic organisms and cells such as tumor cells are preferred. Vaccines comprising HPV-16 E7 oncoprotein are exemplified. Also disclosed are methods of using the vaccines to induce heightened T cell mediated immunity, in particular by cytotoxic T lymphocytes, leading to protection from or treatment of a tumor.

IT **397274-55-4**
RL: PRP (Properties)
(unclaimed sequence; mol. vaccine linking intercellular spreading protein to an antigen)

IT **397274-55-4**
RL: PRP (Properties)
(unclaimed sequence; mol. vaccine linking intercellular spreading protein to an antigen)

RN 397274-55-4 HCAPLUS
CN L-Arginine, L-arginyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L59 ANSWER 34 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:72152 HCAPLUS
DN 136:133605
TI Vaccine comprising a lung tumor associated antigen
IN Cassart, Jean-pol; Gaulis, Swann; Vinals y De Bassols, Carlota
PA Smithkline Beecham Biologicals SA, Belg.
SO PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002006338	A1	20020124	WO 2001-EP7967	20010711 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2000-17512 A 20000717 <--

AB CASB761 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB761 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly lung cancer, lung preneoplasic lesions, autoimmune diseases, and related conditions.

IT **392654-62-5**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vaccine comprising lung tumor-associated antigen CASB761 protein)

IT **392654-62-5**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vaccine comprising lung tumor-associated antigen CASB761 protein)

RN 392654-62-5 HCAPLUS

CN L-Arginine, L-arginyl-L-arginyl-L-asparaginyl-L-α-glutamyl-L-arginyl-L-α-glutamyl-L-arginyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

NH_2

PAGE 2-A



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ball, D	1993	90	5648	Proceedings of the N	HCAPLUS
Black, B	1996	271	26659	Journal of Biologica	HCAPLUS
Del Amo Francisco, F	1993	1171	323	Biochimica et Biophy	
Johnson, J	1990	346	858	Nature	HCAPLUS
Levesque, M	2000			US 6087168 A	HCAPLUS
Lo, L	1998	125	609	Development	HCAPLUS
Sommer, L	1995	15	1245	Neuron	HCAPLUS
Sunita, V	1996	180	605	Developmental Biolog	
Yuji, S	1999	444	43	FEBS Letters	

L59 ANSWER 35 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:31529 HCAPLUS
DN 136:117377
TI Antibodies to B lymphocyte stimulator (BLyS)
IN Ruben, Steven M.; Barash, Steven C.; Choi, Gil H.; Vaughan, Tristan; Hilbert, David
PA Human Genome Sciences, Inc., USA; Cambridge Antibody Technology Ltd.
SO PCT Int. Appl., 3148 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 19

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002002641	A1	20020110	WO 2001-US19110	20010615 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1577391 A1 20050921 EP 2005-12261 19961025 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
CA 2407910 AA 20020110 CA 2001-2407910 20010615 <--
EP 1294769 A1 20030326 EP 2001-946365 20010615 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004509615 T2 20040402 JP 2002-507892 20010615 <--
CN 1492878 A 20040428 CN 2001-811296 20010615 <--
NZ 522700 A 20060224 NZ 2001-522700 20010615 <--
AU 2001054180 A5 20020725 AU 2001-54180 20010703 <--
AU 779750 B2 20050210
JP 2004129667 A2 20040430 JP 2003-362615 20031022 <--
PRAI US 2000-212210P P 20000616 <--
US 2000-240816P P 20001017 <--
US 2001-276248P P 20010316 <--
US 2001-277379P P 20010321 <--
US 2001-293499P P 20010525 <--
AU 1996-76745 A3 19961025 <--
EP 1996-939612 A3 19961025 <--
JP 1998-520411 A3 19961025 <--
WO 2001-US19110 W 20010615 <--

AB The authors disclose the preparation and characterization of single-chain antibodies that specifically bind to BLyS. The present invention also relates to methods and compns. for detecting, diagnosing, or treating a disease or disorder associated with aberrant BLyS expression.

IT **389116-42-1**
RL: PRP (Properties)
(amino acid sequence; heavy chain CDR3 for human antibodies to B lymphocyte stimulator)

IT **389116-42-1**
RL: PRP (Properties)
(amino acid sequence; heavy chain CDR3 for human antibodies to B lymphocyte stimulator)

RN 389116-42-1 HCAPLUS
CN L-Arginine, L-arginyl-L-leucyl-L-isoleucyl-L-arginyl-L-lysyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Nardelli	2001	97	198	Blood	HCAPLUS

L59 ANSWER 36 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:935354 HCAPLUS
DN 136:64094
TI The use of synthetic, non-hormonal 21-aminosteroids, derivatives, metabolites, and precursors thereof in the treatment of viral infections
IN Prendergast, Patrick Thomas
PA Kotze, Gavin Salomon, S. Afr.
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001097749	A2	20011227	WO 2001-IB1101	20010622 <--
	WO 2001097749	A3	20020523		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001074383	A5	20020102	AU 2001-74383	20010622 <--
PRAI	IE 2000-511	A	20000623	<--	
	IE 2001-275	A	20010321	<--	

WO 2001-IB1101 W 20010622 <--

AB The invention discloses the use of synthetic, non-hormonal 21-aminosteroids, derivs., metabolites, and precursors thereof in the treatment of viral infections, particularly hepatitis and retroviral infection by HIV. Synthetic non-hormonal 21-aminosteroids are disclosed for use in the prophylaxis and therapy of hepatitis viral infections. These compds. can be administered alone or in combination with conventional antiviral agents.

IT **153127-49-2**, ALX40-4C
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aminosteroids, derivs., metabolites, and precursors for treatment of viral infection, and use with other agents)

IT **153127-49-2**, ALX40-4C
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aminosteroids, derivs., metabolites, and precursors for treatment of viral infection, and use with other agents)

RN 153127-49-2 HCAPLUS

CN D-Argininamide, N2-acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-, nonaacetate (9CI) (CA INDEX NAME)

CM 1

CRN 143413-49-4
CMF C56 H113 N37 O10

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



CM 2

CRN 64-19-7
CMF C2 H4 O2



L59 ANSWER 37 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:885823 HCAPLUS
DN 136:42834
TI Tumor activated prodrug compounds
IN Trouet, Andre; Dubois, Vincent; Oronsky, Arnold
PA Universite Catholique De Louvain, Belg.
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001091798	A2	20011206	WO 2001-EP6106	20010529 <--
	WO 2001091798	A3	20021205		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2408103	AA	20011206	CA 2001-2408103	20010529 <--
	EP 1286700	A2	20030305	EP 2001-957808	20010529 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003534387	T2	20031118	JP 2001-587810	20010529 <--
	US 2004014652	A1	20040122	US 2003-296954	20030616 <--
PRAI	US 2000-208996P	P	20000601	<--	
	EP 2000-870130	A	20000615	<--	

EP 2000-870306 A 20001218 <--
WO 2001-EP6106 W 20010529 <--

OS MARPAT 136:42834

AB The invention is directed to novel prodrug compds., compns. comprising the prodrugs, methods of making and using them. The prodrugs comprise a biol. active entity linked to a masking moiety via a linking moiety. The prodrug compds. are selectively activated at or near target cells and display lower toxicity and possibly a longer in vivo or serum half-life than the corresponding naked biol. active entity. A IGF-1 antagonist is used to prepare a dual prodrug with doxorubicin. For the dual prodrug, **conjugation** takes place at the carboxyterminus of the antagonist rather than on its free N-terminal amino group. The in vivo toxicity of the dual prodrug is evaluated, and its chemotherapeutic activity is compared to that of Dox and of the IGF-1 antagonist, alone or in combination.

IT **143413-47-2D**, prodrugs **153127-44-7D**, prodrugs
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor activated prodrug compds.)

IT **143413-47-2D**, prodrugs
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor activated prodrug compds.)

RN 143413-47-2 HCAPLUS

CN L-Arginine, L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-A



L59 ANSWER 38 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:489483 HCAPLUS
DN 135:102578
TI BH4-fused polypeptides
IN Shimizu, Shigeomi; Tsujimoto, Yoshihide
PA Shionogi + Co., Ltd, Japan
SO PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001048014	A1	20010705	WO 2000-JP9274	20001226 <--
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	EP 1243595	A1	20020925	EP 2000-985913	20001226 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	US 2003152946	A1	20030814	US 2002-169223	20020627 <--
PRAI	JP 1999-371449	A	19991227 <--		
	WO 2000-JP9274	W	20001226 <--		

AB BH4-fused polypeptides which contain the amino acid sequence of a polypeptide capable of exerting an effect of enabling uptake into cells or a derivative sequence thereof, and an amino acid sequence selected from the group consisting of: (A) amino acid sequences at least containing the BH4 domain sequence (SEQ ID NO:1) of an anti-apoptosis Bcl-2 family protein, (B) amino acid sequences derived from the amino acid sequence represented by SEQ ID NO:1 by substitution, deletion or insertion of at least one amino acid residue, and (C) amino acid sequences having a sequence homol.

of at least 50 with the amino acid sequence represented by SEQ ID NO:1, and are capable of inhibiting apoptosis; apoptosis inhibitors containing these BH4-fused proteins; a method of treating ischemic diseases which comprises administering these apoptosis inhibitors to patients with ischemic diseases to thereby inhibit apoptosis and treat the ischemic diseases; and use of the BH4-fused proteins for producing preventives or remedies for ischemic diseases. Thus, apoptosis can be efficiently inhibited and it is expected that the BH4-fused proteins are applicable to remedies for AIDS, neurodegenerative diseases, myelodysplastic diseases, ischemic diseases, infective multiple failure, fulminant hepatitis, diabetes, etc.

IT **123251-89-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(BH4-fused polypeptides for treatment of AIDS, neurodegenerative diseases, myelodysplastic diseases, ischemic diseases, infective multiple failure, fulminant hepatitis and diabetes)

IT **123251-89-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(BH4-fused polypeptides for treatment of AIDS, neurodegenerative diseases, myelodysplastic diseases, ischemic diseases, infective multiple failure, fulminant hepatitis and diabetes)

RN 123251-89-8 HCAPLUS

CN L-Arginine, L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Shimizu, S	1999	399	483	Nature	HCAPLUS
Tsujimoto, Y	1985	228	1440	Science	HCAPLUS

L59 ANSWER 39 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:489209 HCAPLUS
DN 135:111952
TI Histidine copolymer for delivery of drugs into cells
IN Mixson, A. James
PA USA
SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001047496	A1	20010705	WO 2000-US34603	20001220 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2394758	AA	20010705	CA 2000-2394758	20001220 <--
	EP 1242052	A1	20020925	EP 2000-986605	20001220 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003045465	A1	20030306	US 2001-18103	20011105 <--
	US 2003165567	A1	20030904	US 2002-131909	20020425 <--
	US 7070807	B2	20060704		
PRAI	US 1999-173576P	P	19991229 <--		
	WO 2000-US34603	W	20001220 <--		
	US 2001-18103	A2	20011105 <--		

AB The invention provides a pharmaceutical agent delivery composition comprising: (i) a transport polymer comprising a linear or branched peptide having from about 10 to about 300 amino acid residues, having from about 5 to 100 histidine residues, and optionally having from 0 to about 95 non-histidine amino acid residues; (ii) at least one pharmaceutical agent; and optionally (iii) one or more intracellular delivery components in association with the transport polymer. The invention also provides methods for using such composition to deliver the pharmaceutical agent to the interior of cells.
IT **349451-29-2**

RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(biol. transport-promoting; histidine copolymer for delivery of drugs into cells)

IT **349451-29-2**

RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(biol. transport-promoting; histidine copolymer for delivery of drugs into cells)

RN 349451-29-2 HCAPLUS

CN L-Arginine, L-arginyl-L-histidyl-L-arginyl-L-histidyl-L-arginyl-L-histidyl-L-arginyl-L-histidyl-L-arginylglycyl-L-arginyl-L-histidyl-L-arginyl-L-histidyl-L-arginyl-L-histidyl-L-arginyl-L-histidyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Mathiowitz	1999			US 5985354 A	HCAPLUS

L59 ANSWER 40 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:440198 HCAPLUS
DN 135:121177
TI Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
IN Sette, Alessandro; Sidney, John; Southwood, Scott; Livingston, Brian D.; Chesnut, Robert; Baker, Denise Marie; Celis, Esteban; Kubo, Ralph T.; Grey, Howard M.
PA Epimmune Inc., USA
SO PCT Int. Appl., 448 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 18

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001024810	A1	20010412	WO 2000-US27766	20001005 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2386499	AA	20010412	CA 2000-2386499	20001005 <--
	EP 1225907	A1	20020731	EP 2000-972031	20001005 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003510099	T2	20030318	JP 2001-527809	20001005 <--
PRAI	US 1999-412863	A	19991005 <--		
	WO 2000-US27766	W	20001005 <--		

AB This invention uses knowledge of the mechanisms by which antigens are recognized by T cells to identify and prepare human immunodeficiency virus (HIV) epitopes, and to develop epitope-based vaccines directed towards HIV. More specifically, this application communicates the discovery of pharmaceutical compns. and methods of use in the prevention and treatment of HIV infection.
IT **334752-75-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HIV A03 motif peptides with binding information; epitopes of HIV-1, cytotoxic T lymphocyte and helper T lymphocyte as vaccine for inducing cellular immune responses to human immunodeficiency virus-1)
IT **334752-75-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HIV A03 motif peptides with binding information; epitopes of HIV-1, cytotoxic T lymphocyte and helper T lymphocyte as vaccine for inducing cellular immune responses to human immunodeficiency virus-1)
RN 334752-75-9 HCAPLUS
CN L-Arginine, L-arginyl-L-leucyl-L-isoleucyl-L-α-aspartyl-L-arginyl-L-isoleucyl-L-arginyl-L-α-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L59 ANSWER 41 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:435102 HCAPLUS
DN 135:56043
TI Complementary peptide ligands generated from higher eukaryote genome sequences
IN Roberts, Gareth Wyn; Heal, Jonathan Richard
PA Proteom Limited, UK
SO PCT Int. Appl., 488 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001042276	A1	20010614	WO 2000-GB4773	20001213 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,

LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001018721 A5 20010618 AU 2001-18721 20001213 <--
EP 1244691 A1 20021002 EP 2000-981486 20001213 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRAI GB 1999-29471 A 19991213 <--
WO 2000-GB4773 W 20001213 <--

AB The invention relates to the identification of complementary peptides from the anal. of protein and nucleotide sequence databases from higher eukaryote genomes excluding human and plants. These specific complementary peptides interact with their relevant target proteins encoded in the eukaryote genome. Specific complementary peptides to the proteins encoded in the eukaryote genome can be used as reagents and drugs from drug discovery programs and as lead ligands to facilitate drug design and development.

IT **345608-54-0**
RL: PRP (Properties)
(Unclaimed; complementary peptide ligands generated from higher eukaryote genome sequences)

IT **345591-17-5 345603-11-4 345603-21-6**
RL: PRP (Properties)
(unclaimed sequence; complementary peptide ligands generated from higher eukaryote genome sequences)

IT **345608-54-0**
RL: PRP (Properties)
(Unclaimed; complementary peptide ligands generated from higher eukaryote genome sequences)

RN 345608-54-0 HCAPLUS

CN L-Arginine, L-arginyl-L-seryl-L-leucyl-L-arginyl-L-seryl-L-leucyl-L-arginyl-L-seryl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RSLRSLRSLR

PAGE 1-A



PAGE 1-B



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Heal, J	1999	36	1131	MOLECULAR IMMUNOLOGY	
William, R	1988	183	63	METHODS IN ENZYMOLOG	
William, R	1988	85	2444	PROC NATL ACAD SCI U	

L59 ANSWER 42 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:338365 HCAPLUS
DN 134:344610
TI Cytotoxic T lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma
IN Hogan, Kevin T.; Ross, Mark H.; Slingluff, Craig L.
PA Argonex Pharmaceuticals, USA
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032193	A1	20010510	WO 2000-US29679	20001027 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-162480P P 19991029 <--

AB The present invention relates to compns. and methods for the prevention, treatment, and diagnosis of cancer, specifically malignant melanoma. The invention discloses peptides derived from one or more presently unidentified genes, as well as variants of these proteins that can be used to stimulate a CTL response against melanoma. Further disclosed, is a peptide derived from gp100, which can also be used to stimulate a CTL response against melanoma.

IT **338458-37-0 338458-39-2 338458-40-5**
338458-41-6 338458-42-7 338458-43-8
338458-44-9 338458-45-0 338458-46-1
338458-47-2 338458-48-3 338458-49-4
338458-50-7 338458-51-8 338458-52-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(cytotoxic T lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma)

IT **338458-37-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(cytotoxic T lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma)

RN 338458-37-0 HCAPLUS

CN L-Arginine, L-arginyl-L-leucyl-L-seryl-L-asparaginyl-L-arginyl-L-leucyl-L-leucyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Epimmune Inc	1999			WO 9945954 A1	HCAPLUS
University Of Virginia	1997			WO 9734613 A1	HCAPLUS

L59 ANSWER 43 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:311711 HCAPLUS
DN 135:43973
TI Characteristics of membrane permeable arginine-rich peptides
AU Suzuki, Tomoki; Ohashi, Wakana; Nakase, Ikuhiko; Tanaka, Seigo; Ueda, Kunihiro; Futaki, Shiroh; Sugiura, Yukio
CS Institute for Chemical Research, Kyoto University, Kyoto, 611-0011, Japan
SO Peptide Science (**2001**), Volume Date 2000, 37th, 89-92
CODEN: PSCIFQ; ISSN: 1344-7661
PB Japanese Peptide Society
DT Journal
LA English
AB Arginine-rich basic peptides have been reported to be cell membrane-permeable and to have a function of protein delivery into cells. Arginine residues in these peptides are considered to play a critical role for the characteristics. Fluorescence microscopic observation and quantification of the internalized (Arg)n peptides (n=4,6,8,10,12,16) to

mouse macrophage RAW264.7 cells revealed the existence of the optimal chain length for the efficient translocation.

IT **74386-12-2 148796-87-6**
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(cell membrane permeability for arginine-rich peptides)

IT **74386-12-2**
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(cell membrane permeability for arginine-rich peptides)

RN 74386-12-2 HCAPLUS

CN L-Arginine, L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A







PAGE 2-B



PAGE 3-A





RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Derossi, D	1994	269	10444	J Biol Chem	HCAPLUS
Futaki, S	2000	1999	241	Peptide Science	
Vives, E	1997	272	16010	J Biol Chem	HCAPLUS

L59 ANSWER 44 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:166563 HCAPLUS
DN 134:337296
TI Arginine-rich peptides: an abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery
AU Futaki, Shiroh; Suzuki, Tomoki; Ohashi, Wakana; Yagami, Takeshi; Tanaka, Seigo; Ueda, Kunihiro; Sugiura, Yukio
CS Institute for Chemical Research, Kyoto University, Kyoto, 611-0011, Japan
SO Journal of Biological Chemistry (**2001**), 276(8), 5836-5840
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
AB A basic peptide derived from human immunodeficiency virus (HIV)-1 Tat protein (positions 48-60) has been reported to have the ability to translocate through the cell membranes and accumulate in the nucleus, the characteristics of which are utilized for the delivery of exogenous proteins into cells. Based on the fluorescence microscopic observations of mouse macrophage RAW264.7 cells, we found that various arginine-rich peptides have a translocation activity very similar to Tat-(48-60). These included such peptides as the D-amino acid- and arginine-substituted Tat-(48-60), the RNA-binding peptides derived from virus proteins, such as HIV-1 Rev, and flock house virus coat proteins, and the DNA binding segments of leucine zipper proteins, such as cancer-related proteins c-Fos and c-Jan, and the yeast transcription factor GCN4. These segments have

no specific primary and secondary structures in common except that they have several arginine residues in the sequences. Moreover, these peptides were internalized even at 4°. These results strongly suggested the possible existence of a common internalization mechanism ubiquitous to arginine-rich peptides, which is not explained by a typical endocytosis. Using (Arg)n (n = 4-16) peptides, we also demonstrated that there would be an optimal number of arginine residues (n .apprx. 8) for the efficient translocation.

IT **208646-07-5**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(R10; arginine-rich peptides as potential carriers for intracellular protein delivery)

IT **337516-36-6**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(R12; arginine-rich peptides as potential carriers for intracellular protein delivery)

IT **208646-07-5**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(R10; arginine-rich peptides as potential carriers for intracellular protein delivery)

RN 208646-07-5 HCAPLUS

CN L-Argininamide, L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 3-A



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Calnan, B	1991	252	1167	Science	HCAPLUS
Chang, H	1997	11	1421	AIDS	HCAPLUS
Derossi, D	1994	269	10444	J Biol Chem	HCAPLUS
Derossi, D	1996	271	18188	J Biol Chem	HCAPLUS
Derossi, D	1998	8	84	Trends Cell Biol	HCAPLUS
Fawell, S	1994	91	664	Proc Natl Acad Sci U	HCAPLUS
Futaki, S	1997	5	1883	Bioorg Med Chem	HCAPLUS
Gorlich, D	1996	271	1513	Science	HCAPLUS
Huq, I	1999	38	5172	Biochemistry	HCAPLUS

Kalderon, D	1984	39	499	Cell	HCAPLUS
Lin, Y	1995	270	14255	J Biol Chem	HCAPLUS
Nagahara, H	1998	4	1449	Nat Med	HCAPLUS
Rojas, M	1996	271	27456	J Biol Chem	HCAPLUS
Rojas, M	1998	16	370	Nat Biotechnol	HCAPLUS
Schwarze, S	1999	285	1569	Science	HCAPLUS
Schwarze, S	2000	21	45	Trends Pharmacol Sci	HCAPLUS
Tachibana, R	1998	251	538	Biochem Biophys Res	HCAPLUS
Tan, R	1995	92	5282	Proc Natl Acad Sci U	HCAPLUS
Vives, E	1997	272	16010	J Biol Chem	HCAPLUS

L59 ANSWER 45 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:152524 HCAPLUS
DN 134:212694
TI Compositions and methods for enhancing drug delivery across and into epithelial tissues
IN Rothbard, Jonathan B.; Wender, Paul A.; McGrane, P. Leo; Sista, Lalitha V. S.; Kirschberg, Thorsten A.
PA Cellgate, Inc., USA
SO PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001013957	A2	20010301	WO 2000-US23440	20000824 <--
	WO 2001013957	A3	20011004		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2381425	AA	20010301	CA 2000-2381425	20000824 <--
	EP 1210121	A2	20020605	EP 2000-957830	20000824 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003507438	T2	20030225	JP 2001-518092	20000824 <--
	AU 769315	B2	20040122	AU 2000-69394	20000824 <--
	AU 2000069394	A5	20010319		
	US 6730293	B1	20040504	US 2000-645689	20000824 <--
PRAI	US 1999-150510P	P	19990824 <--		
	WO 2000-US23440	W	20000824 <--		

OS MARPAT 134:212694
AB This invention provides compns. and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, and the like. The compns. and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compns. and methods employ a delivery-enhancing transport that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound The delivery enhancing polymers include, for example, poly-arginine mols. that are preferably between about 6 and 25 residues in length.
IT **328234-41-9P 328234-42-0P**

RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compns. and methods for enhancing drug delivery across and into epithelial tissues)

IT **328234-41-9P**

RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compns. and methods for enhancing drug delivery across and into epithelial tissues)

RN 328234-41-9 HCAPLUS

CN Cyclosporin A, 6-[(2S,3R,4R,6E)-3-[(mercaptoacetyl)oxy]-4-methyl-2-(methylamino)-6-octenoic acid]-, (6→8')-thioether with N2-[6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]-1-oxohexyl]-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-L-cysteinamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



L59 ANSWER 46 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:145156 HCAPLUS
DN 134:206555
TI Methods and compositions for impairing multiplication of HIV-1
IN Goldstein, Gideon
PA Thymon L.L.C., USA
SO U.S., 63 pp., Cont.-in-part of U.S. 5,891,994.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6193981	B1	20010227	US 1998-113921	19980710 <--
	US 5891994	A	19990406	US 1997-893853	19970711 <--
	US 6525179	B1	20030225	US 1999-451067	19991130 <--
	US 2003194408	A1	20031016	US 2002-86208	20020228 <--
	US 7008622	B2	20060307		
	US 2003166832	A1	20030904	US 2002-262435	20020930 <--
PRAI	US 1997-893853	A2	19970711 <--		
	US 1998-113921	A3	19980710 <--		
	US 1999-451067	A3	19991130 <--		

AB A composition which elicits antibodies to greater than 95%, and even greater than 99%, of the known variants of HIV-1 Tat protein contains at least one peptide or polypeptide of the formula of Epitope I (based on amino acids 2-10 of HIV-1 Tat consensus sequence) and optionally one or more of a peptide or polypeptide of Epitope II (based on amino acids 41 to 51 of that sequence), of Epitope III (based on amino acids 52-62 of that sequence), or of Epitope IV (based on amino acids 62 through 72 of that sequence with a C-terminal Pro). Vaccinal and pharmaceutical compns. can contain one or more such peptides associated with carrier proteins, in multiple antigenic peptides or as part of recombinant proteins. Various combinations of the Epitope I through IV peptides can provide other compns. useful in eliciting anti-Tat antibodies which cross-react with multiple strains and variants of HIV-1 Tat protein. Vaccinal and pharmaceutical compns. can contain the antibodies induced by the peptide

compns. for use in passive therapy. Diagnostic compns. and uses are described for assessing the immune status of vaccinated patients.

IT **123251-89-8**
RL: PRP (Properties)
(unclaimed sequence; methods and compns. for impairing multiplication of HIV-1)

IT **123251-89-8**
RL: PRP (Properties)
(unclaimed sequence; methods and compns. for impairing multiplication of HIV-1)

RN 123251-89-8 HCAPLUS

CN L-Arginine, L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File

Aldovini, A	1986	83	6672	Proc Natl Acad Sci U	HCAPLUS
Anon	1987			WO 8702989	HCAPLUS
Anon	1987			WO 8702989	HCAPLUS
Anon	1991			WO 9109958	HCAPLUS
Anon	1991			WO 9110453	HCAPLUS
Anon	1992			WO 9207871	HCAPLUS
Anon	1992			WO 9214755	HCAPLUS
Anon	1995			WO 9531999	HCAPLUS
Anon	1990		602	Webster's Ninth New	
Baumberger, C	1993	7	S59	AIDS	
Brake, D	1990	64	962	J Virol	HCAPLUS
Brake, D	1990	64	962	J of Virology	HCAPLUS
Cantin	1992			US 5110802	HCAPLUS
Clerici, M	1994	8	1391	AIDS	MEDLINE
Coombs, R	1996	174	704	J Infect Dis	MEDLINE
Daniel, M	1992	258	1938	Science	HCAPLUS
Dykes	1993			US 5238822	HCAPLUS
Edwards	1992			US 5158877	HCAPLUS
Fawell, S	1994	91	664	Proc Natl Acad Sci U	HCAPLUS
Frankel	1997			US 5674980	HCAPLUS
Frankel, A	1989	86	7397	Proc Natl Acad Sci U	HCAPLUS
Gaynor	1997			US 5597895	HCAPLUS
Goldstein, G	1996	2	960	Nature Medicine	HCAPLUS
Harlow	1988		96	Antibodies, a labora	
Haynes, B	1993	260	1279	Science	MEDLINE
Krone, W	1988	26	261	J Med Virol	HCAPLUS
Kusumi, K	1992	66	875	J Virol	HCAPLUS
Larder, B	1989	243	1731	Science	HCAPLUS
Lee, T	1994	7	381	J Acq Imm Def Synd	MEDLINE
Letvin, N	1993	329	1400	N Engl J Med	MEDLINE
Li, C	1997	94	8116	Proc Natl Acad Sci U	HCAPLUS
Mann, D	1991	10	1733	EMBO J	HCAPLUS
Mannino	1989			US 4871488	HCAPLUS
McPhee, D	1988	233	393	FEBS Letters	HCAPLUS
Mellors, J	1996	272	1167	Science	HCAPLUS
Meyerhans, A	1989	58	901	Cell	HCAPLUS
Osborn, J	1995	9	26	J Acq Imm Def Syndr	MEDLINE
Paul, W	1995	82	177	Cell	HCAPLUS
Preston, B	1988	242	1168	Science	HCAPLUS
Re, M	1995	10	408	J Acq Imm Def Synd H	HCAPLUS
Roberts, J	1988	242	1171	Science	HCAPLUS
Rodman	1997			US 5606026	HCAPLUS
Saag, M	1993	329	1065	N Engl J Med	MEDLINE
Saag, M	1996	2	625	Nature Medicine	HCAPLUS
Saksela, K	1994	91	1104	Proc Natl Acad Sci U	HCAPLUS
Sande, M	1993	270	2583	JAMA	MEDLINE
Seligmann, M	1994	343	871	Lancet	
Steinaa, L	1994	139	263	Arch Virol	HCAPLUS
Suzue	1996	156	873	J Immun	HCAPLUS
Suzue, K	1996	156	873	J Immunol	HCAPLUS
Tam, J	1988	85	5409	Proc Natl Acad Sci U	HCAPLUS
Tindall, B	1991	5	1	AIDS	MEDLINE
Wain-Hobson	1991			US 5019510	HCAPLUS
Welles, S	1996	174	696	J Infect Dis	MEDLINE
Wolinsky, S	1996	272	537	Science	HCAPLUS
Zauli, G	1995	10	306	J Acq Imm Def Synd H	HCAPLUS

L59 ANSWER 47 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:808224 HCAPLUS

DN 134:86468
TI Guanidinoglycosides: A Novel Family of RNA Ligands
AU Luedtke, Nathan W.; Baker, Tracy J.; Goodman, Murray; Tor, Yitzhak
CS Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, 92093-0358, USA
SO Journal of the American Chemical Society (**2000**), 122(48), 12035-12036
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
OS CASREACT 134:86468
AB The authors reported the preparation of guanidinoglycosides, in which the amine groups of natural aminoglycosides were converted into guanidinium groups by treatment with (Boc-NH)2C:NSO2CF3 [BOC = (H3C)3OC(O)], a new guanidinylation reagent. Using the HIV-1 Rev-REE interaction, the effect on RNA binding and potential antiviral activity of guanidinylated compds. was evaluated. Between 5- and 10-fold increases in inhibitory activity were observed for modified kanamycin A, kanamycin B, tobramycin, neomycin B, and paromomycin. A solid-phase method was used to evaluate the RNA specificity of the guanidinylated compds.
IT **317816-45-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of guanidinoglycosides as RNA ligands)
IT **317816-45-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of guanidinoglycosides as RNA ligands)
RN 317816-45-8 HCAPLUS
CN L-Cysteinamide, N-(3-carboxy-1-oxopropyl)-L-threonyl-L-arginyl-L-glutaminyl-L-alanyl-L-arginyl-L-arginyl-L-asparaginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-tryptophyl-L-arginyl-L-α-glutamyl-L-arginyl-L-glutaminyl-L-arginyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-S-(2-amino-2-oxoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A





PAGE 2-B



PAGE 3-A





PAGE 4-A





RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Baker, T	1999		1423	Synthesis	HCAPLUS
Battiste, J	1996	273	1547	Science	HCAPLUS
Chen, Q	1997	36	11402	Biochemistry	HCAPLUS
de Guzman, R	1998	48	181	Biopolymers	HCAPLUS
Feichtinger, K	1998	63	8432	J Org Chem	HCAPLUS
Frankel, A	1998	67	1	Annu Rev Biochem	HCAPLUS
Griffey, R	1999	96	10129	Proc Natl Acad Sci U	HCAPLUS
Hendrix, M	1997	119	3641	J Am Chem Soc	HCAPLUS
Holland, S	1992	66	3699	J Virol	HCAPLUS
Hope, T	1999	365	186	Arch Biochem Biophys	HCAPLUS
Hoshi, H	1991	44	680	J Antibiot	HCAPLUS
Kirk, S	1999	7	1979	Bioorg Med Chem	HCAPLUS
Kirk, S	2000	122	980	J Am Chem Soc	HCAPLUS
Kjems, J	1992	11	1119	EMBO J	HCAPLUS
Litovchick, A	2000	39	2838	Biochemistry	HCAPLUS
Luedtke, N	2000	39	1788	Angew Chem Intl Ed	HCAPLUS
Mei, H	1995	5	2755	Bioorg Med Chem Lett	HCAPLUS
Michael, K	1998	4	2091	Chem Eur J	HCAPLUS
Moazed, D	1987	327	389	Nature	HCAPLUS
Pollard, V	1998	52	491	Annu Rev Microbiol	HCAPLUS
Steicher, W	1983	9	591	Drugs Exp Clin Res	
Sucheck, S	2000	39	1080	Angew Chem, Int Ed	HCAPLUS
Tan, R	1994	33	14579	Biochemistry	HCAPLUS
Tan, R	1993	73	1031	Cell	HCAPLUS
Tilley, L	1992	89	758	Proc Natl Acad Sci U	
Tor, Y	1998	5	R277	Chem Biol	HCAPLUS
Walter, F	1999	3	694	Curr Opin Chem Biol	HCAPLUS
Wang, H	1997	119	8734	J Am Chem Soc	HCAPLUS
Weiss, M	1998	48	167	Biopolymers	HCAPLUS

Zapp, M |1993 |74 |969 |Cell |HCAPLUS

L59 ANSWER 48 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:34905 HCAPLUS
DN 132:113080
TI Peptides based on the sequence of human lactoferrin and their use in prevention and treatment of infections, inflammations, and tumors
IN Hanson, Lars A.; Mattsby-Baltzer, Inger; Baltzer, Lars; Dolphin, Gunnar T.
PA A+ Science Invest AB, Swed.
SO PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000001730	A1	20000113	WO 1999-SE1230	19990706 <--
	W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2333306	AA	20000113	CA 1999-2333306	19990706 <--
	AU 9950760	A1	20000124	AU 1999-50760	19990706 <--
	AU 752640	B2	20020926		
	EP 1095061	A1	20010502	EP 1999-935241	19990706 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002519438	T2	20020702	JP 2000-558131	19990706 <--
	NZ 509622	A	20030530	NZ 1999-509622	19990706 <--
PRAI	SE 1998-2441	A	19980706 <--		
	SE 1998-2562	A	19980717 <--		
	SE 1998-4614	A	19981229 <--		
	WO 1999-SE1230	W	19990706 <--		

OS MARPAT 132:113080
AB The invention relates to new peptides formed of at least seven subsequent amino acids of the amino acids in position 12-40, counted from the N-terminal end, in the sequence constituting human lactoferrin, and preferably modifications thereof. The invention also relates to medicinal products comprising such peptides, especially intended for treatment and prevention of infections, inflammations and tumors. Furthermore, the invention relates to food stuff, e.g. infant formula food, comprising the above mentioned peptides.
IT **254433-70-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(peptides based on the sequence of human lactoferrin and their use in prevention and treatment of infections, inflammations, and tumors)
IT **254433-70-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(peptides based on the sequence of human lactoferrin and their use in

prevention and treatment of infections, inflammations, and tumors)
RN 254433-70-0 HCAPLUS
CN L-Arginine, L-arginyl-L-asparaginyl-L-methionyl-L-arginyl-L-lysyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Chapple, D	1998	66	2434	Infection and Immuni	HCAPLUS
Holdingbolaget Vid Gote	1998			WO 9806425 A1	HCAPLUS
Koga, Y	1996			JP 08-073499 A2	HCAPLUS
Morinaga Milk Industry	1995			JP 07-145196 A2	HCAPLUS
Morinaga Milk Industry	1995			JP 07-274970 A2	HCAPLUS
Morinaga Milk Industry	1995			JP 07-309771 A2	HCAPLUS
Morinaga Milk Industry	1996			JP 08-143468 A2	HCAPLUS
Morinaga Milk Industry	1998			WO 9806424 A1	HCAPLUS
Morinaga Milk Industry	1997			JP 09-165342 A2	HCAPLUS
Odell, E	1996	382	175	FEBS Letters	HCAPLUS
Senju Pharma Co	1996			JP 08-040925 A2	HCAPLUS
Tomita, M	1994			US 5304633 A	HCAPLUS
Yamamoto, N	1996			US 5565425 A	HCAPLUS

L59 ANSWER 49 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:811095 HCAPLUS
DN 132:44975
TI Modulating platelet function
IN Luster, Andrew D.; Abi-Younes, Sylvie
PA The General Hospital Corporation, USA
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 9965507	A1	19991223	WO 1999-US13851	19990618 <--
	W: AU, CA, JP, MX				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9946968	A1	20000105	AU 1999-46968	19990618 <--
	US 2001033841	A1	20011025	US 2001-804606	20010312 <--
PRAI	US 1998-89970P	P	19980619 <--		
	US 1999-336414	B1	19990618 <--		
	WO 1999-US13851	W	19990618 <--		

AB Disclosed herein is a method of identifying a compound which affects the interaction between stromal cell derived factor-1 (SDF-1) and platelets, comprising the steps of: (a) contacting SDF-1 with platelets in the presence of a test compound in a test sample; (b) contacting SDF-1 with platelets in the absence of a test compound in a control sample; (c) measuring the SDF-1 effect in said test and said control samples; and (d) identifying compds. which increase or decrease said SDF-1 effect in the test sample compared to the control sample. Also disclosed is a method of treating a patient with a vascular disease by administering an inhibitor of the interaction between SDF-1 and platelets, in an amount effective to reduce the symptoms of said disease. Also disclosed is a method of stimulating the interaction between SDF-1 and platelets, as well as methods to identify compds. that modulate the above interaction.

IT **153127-49-2**, ALX40-4C
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modulating platelet function by interaction with stromal cell-derived factor-1 and CXCR4 and therapeutic application)

IT **153127-49-2**, ALX40-4C
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modulating platelet function by interaction with stromal cell-derived factor-1 and CXCR4 and therapeutic application)

RN 153127-49-2 HCAPLUS
CN D-Argininamide, N2-acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-, nonaacetate (9CI) (CA INDEX NAME)

CM 1

CRN 143413-49-4
CMF C56 H113 N37 O10

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



CM 2

CRN 64-19-7
CMF C2 H4 O2



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File

Schols	1997	186	1383	J Exp Med	HCAPLUS
The National Institutes	1997			WO 9728258 A1	HCAPLUS
The United States of Am	1998			WO 9809642 A2	HCAPLUS

L59 ANSWER 50 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:634870 HCAPLUS
DN 132:48807
TI The Role of Positively Charged Residues in CXCR4 Recognition Probed with Synthetic Peptides
AU Luo, Zhaowen; Zhou, Naiming; Luo, Jiansong; Hall, James W.; Huang, Ziwei
CS Kimmel Cancer Institute, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, 19107, USA
SO Biochemical and Biophysical Research Communications (**1999**), 263(3), 691-695
CODEN: BBRCA9; ISSN: 0006-291X
PB Academic Press
DT Journal
LA English
AB A high pos. charge is the common characteristic shared by the β-sheet region of stromal cell-derived factor-1 (SDF-1) and CXCR4 antagonists such as ALX40-4C consisting of nine D-arginines. This raises the question that the pos. charged residues may play a role in recognition of CXCR4. To test this hypothesis, two studies were carried out using synthetic peptides. In the first study, peptide analogs possessing amino acid sequences from both the N-terminus and the β-sheet region of SDF-1 were used as models to study the functional role of the β-sheet region of SDF-1. The attachment of pos. charged residues to the N-terminal peptide sequence of SDF-1 was found to enhance the ability of the peptides in CXCR4 binding and inhibiting CXCR4-mediated T-tropic HIV-1 entry. In the second study, two peptides containing nine arginines and the N-terminal signal sequence of SDF-1 were used as models to study the receptor binding mechanism of CXCR4 antagonists of high pos. charges such as ALX40-4C. One peptide did not show signaling activity as indicated by the lack of calcium influx while another peptide induced unusual calcium influx distinct from that induced by the SDF-1 N-terminal peptide. In addition, the signal induced by the SDF-1 N-terminal peptide was inhibited by ALX40-4C. Therefore, the first study provides exptl. support for the role of the highly pos. β-sheet region of SDF-1 in CXCR4 binding. The second study suggests that the binding site of ALX40-4C in CXCR4 may partially overlap with that of the SDF-1 N-terminal peptide. Both findings should be valuable for the design of SDF-1 agonists and antagonists. (c) 1999 Academic Press.
IT **143413-49-4**
RL: PRP (Properties)
(peptide analogs of β-sheet region of stromal cell-derived factor-1 and CXCR4 antagonist to probe role of pos. charged residues in CXCR4 recognition and binding)
IT **143413-49-4**
RL: PRP (Properties)
(peptide analogs of β-sheet region of stromal cell-derived factor-1 and CXCR4 antagonist to probe role of pos. charged residues in CXCR4 recognition and binding)
RN 143413-49-4 HCAPLUS
CN D-Argininamide, N2-acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Aiuti, A	1997	185	111	J Exp Med	HCAPLUS
Bleul, C	1996	382	829	Nature	HCAPLUS
Crump, M	1997	16	6996	EMBO J	HCAPLUS
Dealwis, C	1998	95	6941	Proc Natl Acad Sci U	HCAPLUS
Doranz, B	1996	85	1149	Cell	HCAPLUS
Doranz, B	1997	186	1395	J Exp Med	HCAPLUS
Doranz, B	1997	71	6305	J Virol	HCAPLUS
Endres, M	1996	87	745	Cell	HCAPLUS
Feng, Y	1996	272	872	Science	HCAPLUS
Heveker, N	1998	8	369	Curr Biol	HCAPLUS
Li, S	1998	273	16442	J Biol Chem	HCAPLUS

Luo, Z	1997	10	1039	Protein Eng	HCAPLUS
Murakami, T	1997	186	1389	J Exp Med	MEDLINE
Rucker, J	1997	288	118	Methods Enzymol	HCAPLUS
Satoh, T	1997	272	12175	J Biol Chem	HCAPLUS
Schols, D	1997	186	1383	J Exp Med	HCAPLUS
Wells, T	1996	59	53	J Leukocyte Biol	HCAPLUS

L59 ANSWER 51 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:515617 HCAPLUS
DN 131:308003
TI Selective cleavage of the HIV-1 TAR-RNA with a peptide-cyclen **conjugate**
AU Michaelis, Katrin; Kalesse, Markus
CS Institut fur Organische Chemie der Universitat, Hannover, D-30167, Germany
SO Angewandte Chemie, International Edition (**1999**), 38(15), 2243-2245
CODEN: ACIEF5; ISSN: 1433-7851
PB Wiley-VCH Verlag GmbH
DT Journal
LA English
AB A peptide-cyclen **conjugate** was prepared by solid-phase synthesis that showed the ability to cleave the TAR-RNA of HIV-1 in the absence of metal ions. Surprisingly, addition of the metal ions Eu(III) or Zn(II) seemed to interfere with the cleavage reaction. No cleavage was observed in the presence of peptides lacking the cyclen moiety.
IT **123251-89-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and selective cleavage of the HIV-1 TAR-RNA with a peptide-cyclen **conjugate**)
IT **123251-89-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and selective cleavage of the HIV-1 TAR-RNA with a peptide-cyclen **conjugate**)
RN 123251-89-8 HCAPLUS
CN L-Arginine, L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Aboul-Ela, F	1995	253	313	J Mol Biol	HCAPLUS
Calnan, B	1991	252	1167	Science	HCAPLUS
Chang, K	1977	99	3794	J Am Chem Soc	HCAPLUS
Churcher, M	1993	230	90	J Mol Biol	HCAPLUS
Delling, U	1992	65	7012	J Virol	
Dingwall, C	1990	9	4145	EMBO J	HCAPLUS
Endo, M	1996	118	5478	J Am Chem Soc	HCAPLUS
Farrow, M	1998	37	3096	Biochemistry	HCAPLUS
Frankel, A	1992	1	1539	Protein Sci	HCAPLUS
Hall, J	1994	1	185	Chem Biol	HCAPLUS
Hamy, F	1993	230	111	J Mol Biol	HCAPLUS
Kimura, E	1997	119	3068	J Am Chem Soc	HCAPLUS
Komijama, M	1997	62	2155	J Org Chem	
Komiyama, M	1995	77		J Chem Soc Chem Comm	

Kurz, K	1998	32	94	Chem Unserer Zeit	HCAPLUS
Kurz, K	1996	79	1967	Helv Chim Acta	HCAPLUS
Matsuda, S	1998	110	3477	Angew Chem	
Matsuda, S	1998	37	3284	Angew Chem Int Ed	HCAPLUS
Oivanen, M	1998	98	961	Chem Rev	HCAPLUS
Puglisi, J	1992	257	76	Science	HCAPLUS
Sharp, P	1989	59	229	Cell	HCAPLUS
Weeks, K	1990	249	1281	Science	HCAPLUS
Yashiro, M	1995		1793	J Chem Soc Chem Comm	HCAPLUS

L59 ANSWER 52 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:38190 HCAPLUS
DN 130:208695
TI The carboxyl terminus of interferon-γ contains a functional polybasic nuclear localization sequence
AU Subramaniam, Prem S.; Mujtaba, Mustafa G.; Paddy, Michael R.; Johnson, Howard M.
CS Department of Microbiology and Cell Science, University of Florida, Gainesville, FL, 32611, USA
SO Journal of Biological Chemistry (**1999**), 274(1), 403-407
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
AB Cytokines such as interferon-γ (IFN-γ), which utilize the well studied JAK/STAT pathway for nuclear signal transduction, are themselves translocated to the nucleus. The exact mechanism for the nuclear import of IFN-γ or the functional role of the nuclear translocation of ligand in signal transduction is unknown. The authors show here that nuclear localization of IFN-γ is driven by a simple polybasic nuclear localization sequence (NLS) in its C terminus, as verified by its ability to specify nuclear import of a heterologous protein allophycocyanin (APC) in standard import assays in digitonin-permeabilized cells. Similar to other nuclear import signals, the authors show that a peptide representing amino acids 95-132 of IFN-γ [IFN-γ(95-132)] containing the polybasic sequence 126RKRKRSR132 was capable of specifying nuclear uptake of the autofluorescent protein, APC, in an energy-dependent fashion that required both ATP and GTP. Nuclear import was abolished when the above polybasic sequence was deleted. Moreover, deletions immediately N-terminal of this sequence did not affect the nuclear import. Thus, the sequence 126RKRKRSR132 is necessary and sufficient for nuclear localization. Furthermore, nuclear import was strongly blocked by competition with the cognate peptide IFN-γ(95-132) but not the peptide IFN-γ(95-125), which is deleted in the polybasic sequence, further confirming that the NLS properties were contained in this sequence. A peptide containing the prototypical polybasic NLS sequence of the SV40 large T-antigen also inhibited the nuclear import mediated by IFN-γ(95-132). This observation suggests that the NLS in IFN-γ may function through the components of the Ran/importin pathway utilized by the SV40 T-NLS. Finally, the authors show that intact IFN-γ, when coupled to APC, was also able to mediate its nuclear import. Again, nuclear import was blocked by the peptide IFN-γ(95-132) and the SV40 T-NLS peptide, suggesting that intact IFN-γ was also transported into the nucleus through the Ran/importin pathway. Previous studies have suggested a direct intracellular role for IFN-γ in the induction of its biol. activities. Based on the data here, it is suggested that a key intracellular site of interaction of IFN-γ is the one with the nuclear transport mechanism that occurs via the NLS in the C terminus of IFN-γ.

IT **220997-71-7**
RL: PRP (Properties)
(C terminus of interferon-γ containing functional polybasic nuclear localization sequence)

IT **220997-71-7**
RL: PRP (Properties)
(C terminus of interferon-γ containing functional polybasic nuclear localization sequence)

RN 220997-71-7 HCAPLUS
CN L-Arginine, L-arginyl-L-lysyl-L-arginyl-L-lysyl-L-arginyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Adam, S	1992	219	97	Methods Enzymol	HCAPLUS
Arakawa, T	1989	4	217	Drug Design Deliv	HCAPLUS
Arakawa, T	1986	261	8534	J Biol Chem	HCAPLUS
Bader, T	1994	91	11831	Proc Natl Acad Sci U	HCAPLUS
Dobeli, H	1988	7	199	J Biotechnol	
Fidler, I	1985	135	4289	J Immunol	HCAPLUS
Gorlich, D	1996	271	1513	Science	HCAPLUS
Green, M	1998	243	170	Biochem Biophys Res	HCAPLUS
Jans, D	1998	20	400	BioEssays	MEDLINE
Jans, D	1994	8	841	FASEB J	HCAPLUS

Jans, D	1997	406	315	FEBS Lett	HCAPLUS
Jans, D	1997	406	368	FEBS Lett	
Johnson, H	1998	244	607	Biochem Biophys Res	HCAPLUS
Kushnaryov, V	1988	157	109	Biochem Biophys Res	HCAPLUS
Leaman, D	1996	10	1578	FASEB J	HCAPLUS
Lundell, D	1991	4	335	Prot Eng	HCAPLUS
Macdonald, H	1986	138	254	Biochem Biophys Res	HCAPLUS
Newmeyer, D	1988	52	641	Cell	HCAPLUS
Rutherford, M	1996	16	507	J Interferon Cytokin	HCAPLUS
Sanceau, J	1987	84	2906	Proc Natl Acad Sci U	HCAPLUS
Sekimoto, T	1997	16	7067	EMBO J	HCAPLUS
Sekimoto, T	1996	271	31017	J Biol Chem	HCAPLUS
Slodowski, O	1991	202	1133	Eur J Biochem	HCAPLUS
Smith, M	1990	144	1777	J Immunol	HCAPLUS
Szente, B	1994	201	1645	Biochem Biophys Res	
Szente, B	1994	201	215	Biochem Biophys Res	HCAPLUS
Szente, B	1995	155	5617	J Immunol	HCAPLUS
Szente, B	1996	16	813	J Interferon Cytokin	HCAPLUS
Wessendorf, J	1993	268	22100	J Biol Chem	HCAPLUS
Wetzel, R	1990	3	611	Prot Eng	HCAPLUS

L59 ANSWER 53 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:709091 HCAPLUS
DN 129:326081
TI Inhibition of HIV-1 replication by a Tat RNA-binding domain peptide analog
IN Wang, Jihong; Stein, Stanley; Leibowitz, Michael J.; Rabson, Arnold B.
PA The University of Medicine and Dentistry of New Jersey, USA
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9847913	A2	19981029	WO 1998-US7533	19980416 <--
	WO 9847913	A3	19990121		
	W: AU, CA, JP, MX, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9869727	A1	19981113	AU 1998-69727	19980416 <--
PRAI	US 1997-844448	A2	19970418 <--		
	WO 1998-US7533	W	19980416 <--		

OS MARPAT 129:326081
AB The peptidic compds., R-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-X-(biotin)-NH2 (R carboxylic acid residue; X = cysteine or lysine residue), analogs thereof, and the biol. and pharmaceutically acceptable salts thereof, contain the 9-amino acid sequence from the basic domain of the Tat protein responsible for specific interaction with TAR RNA, or an analog thereof. The cysteine or lysine residue provides an attachment site for biotin which acts as a cellular uptake enhancer. These peptides bind a fragment of TAR RNA (ΔTAR) avidly and specifically, as measured in an electrophoretic gel shift assay. Further, they inhibit tat gene-induced expression of a stably transfected CAT (chloramphenicol acetyl transferase) reporter gene linked to the HIV-1 LTR in a model cell assay, but do not inhibit phorbol ester-induced expression of CAT, thereby demonstrating a Tat-dependent mechanism of inhibition. Inhibition of HIV-1 replication after acute infection of MT2 cells was demonstrated by absence of HIV-induced syncytium formation and cytotoxicity, as well as by suppression of reverse transcriptase production These results indicate that these peptides are capable of competing with the TAR RNA-binding domain of

Tat protein and thus are useful as therapeutic agents in the treatment of AIDS.

IT **215315-75-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Tat RNA-binding domain peptide analog for inhibition of HIV-1 replication)

IT **215315-79-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Tat RNA-binding domain peptide analog for inhibition of HIV-1 replication)

IT **215315-75-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Tat RNA-binding domain peptide analog for inhibition of HIV-1 replication)

RN 215315-75-6 HCAPLUS

CN L-Cysteinamide, N2-acetyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginyl-S-[2-[[6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]hexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



L59 ANSWER 54 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:472464 HCAPLUS
DN 127:160187
TI Transport of immunogens into the MHC class I and II pathways by a peptide from HIV tat

AU Rathbard, Jonathan; Kim, Dewey; Mitchell, Dennis; Bockstedt, Dirk; Fong, Lawrence; Nolan, Gary; Fathman, C. Garrison; Engleman, Edgar
CS Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA
SO Alfred Benzon Symposium (**1997**), 40(HLA and Disease: The Molecular Basis), 161-175
CODEN: ABSYB2; ISSN: 0105-3639
PB Munksgaard
DT Journal; General Review
LA English
AB A review with 26 refs. Fluorescently labeled tat peptide (residues 49-57) enters the cytoplasm and nucleus of all hematopoietic cells with the exception of erythrocytes. When **conjugated** to ovalbumin it allowed the protein to effectively enter MHC class I biosynthetic pathway. Results indicate that tat **conjugation** to protein antigens represents a simple, effective method of generating antigen-specific cytotoxic T cells.
IT **123251-89-8**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(protein **conjugates**; transport of immunogens into MHC class I and II pathways by peptide from HIV tat)
IT **123251-89-8**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(protein **conjugates**; transport of immunogens into MHC class I and II pathways by peptide from HIV tat)
RN 123251-89-8 HCAPLUS
CN L-Arginine, L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L59 ANSWER 55 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1995:665157 HCAPLUS
DN 123:47891
TI Peptides for treatment of cytomegalovirus infection
IN Twist, Michael; Sumner-Smith, Martin
PA Allelix Biopharmaceuticals Inc., Can.
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9511038	A1	19950427	WO 1994-CA590	19941021 <--
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2152373	AA	19950427	CA 1994-2152373	19941021 <--
	CA 2152373	C	19981215		
	EP 675731	A1	19951011	EP 1994-930888	19941021 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AU 685862	B2	19980129	AU 1994-79876	19941021 <--
PRAI	US 1993-139757	A	19931022 <--		
	WO 1994-CA590	W	19941021 <--		

AB Described herein are anti-cytomegalovirus (CMV) peptides. In a preferred embodiment, the peptide is acetyl-[D-Arg]9-NH2 (I). The use of these peptides, either per se or in combination with other anti-CMV compds., is disclosed as an effective method for controlling CMV infection. Anti-CMV activity of I was assessed by a plaque reduction assay. I was also effective in controlling drug-resistant CMV strains.

IT **143413-49-4**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cytomegalovirus infection treatment with peptides and virucides)

IT **143413-49-4**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cytomegalovirus infection treatment with peptides and virucides)

RN 143413-49-4 HCAPLUS
CN D-Argininamide, N2-acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L59 ANSWER 56 OF 56 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1994:280279 HCAPLUS
DN 120:280279
TI Intracellular delivery of biochemical agents **conjugated** with peptides
IN Summer-Smith, Martin; Barnett, Richard W.; Reid, Lorne S.; Twist, Michael
PA Allelix Biopharmaceuticals Inc., Can.
SO Can. Pat. Appl., 19 pp.
CODEN: CPXXEB
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CA 2094658	AA	19931024	CA 1993-2094658	19930422 <--

PRAI US 1992-872396 A 19920423 <--

AB The intracellular delivery of biochem. agents, such as therapeutic peptides and oligonucleotides, is facilitated by a carrier peptide coupled therewith. The carrier peptide consists desirably of pos. charged D-amino acids. Acetyl-[D-Arg]9-NH2 (I) was prepared by conventional solid phase synthesis using p-methylbenzylhydrylamine resin as solid support. The uptake of I by cultured HeLa cells after 24 hs was 25.67%.

IT **143413-49-4D, conjugates** with biochem. agents
153127-44-7D, conjugates with biochem. agents
154858-89-6D, conjugates with biochem. agents
RL: BIOL (Biological study)
(for intracellular delivery)

IT **143413-49-4D, conjugates** with biochem. agents
RL: BIOL (Biological study)
(for intracellular delivery)

RN 143413-49-4 HCAPLUS

CN D-Argininamide, N2-acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



=>